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II.  Abstract 
 SHIV infections in rhesus macaques have been used to extensively study 
accessory proteins of HIV-1 involved in pathogenesis as well as in vaccine 
development.  All primate lentiviruses encode for a Vif (virion infectivity factor) protein, 
which is required for HIV-1 replication in primary CD4+ T cells and macrophages.  The 
Vif protein interacts with APOBEC3 (A3) proteins promoting their accelerated 
degradation by the 26S proteosome.  Sequence analysis of Vif proteins from different 
lentiviruses revealed that there are two highly conserved domains in the carboxyl 
terminus that are required for recruitment of the of the Vif-CBF-β-Cul5/Elongin B/C/Rbx-
1 E3 ubiquitin ligase complex.  These domains are the viral BC box, SLQ(Y/F)LAL, and 
Zn2+ binding (H-X5-C-X17-18-C-X3-5-H; HCCH) motifs.  Previous cell culture studies have 
shown that the introduction of amino acid substitutions into the SLQ(Y/F)LA motif 
resulted in decreased binding of Vif to Elongin C, while substitutions into the HCCH 
motif prevented the interaction of Vif with Cullin 5.  In this first study, we introduced two 
amino acid changes in the highly conserved SLQYLA domain (S147A, L148A; 
AAQYLA) of the SIV Vif protein in SHIV.  In vitro, the resulting virus, SHIVVifAAQYLA, 
replicated in A3G negative CEM-SS cells but failed to replicate in A3G positive CEM 
cells.  We also showed that hA3G was incorporated into the virion.  Following these in 
vitro studies, SHIVVifAAQYLA was inoculated into three rhesus macaques, which were 
followed for over six months to assess various viral and immunological factors 
throughout the duration of infection.  All three macaques did not develop significant 
CD4+ T cell loss over the course of infection, had plasma viral loads that were over 100-
fold lower than macaques inoculated with parental SHIVKU-1bMC33, and developed no 
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histological lesions in various lymphoid tissues, and developed immunoprecipitating 
antibodies.  DNA and RT-PCR analysis revealed that only a select number of tissues 
were infected with virus, while sequence analysis of PBMC and select tissue DNA (at 
necropsy) showed that the site-directed changes were stable during the first three 
weeks after inoculation but thereafter the S147A amino acid sunstitution changed to a 
threonine in two of the three macaques.  However, the L148A substitution remained 
stale in the vif amplified from the PBMC and select tissues at necropsy in all three 
macaques.  Extensive sequence analysis of the vif, vpu, nef, and env genes revealed a 
increased number of G-to-A mutations in the genes amplified from macaques inoculated 
with SHIVVifAAQYLA.  The majority of these mutations (>85%) were in the context of 
5’-TC (minus strand) and not 3’-CC, suggesting that one or more of the rhesus A3 
proteins may be responsible for the observed mutational patterns.  To determine if 
infectious virus was present in the plasma at necropsy, plasma from the three 
macaques inoculated with SHIVVifAAQYLA were pooled and intravenously inoculated into a 
naïve macaque.  This macaque maintained its levels of circulating CD4+ T cells 
throughout the duration of infection, maintained viral loads below the limits of detection, 
and did not produce immunoprecipitating antibodies.  However, gag was present in the 
DNA and RNA isolated from PBMC throughout infection and in select tissues at 
necropsy.  The results from this first study showed for the first time the importance of 
the SLYQLA domain in vivo in viral pathogenesis.  It also showed that mutations in vif 
could lead to a persistent infection in rhesus macaques resulting in the accumulation of 
G-to-A substitutions in the viral genome.   
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In the second study, we used the SHIV/macaque model of infection to compare 
the replication and pathogenicity of SHIVs that express a Vif protein in which the entire 
SLQYLA (SHIVVif5A) or HCCH (SHIVVifHCCH(-)) domains were substituted with alanine 
residues.  Each virus was inoculated into three rhesus macaques where various viral 
and immunological parameters were followed for six months.  Our in vitro results 
indicate that in the presence of these mutant Vif viruses, rhA3G is incorporated into the 
virion, stably expressed, restricts, and accumulates G-to-A substitutions (plus strand) in 
the nef gene of the mutated viral genomes.  In vivo, all macaques maintained a stable 
level of circulating CD4+ T cells, developed low viral burdens, maintained engineered 
mutations, yielded no histological lesions, and developed immunoprecipitating 
antibodies by 12 weeks post-inoculation.  However, the production of viral RNA only 
persisted in macaques inoculated with SHIVVifHCCH(-).  The analysis of vif sequences 
amplified from PBMC DNA between weeks 0-16 during SHIVVifHCCH(-) infection revealed 
an increased number of G-to-A substitutions that increased with time in two of the three 
macaques.  Sequence analysis of nef and vpu from the small intestine (ileum), thymus, 
and the spleen showed G-to-A substitutions in nef genes isolated from macaques 
inoculated with SHIVVifHCCH(-).  Macaques inoculated with SHIVVif5A effectively controlled 
the virus three weeks post-inoculation and no viral sequences could be amplified from 
tissue DNA.  These studies showed that the SLQYLA and HCCH domains are critical 
for viral pathogenesis in vivo and that there may exist APOBEC3 negative reservoirs in 
the rhesus macaque that allow for low levels of viral replication and persistence but not 
disease.  Therefore, this study suggests that mutations targeted to one or more 
functional conserved domains within the Vif protein may limit viral replication and 
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generate an effective immune response leading to the “self-inactivation” of the virus by 
the activities of various APOBEC3 proteins resulting in a possible live-attenuated 
vaccine candidate.   
The APOBEC3 family of restriction factors has been shown to inhibit certain 
retroviruses and retroelements.  The APOBEC3 family in humans is comprised of seven 
cytidine deaminases (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) that catalyze the 
deamination of cytidine to uracil on single-stranded DNA or RNA. While the human 
APOBEC3 repertoire has been extensively studied, the full complement of these 
proteins in the rhesus macaque remains unknown.  Sequencing of the rhesus macaque 
genome has led to the identification of the rhesus homologues A3B, A3C, A3D, A3F, 
A3G, and A3H.  Finally, we identified a human A3A (hA3A) homologue in the rhesus 
macaque (rhA3A) and presents evidence that both the human and rhesus Apobec3 
genes are orthologous. We show that rhA3A is highly expressed in activated CD4+ T 
cells, widely expressed in both the visceral and central nervous system tissues of the 
rhesus macaque, and is degraded in the presence of the human immunodeficiency 
virus (HIV-1) and simian-human immunodeficiency virus (SHIV) genomes in a Vif-
dependent manner.    Our results also indicate that rhA3A reduced the level of 
infectious SHIVΔvif by approximately 20-fold and HIV-1Δvif by 3-fold.  Human and 
monkey A3A amino acid sequences are 81% homologous and can be distinguished by 
a three amino acid indel located between residues 27-30. When these residues were 
deleted from rhA3A (rhA3AΔSVR), the antiviral activity of rhA3A was abolished 
suggesting that these residues are critical for lentivirus inhibition.  Select APOBEC3 
proteins are incorporated into the virion and can inhibit reverse transciption and/or 
	   vii	  
induce G-to-A hypermutation in nascent reverse transcripts in the next target cell. 
Previous studies revealed that rhA3G is incorporated into SHIVΔvif virions and exerts its 
antiviral activity in target cells by an increase in cytidine deamination of newly 
synthesized minus-strand viral DNA from cytosines to uracils, leading to G-to-A 
substitutions (plus strand) in the viral genome. We were able to detect the incorporation 
of rhA3A into SHIVΔvif and to a lesser extent in SHIV virions; however, we were unable 
to detect the incorporation of rhA3A into either HIV-1 or HIV-1Δvif virions. Even though 
rhA3A is incorporated into SHIVΔvif virions and potently restricts SHIVΔvif similar to 
rhA3G, rhA3A produced an approximately 5-fold decrease in the number of G-to-A 
mutations compared to rhA3G. Unlike hA3A, rhA3A did not inhibit adeno-associated 
virus 2 (AAV-2) replication and L1 retrotransposition.  This data suggests for the first 
time an evolutionary switch in primate A3A virus specificity and provides evidence that a 
primate A3A protein can inhibit lentiviral replication.   
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VI.  Chapter 1:  Introduction 
 
Epidemiology 
 The human immunodeficiency virus type 1 (HIV-1) is the causative agent of 
acquired immune deficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983; Gallo et al., 
1984).   Since its discovery in 1981, the HIV-1 pandemic has killed more than 25 million 
people and infects about 0.6% of the world population (UNAIDS Report on the Global 
AIDS Epidemic, 2010; Figure 1). By the end of 2009, the Joint United Nations Program 
on HIV/AIDS (UNAIDS) reports that there are approximately 33.3 million people living 
with HIV-1, with 22.5 million of those infected individuals residing in Sub-Saharan Africa.  
During 2009, there were approximately 2.6 million newly acquired infections and 1.8 
million AIDS-related deaths (UNAIDS Report, 2009). The high rate of viral replication, 
low fidelity of reverse transcription, and frequent recombination events leads to the 
genetic diversity of the HIV-1 species.  While there is no known cure for HIV-1 infection, 
the introduction of highly active anti-retroviral therapy (HAART) in 1996 has led to long 
lasting viral suppression reducing both the morbidity and mortality of HIV-1 infection 
(Palella et al., 1998).  However current drugs do not eradicate HIV-1 and factors such 
as resistance to antiretroviral therapy occurs due to the genetic diversity of HIV-1, 
limited treatment options in developing countries, non-compliance, inability to afford 
treatments, and drug toxicity contribute to continues virus spread. Further 
understanding of HIV-1 cell biology and pathogenesis will be required to expand drug 
discovery focusing on viral/host protein interactions or the identification of cellular  
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Figure 1.   Global prevalence of HIV-1 infections according to the UNAIDS 2009 
report on the global AIDS epidemic  
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targets conferring antiviral activity against HIV-1 thus making it possible to produce a 
safe and effective vaccines or antiviral treatments.  
 
Classification 
Simian and human immunodeficiency viruses (SIV, HIV-1, and HIV-2) are 
genetically related and classified in the Genus Lentivirus of the Family Retroviridae.  
Other members of the Genus Lentivirus include bovine immunodeficiency virus (BIV), 
equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV), caprine 
arthritis encephalitis virus (CAVE), and visna/maedi virus (MVV).  Distinct SIVs has 
been isolated from more than 20 African nonhuman primate species, where there is 
extensive viremia in these monkeys without exaggerated immune response (Hahn et 
al., 2000; Rey-Cuille et al., 1998).  Therefore, most of these particular isolates cause a 
nonpathogenic infection in their primary host (Hahn et al., 2000).  However, several 
SIVs have been isolated from Macaca nemestrina (pig-tailed macaques; SIVMNE) and 
the Asian macaque species Macaca mulatta (rhesus macaque; SIVMAC).  These viruses 
cause an AIDS-like disease in these macaques and arose from an initially infected 
rhesus macaque that was being housed with an infected sooty mangabey (Hahn et al., 
2000) 
The extensive genetic heterogenicity of HIV-1 is often classified by the lack of 
proofreading by the reverse transcriptase (RT), host selective pressures, rapid turnover 
of the virus in vivo, and recombination events that occur during replication (Ho et al., 
1995; Michael et al., 1999; Op de Coul et al., 2001; Roberts et al., 1988;Temin et al., 
1994).  HIV-1 is classified into three phylogenic groups: group M (main), group O 
	   5	  
(outlier), group N (non-M/O), and group P (Ayouba et al., 2000; Gurtler et al., 1994; 
Simon et al., 1998). Group P was recelty identified from two individuals originating from 
Cameroon (Ayouba et al., 2001; Plantier et al., 2009; Roques et al., 2004; Simon et al., 
1998; Vallari et al., 2011).  From phylogenetic data we can infer that HIV-1 group M and 
N originated by no fewer than three independent zoonotic cross-species transmission 
events of chimpanzee SIV (SIVCPZ; Pan troglodytes) (Gao et al., 1999; Santiago et al., 
2002).  Group O and P are phylogenically related to SIVgor (wild-living Western lowland 
gorillas, Gorilla gorilla), which was derived from an ancestor of a divergent SIVCPZ 
lineage in chimpanzees (Keele et al., 2006; Plantier et al., 2009; Takehisa et al., 2009; 
Van Heuverswyn et al., 2006).  Of the three main goups, group M is responsible for the 
HIV-1 pandemic and has evolved into nine distinct phylogenetic groups: A, B, C, D, F, 
G, H, J, and K (Hemelaar et al., 2006). Within a given subtype there are sub-subtypes 
that appear to be more genetically related.  These would include the subtypes A, B, and 
F, which are further classified into sub-subtypes A1, A2, B, B’, F1, F2, respectively (Gao 
et al., 2001; Triques et al., 2000).  The phylogenetic subtypes are currently based on 
either the sequence analysis of the full-length viral genome or on nucleotide sequences 
from multiple subgenomic regions such as gag, pol, and env.  Often multiple individuals 
become infected with two or more subtypes to produce intersubtype recombinant forms 
(Peeters et al., 2001; Robertson et al., 2000).  When at least three epidemiologically 
unlinked individuals become infected with an identical recombinant virus that has been 
characterized by full-length genome sequencing, the virus can be characterized as a 
circulating recombinant form (CRF) (Peeters et al., 2001; Robertson et al., 2000).  
Currently, there are 43 CRFs, with the highest diversity occurring in West Africa (Los 
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Alamos National Laboratory database, 2009).  CRFs can be linked to areas where the 
parental strains are co-circulating.  This increases the probability that individuals will 
become infected with several different genetic forms (“superinfected”) resulting in the 
generation of unique recombinant forms (URFs) (McCutchan et al., 2006).  To date, 
90% of the epidemic is comprised of four subtypes (A, B, C, and D) and two CRFs 
(CRF01_AE and CRF02_AG) (Gilbert et al., 2007).   The global distribution of these 
subtypes and recombinants are in Figure 2.    
HIV-2, while much less wide spread than HIV-1 is classified into eight 
phylogenetic groups, A-H (Hemelaar et al., 2011).  Unlike HIV-1, HIV-2 is thought to 
have originated from zoonotic transmissions from the sooty mangabey (Cerococebus 
atys) due to phylogenic similarity in genomic structure (Sharp et al., 1995).  It appears 
that seven independent transmissions from sooty mangabeys to humans occurred to 
result in the various HIV-2 subtypes (Chen et al., 1997; Gao et al., 1994; Yamaguchi et 
al., 2000).   
 
Geographic Distribution  
 The size of the HIV-1 epidemic cause by group M, N, non-M/N varies 
considerably.  HIV-1 group M is responsible for the majority of the global infections, 
approximently 33 million people.  Unlike group M, group O is endemic West-Central 
Africa and Cameroon constituting only 1-5% of infections, group N has been found in a 
small group of people in Cameroon, and group P has only been identified in two 
individuals in Cameroon (Ayouba et al., 2001; Plantier et al., 2009; Roques et al., 2004; 
Simon et al., 1998; Vallari et al., 2011).  On a global scale, the most prevalent group M 
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subtypes are A, B, and C.  Subtype C infections account for almost 50% of all worldwide 
HIV-1 infections and are predominantly found in >80% of infections in southern Africa 
and India.  Subtype A viruses are predominantly located in central and eastern Africa 
(Kenya, Uganda, Tanzania, and Rwanda) as well as the eastern Eurpoean countries 
formally known as the Solviet Union.  The Subtype B viruses are mainly located in 
western and central Europe, the Americas, Austrailia, and in several countries of 
Southeast Asia, northern Africa.  This subtype is also common in south african and 
russian homosexual men (Buonaguro et al., 2007).  The relavence of CRFs in HIV-1 
infection is increasingly on the rise accounting for approximently 18% of HIV-1 
infections (Hemelaar et al., 2006; Osmanov et al., 2002).  CFR01-AE and CRF02-AG 
represent the most prodomdinant CRFs from Southeast Asia and West/West Central 
Africa, respectively (Figure 2) (McCutchan et al., 1999; Montavon et al., 2000).   
The HIV-2 is endemic primarily to West Africa, although there is recent spread to 
parts of Europe and the southwestern region of India.  In Guinea-Bissau, there is 
prevalence up to 8-10% and Gambia is as high as 28% (Ghys et al., 1997; Langley et 
al., 1996; Poulsen et al., 1989; Wilkins et al., 1993).  This is of concern because dual 
HIV-1 and HIV-2 infections are occurring more frequently in regions once considered 
endemic to HIV-2, which may lead to recombination events between the two viruses 
(Andersson et al., 1999; 2000; Ishikawa et al., 1998).  The majority of HIV-2 infections 
are subtype A and predominant in Guinea-Bissau and Europe.  To a lesser extent, HIV-
2 subtype B is isolated predominantly from the eastern parts of west Africa and 
occassionally in Europe.  More interestingly, the highest diversity of HIV-2  
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Figure 2.  Global distribution and genetic diversity of the nine major subtypes and 
recombinants of HIV-1.  The various colors indicate a total of ten different 
epidemic patterns that have been observed.   
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subtypes (subtypes A, B, E, and F), ~0.02% of infections, have been isolated in Sierra 
Leone (Reeves et al., 2002).   
 
Genomic Structure of Lentiviruses 
 HIV-1 encodes three structural and enzymatic polyproteins; Gag (group-specific 
antigen), Pol (polymerase), and Env (envelope), which are analogous to proteins 
commonly found in all retroviruses.  Additionally, the HIV-1 genome encodes two 
regulatory proteins; Tat (transcriptional activator), Rev (regulator of virion), as well as 
four accessory proteins, Nef (negative factor), Vif (virion infectivity factor), Vpr (viral 
protein R), and Vpu (viral protein U) (Frankel and Young, 1998).   In contrast to HIV-1, 
HIV-2 and SIVsm phylogenetic lineages encode for an ortholog of HIV-1 Vpr known as 
Vpx (Viral protein X) (Goujon et al., 2007; Mailm et al., 2008; Sharova et al., 2008). 
Origianally, HIV-2 Vpr/Vpx was viewed as the functional counterpart of HIV-1 Vpr; 
however, more recent evidence shows that the targeted substrate and function of these 
proteins differs greatly (Gibbs et al., 1994; 1995; Goujon et al., 2007; 2008; Hirsch et al., 
1998; Kawamura et al., 1994; Yu et al., 1991; Mahalingam et al., 2001; Mangeot et al., 
2002; Ueno et al., 2003; Wolfrum et al., 2007).  Furthermore, HIV-1, SIV chimpanzees 
(SIVCPZ), and select monkeys in the Cercopithecus genus express a Vpu homologue. 
However, HIV-2 and the majority of SIV lineages do not encode for a vpu gene (Barlow 
et al., 2003; Beer et al., 1999; 2001; McCormick-Davis et al., 2000; Strebel et al., 1998).  
Figure 3 illustrates the genomic structures of these members of the Genus Lentiviruses.   
 
Viral Replication Cycle & Current HIV Therapeutic Targets 
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 Using the envelope glycoprotein, gp120, HIV-1 initiates contact with the target 
cell by recognition of the CD4 recptor and then to a secondary chemokine coreceptor, 
CXCR4 or CCR5 (Figure 4) (Jakobsen et al., 2010).  The CD4 receptor is a 
transmembrane glycoprotein expressed on the surface of T lymphocytes, T lymphocyte 
precursors in the bone marrow and thymus, monocytes, macrophages, dendritic cells, 
eosinophils, and microglial cells (Gorry and Ancuta, 2011).  The high affinity binding of 
gp120 to CD4 tiggers a conformational change in gp120 that exposes the V3 loop 
region of gp120 that interacts with the secondary extracellular loop of the coreceptor.  A 
gp120-bridging sheet is formed between specific domains of gp120 after the binding of 
CD4 interacts with the N-terminus of the coreceptor (Moore and Nara, 1991; Chesebro 
et al., 1992; Wyatt et al., 1992; Milich et al., 1993; Ross et al., 1998; Hoffman and 
Doms, 1999; Ogert et al., 2001; Cormier and Dragic, 2002; Hoffman et al., 2002; 
Nabatoc et al., 2004; Rizzuto et al., 1998; Sterjovski et al., 2010).  The CD4-bound 
gp120 with coreceptor causes further conformational changes that expose the N-
terminus of gp41, which contains a fusion peptide that inserts into the host cell 
membrane.  This occurs through a gp41 ectodomain that forms an extended coiled coil 
conformation and a six-helix bundle structure.  This promotes the juxaposition of the 
viral and host cell membrane, which is a stable structure allowing the fusion between  
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Figure 3.  Schematic representation of the genomic structures from various 
members of the Lentiviridae subfamily: HIV-1, SIVCPZ, HIV-2, SIVSM, and SIVMAC. 
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viral and cellular membranes resulting in a pore that allows for the release of the viral 
core into the host cell (Gorry and Ancuta, 2011; Helseth et al., 1991; Miller et al., 1993; 
Srinivas et al., 1992).  There are a total of 12 different membrane proteins that have 
been identified as co-receptors for HIV-1.  However, CXCR4 and CCR5 are the primary 
co-receptors for either T cell line tropic (T-tropic) or macrophage tropic (M-tropic) HIV-1 
isolates, respectively (Berger et al., 1999; Deng et al., 1996; Deng et al., 1997; Doranz 
et al., 1996; Dragic et al., 1998; Feng et al., 1996; Gorry and Ancuta, 2011; Jakobsen et 
al., 2010; Liao et al., 1997).  During the progression to the late stages of HIV-1 infection, 
40-50% of infected individuals switch co-receptor specificity to either CXCR4 (X4 
viruses) or to dual-tropic co-receptor specificity CCR5 and CXCR4 (R5/X4).  The 
broadened cell tropism by co-receptor switching contributes to the development of a 
more rapid disease progression (Coetzer et al., 2008; Corry and Ancuta et al., 2011).  
Currently there are two anti-retrovirals that inhibit HIV-1 entry into target cells: one 
fusion inhibitor, enfuvirtide, and one CCR5 antagonist, maraviroc (De Clercq et al., 
2009).   
 After the membranes fuse, the viral core is released into the cytoplasm of the cell 
(Figure 4).  Viral uncoating is initiated with both cellular factors and the viral proteins 
MA, Nef, and Vif.  The viral RNA genome is reverse transcribed using reverse 
transcriptase (RT) into a double stranded DNA copy of the viral genome (Hirsch and 
Curran, 1990; Harrich and Hooker, 2002).  Correct regulation of the core uncoating is 
necessary for completion of the early stages during HIV-1 replication.  TRIM5α exerts 
an anti-retroviral effect by targeting intact or partially uncoated viral cores (Forshey et 
al., 2005; Hatziiannou et al., 2004; Kar et al., 2008; Langelier et al., 2008; Sebastian 
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and Luban, 2005; Shi and Aiken, 2006; Stremlau et al., 2006).  This block to replication 
occurs post-entry but pre-reverse transcription.  TRIM5α inhibits replication by causing 
rapid and premature disassembly of the viral core and by recruiting cellular proteosomal 
degradation machinery (Anderson et al., 2006; Campbell et al., 2008; Rold and Aiken, 
2008; Perron et al., 2007; Stremlau et al., 2006; Wu et al., 2006).  This factor is species 
specific; for example, HIV-1 is not inhibited by human TRIM5α as efficiently as rhesus 
or owl monkey TRIM5α (Bieniasz, 2004; Hatziioannou et al., 2004; Keckesova et al., 
2004; Luban, 2007; Nisole et al., 2005; Ozato et al., 2008; Perron et al., 2004; Stremlau 
et al., 2004; Towers, 2007; Yap et al., 2004).  The reverse transcriptase (RT) is the 
target for three different classes of inhibitors:  nucleoside RT inhibitors (NRTIs), 
nucleotide RT inhibitors (NtRTIs), and non-nucleoside RT inhibitors (NNRTIs).  Both the 
NRTIs and NtRTIs interact with the substrate binding site of the RT and the NNRTIs 
interact with an allosteric site located a short distance away from the substrate binding 
site.  The seven NRTIs approved for use today are zidovudine (AZT), didanosine (ddI), 
zalcitabine (ddC), stavudine (d4T), lamivudine (3TC), abacavir (ABC), and emtricitabine 
((-) FTC).  There is one NtRTI approved for use today, tenofovir, and our NNRTIs: 
nevirapine, delavirdine, efavirenz, and etravirine (De Clercq, 2009).   
 Following uncoating the reverse transcriptase, the formation of the preintegration 
complex occurs (PIC) (Figure 4). This complex contains the viral reverse transcribed 
double-stranded DNA, matrix protein (MA), integrase (IN), viral protein R (vpr), the 
central DNA flap, and several host proteins (Miller et al., 1997).  The PIC complex must 
transverse the nuclear pore complex (NPC) of the nuclear membrane to be imported 
into the nucleus and integrate into the host genome (Zennou et al., 2000).  The NPC 
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spans the nuclear membrane and provides an aqueous channel allowing the bi-
directional transport of proteins up to approximently 60-kDa in size (Mattaj et al., 1998; 
Nigg et al., 1997; Weis et al., 1998).  The translocation is completed using a class of 
proteins known as importins and exportins.  These proteins engage import and export 
signals within the proteins that are being mediated for transport (Nigg et al., 1997; Weis 
et al., 1998).  The exact mechanism of the PIC-associated proteins in nuclear 
transportion through the NPC is unknown.  However, research has shown that there is a 
non-classical nuclear import signal buried in the catalytic domain of IN (Bouyac-Bertoia 
et al., 2001).  Also, there is preliminary evidence suggesting that the transit involves the 
association of the PIC with microtubules (Hope, unpublished data).  Furthermore, a 
central DNA flap, which is a triple-stranded intermediate, is created during reverse 
transcription.  The central DNA flap acts as an import signal for the PIC (Hamm et al., 
1990; Zennou et al., 2000).  When this structure is mutated, the HIV-1 genomes 
accumulated at or just inside the nuclear envelope similar to an IN nuclear localization 
mutant (Zennou et al., 2000).  While the PIC complex is still in the cytoplasm, the viral 
cDNA is primed for integration.  The IN trims the 3’ strand of the U3 and U5 LTRs of the 
viral cDNA and the ends of the viral genome in a process known as 3’-processing (3’-P).  
During this reaction, IN catalyzes an endonucleolytic cleavage at the 3’ site of the 
conserved CA dinucleotide releasing a terminal GT dinucleotide.  The CA-3’-hydroxyl 
ends generated provide nucleophile groups used for the strand transfer.   The PIC 
complex migrates into the nucleus as described above, and IN catalyses the insertion of 
the two viral cDNA ends into the host chromosome (Figure 4).  During strand transfer, 
the two 3’-hydroxyl ends ligate to the host chromosome with a five-base pair stagger 
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across the major groove DNA resulting in a two–base overhang on the viral cDNA 5’-
end and a five-base pair single-stranded gap at each junction, which is repaired by host 
enzymes (Grandgenett, 2005; Holman and Coffin, 2005; Marcband et al., 2006; 
Marshall, et al., 2007; Van Maele and Debyser, 2005; Wu et al., 2005).  There is only 
one integrase inhibitor available for clinical use, raltegravir.  Raltegravir targets the 
strand transfer reaction.   There is a similar drug now in Phase III trails that also inhibits 
strand transfer known as Elvitrgravir (De Chercq, 2009).   
 After the proviral DNA is integrated, cellular RNA polymerase II begins the first 
rounds of transcription of the proviral DNA.  The RNA polymerase II binds cellular 
factors to the viral long terminal repeat (LTR) and transcription of basal amounts of Tat, 
Rev, and Nef begin (Jordan et al., 2001).  The HIV-1 LTRs flank the viral DNA and the 
3’ LTR contains three distinct regions.  These regions are the unique 3’ region (U3), the 
repeated domain (R), and the unique 5’ region (U5).    These LTR enhancer/promoter 
sequences are required for the replication of HIV in T cell lines.  The U3 region is further 
divided into three regions:  the core promoter, enhancer, and modulatory regions (Fields 
et al., 2007).  The LTR also has closely related cis-acting elements that allow for 
promotion of transcription by RNA polymerase II.  These include the TATA boxes that 
bind transcription factor IID, three Sp1 binding sites, enhancers containing two NF-kB 
binding sites, modulatory regions that contain purine box arrays, and sites that bind the 
Ets family members (reviewed in Kilareski et al., 2009).   During the initial stage of 
infection, only multiply spliced mRNAs of the regulatory proteins are expressed; Tat, 
Nef, and Rev. Once sufficient amounts Tat are expressed (Figure 4), Tat activates 
futher transcription of HIV-1 genes by binding the TAR element of the LTR and other 
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cellular transcription factors (Harrich et al, 1996; Harrich and Hooker, 2002).  After 
sufficient amounts of Rev are expressed, Rev non-spliced and singly spliced mRNAs 
are produced and transported to the polysomes leading the production of other viral 
proteins; such as Gag, Pol, Env, Vpr, Vpu, and Vif, and genomic RNA (Pollard and 
Malim, 1998).  Rev binds the Rev responsive element (RRE) found in singly spliced and 
unspliced viral RNA.  This facilitates their transport through the nuclear membreane and 
into the cytoplasm (Sierra et al., 2005).  The envelope glycoprotein precursr, gp160, is 
synthesized in the rough endoplasmic reticulum where high mannose moieties are 
added to the N-linked glycosylation sites (Asp-X-Ser/Thr).  The proteins are then 
transported to the Golgi complex where the high mannose side chains are trimmed and 
complex carbohydrates are added.  Additionally, the gp160 is cleaved by a host 
protease in the Golgi complex resulting in gp120 and the gp41 transmembrane protein.  
The gp120/gp41 complex proteins are transported by vescular trafficking to the cell 
plasma membrane, which together with two copies of the viral RNA and the Gag and 
Gag-Pol precursor proteins initiate assembly (Briggs et al., 2003; Derdowski et al., 
2004; Sandefur et al., 2000; Figure 4).  The Gag polyprotein precursor, Pr55Gag, is 
essential for assembly and recruitment of components required for the formation of the 
virion by promoting interaction between various structural components, encapsidating 
the viral RNA, and associating with the envelope proteins to stimulate the budding 
process. Pr55Gag oligomerizes underneath the plasma membrane through protein-
protein and protein-RNA interactions with the HIV-1 matrix (MA) protein facing and 
directly inserting into the lipid bilayer (Lee et al., 1999; Lee and Yu et al., 1998; 
Lingappa et al., 1997; Tritel and Resh, 2000).  The budding of HIV-1 occurs by hijacking 
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the cellular endosomal sorting machinery (Bieniasz, 2006; Demirov and Freed, 2004; 
Morita and Sundquist, 2004).  The p6 region of Pr55Gag binds to the ESCORT-1 
(Endosomal Sorting Complex Required for Transport I) component Tsg101 or ALIX 
through the secondary assembly late domains PTAP and YPLTSL, repectively (Demirov 
et al., 2002; Gottlinger et al., 1991; Huang et al., 1995).  ALIX binds and recruits the 
Snf7 subunit of ESCORT-III (McCullough et al., 2008).  ESCORT-III excises the 
membrane neck between the viral particle and the plasma membrane.  After the 
recruitment of all the necessary components of the virion, the immature viron buds from 
the plasma membrane containing the host lipid bilayer as its outer envelope (Freed, 
2002; Ono and Freed, 2001).  While T cells exclusively bud from the plasma membrane, 
HIV-1 vrions bud into vesicular structures in macrophages, which are subsequentally 
released at the cell surface.  Gag is the only protein required to form and release virion-
like particles (Gelderblom, 1991; Ono, 2009; Orenstein et al., 1998).   Currently, there 
are no anti-retrovirals that target viron assembly and budding approved for clinical trials.   
 The immature particle buds from the plasma membrane and the viral protease 
(PR) proteolytically processes by cleaving the Pr55Gag and the Gag-Pol precursor 
(Pr160Gag-Pol) yielding cleaved Gag and Pol proteins (Adamson and Freed, 2007; Vogt, 
1996).  During proteolytic cleavage the virion undergoes morphological changes 
resulting in a spherical particle with a dense core containing the genomic RNA (Figure 
5) (Ganser et al., 1999; Yeager et al., 1998).  Currently, there are ten protease inhibitors 
approved for clinical use.  These include saquinavir, ritonavir, indinavir, nelfinavir, 
amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir, and darunvir (De Clercq et 
al., 2009).  
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Viral Proteins 
 All of the proteins encoded by HIV-1 contribute to producing optimal conditions 
for HIV-1 to replicate in the host cell as well as evade the host immune system resulting 
in productive infection.  The HIV-1 genome is flanked by two long terminal repeats 
(LTR) regions that do not encode for any viral proteins but are necessary for integration 
into the host cell genome and for encoding promoter enhancer binding sites (5’LTR).  
 
Gag 
 The gag gene is expressed as a 55-kDa polyprotein precursor Pr55 that is 
cleaved to produce the mature HIV-1 virion.  These are the matrix (MA or p17), capsid 
(CA or p24), and nucleocapsid (NC or p7) proteins.  Additionally, the proteolytic 
cleavage of Pr55 results in a C-terminal domain called p6 as well as two spacer proteins 
known as p1 and p2 (Henderson et al., 1992; Mervis et al., 1988).  The MA protein is 
located at the N-terminal of Pr55 and remains associated with the lipid envelope of the 
mature virion.  Its membrane association is dependent on an N-terminal myristic acid 
moiety (Bryant and Ratner, 1990; Gottlinger et al., 1989; Spearman et al., 1994).    A 
charged N-proximal region contains a cluster of conserved basic residues that bind the 
acidic phospholipids in the host cell lipid bilayer (Yuan et al., 1993; Zhou et al., 1994).  
This charged N-proximal region is essential for stabilization of Pr55 to the membrane 
and for extracellular particle formation and virus replication.   Interaction  
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Figure 4. HIV-1 replication. 1) Attachment and Entry; 2) Release into the 
cytoplasm and uncoating; 3)  Reverse Transcription; 4)  Integration; 5)  
Transcription of proviral DNA and full-length viral genome RNA; 6)  Nuclear 
export; 7)  Processing of viral proteins; 8) Processing of Env proteins; 9)  
Assembly; 10)  Proteolytic cleavage   
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Figure 5.  Depiction of a mature HIV-1 virion   
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between the MA and the acidic phospholipids enhance Gag membrane binding and 
contribute to Gag bringing the plasma membrane.  A three-dimensional model structure 
shows that MA forms trimers with cationic charged faces resulting in Gag targeting to 
the anionic cytoplasmic leaflet of the plasma membrane (Hill et al., 1996; Matthews et 
al., 1995).  An acidic phospholipid, PI(4, 5)P2, specifically localizes to the cytoplasmic 
leaflet and binds to the conserved basic residue clusters on the MA proteins.  This is 
most likely the reason Gag targets to the cytoplasmic leaflet of the plasma membrane  
(Chen et al., 2008; Ono et al., 2004; Saad et al., 2006).  From recent studies it can be 
inferred that HIV-1 Gag specifically associates with raft-like microdomains in the plasma 
membrane (Lindwasser and Resh, 2001; Nguyen and Hildreth, 2000; Ono and Freed, 
2001).   
 The myristylation site of Gag in the plasma membrane is generally sequestered.  
The insertion of this moiety into the plasma membrane is regulated by the CA protein.  
The CA is composed of two structurally independent, largely helical, domains:  the N-
terminal core and the C-terminal dimerization domain (Adamson et al., 2009; Ganser-
Pornillos et al., 2008).  Multimerization of the CA protein causes a conformational 
change in Gag allowing for the myristic acid to insert with high affinity into the plasma 
membrane (Saad et al., 2006).  The N-terminal domain of CA also interacts with the 
human peptidyl-prolyl cis-trans isomerase cyclophilin A (CyPA) allowing it to be 
incorporated into the virion.  CyPA is an intracellular receptor for the 
immunosuppressant cyclosporin A (CsA), which allows for optimum infectivity of HIV-1 
(Franke et al., 1994; Luban et al., 1993; Handschumacher et al., 1984; Thali et al, 
1994).  CyPA virion incorporation stabilizes the virion and prevents human TRIM5α from 
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uncoating following infection (Sayah and Luban, 2004).  Cleavage of CA-p2 boundry 
occurs late during virus maturation and is required to weaken the CA-CA interactions 
allowing the collapse of the spherical CA shell into a cone (Accola et al., 1998; Pettit et 
al., 1994; Wiegers et al., 1998).   
 The NC region of Pr55 contains two highly conserved copies of a CCHC-type 
zinc finger motif, which coordinates a zinc ion and is essential for virus replication 
(Aldovini and Young, 1990; Bess et al., 1992; Dorfman et al., 1993; Gorelick et al., 
1993; Gorelick et al., 1990; Summers et al., 1992; Summers et al., 1990).  These NC 
domains are also required for the packaging of the two copies of the genomic viral RNA 
into assembling virions (Berkowitz et al., 1996).  The packaging signal (ψ) is located in 
the viral RNA 5’ to the gag initiation codon.  It is composed of four stem loop structures, 
which are required in cis for proper encapsidation of the viral RNA (Berkowitz et al., 
1996).   
 Finally, the p6 domain is variable in both length and sequence.  Both the PTAP 
(near the N-terminus) and LXXLF (Late assembly domain (L); near the C-terminus) 
motif are highly conserved and allow for the recruitment of the ESCORT-associated 
complexes.  These motifs bind the ALIX (LXXLF) and TGS101 (PTAP) preventing the 
inward budding of vesicles into late endosomes and allow the virus to effectively bud 
from the plasma membrane (Bieniasz, 2006; Gottlinger et al., 1991; Huang et al., 1995; 
Ono and Freed, 2004; Rudner et al., 2005).   
 
Pol 
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 Pol is expressed from a 160-kDa Gag-pol precursor protein (Pr160Gag-Pol).  This 
protein is synthesized following a programmed -1 ribosomal framshift that occurs at a 
level of 5-10% of Gag Synthesis, ensuring a strict 20:1 ratio of Gag to Gag-Pol (Jacks et 
al., 1998). Pr160Gag-Pol is cleaved by the protease during maturation into the viral 
enzymatic proteins protease (PR), reverse transcriptase (RT), and integrase (IN).  The 
relevent aspects of PR and IN are briefly described in the overview of viral replication.   
 The reverse transcriptase is a multifunctional enzyme with RNA-directed DNA 
polymerase, DNA-directed DNA polymerase, and ribonuclease H (RNase H) activities.  
The crystal structure of the RT and mapping of resistance mutations has been 
extensively studied and is beyond the scope of this dissertation. However, it is important 
to understand an overview of the reverse transcription process for this dissertation.  The 
RT reverse transcribes the single-stranded RNA from the virion into double stranded 
DNA, which is then integrated as provirus into the host cell.  The negative sense single-
stranded DNA sysnthesis is initiated from the tRNALys.3 bound to the primer binding 
site (PBS) located on the single-stranded viral RNA genome 5’ end.  After primer 
binding, the RT proceeds to the RNA 5’ terminus copying repeat (R) and the unique 5’ 
(U5) sequences.  The concomitant RNase H activity hydrolyzes the ensuing RNA/DNA 
hybrid, which allows the complementary R sequences at the termini of the genome 
promote transfer of nascent DNA to the RNA 3’ terminus.  This allows for continued 
DNA synthesis.  Hydrolysis of the RNA/DNA replication intermediate continues, with the 
exception of the 3’ and central polypurine tract (cPPT).  The cPPT primes the positive 
strand and DNA-dependent synthesis up to eighteen nucleotides of the tRNA primer.  
This creates the complementary positive strand PBS sequence.  Following synthesis, 
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the PPT and tRNA primers are excised and the PBS complementary promotes a 
second strand transfer event.  This allows for bidirectional DNA synthesis creating a 
double-stranded proviral DNA flanked by the LTR sequences (reviewed in Götte et al., 
2010).   The lack of proofreading by the RT leads to 10- to 100- fold increase in errors.  
The processivity of RT is also very low and recombination of DNA during DNA synthesis 
occurs resulting in additional mutations in the HIV-1 genome.  Therefore, the errors 
produced by the RT, while reverse transcribing the viral genome, allow the virus to 
quickly evolve and become resistant to antiretroviral treatment (Jonckheer et al., 2000).   
 
Env 
 Env is synthesized as a polyprotein, gp160, precursor from a singly spliced 
bicistronic vpu/env mRNA on the rough endoplasmic reticulum (RER).  This precursor is 
cleaved at an N-terminal ER sequence that targets Env to the RER.  The signal 
sequence is then removed by cellular signal peptidases within the ER.  The gp41 
transmembrane domain prevents gp160 from being fully released into the lumen of the 
ER.  The precursor is glycosylated with N- and O-linked oligosaccharide side chains 
(Allan et al., 1985; Leonard et al., 1990; Bernstein et al., 1994).  This allows for 
oligomerization of gp160 into trimers and facilitating their trafficking to the Golgi complex 
where it acquires high-mannose oligosaccharide side chains and complex modifications 
in the trans-Golgi network (Earl et al., 1990; Earl et al., 1991; Pinter et al., 1989; 
Schawaller et al., 1989).  This is to prevent the premature interaction of oligomerized 
gp160 with CD4 in the secretory pathway.  Since gp120 binds to the CD4 receptor on 
susceptible cells, the viral accessory protein Vpu binds to CD4 to downregulate its 
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expression by targeting it to the proteosome for ubiquitin-mediated proteasomal 
degradation (Fujita et al., 1997; Margottin et al., 1998; Schubert et al., 1998).  In the 
Golgi complex, gp160 is proteolytically cleaved by cellular furin to yield the mature 
surface glycoprotein gp120 and the transmembrane protein gp41.  This cleavage is 
absolutely essential for viral infectivity.  Following cleavage, three molecules of each 
gp120 and gp41 form a heterotrimeric HIV-1 glycoprotein spike.  These glycoproteins 
remain associated through weak, noncovalent bonds, and are transported to the surface 
for incorporation into the budding virion (Egan et al., 1996; Rowell et al., 1995).  Env is 
rapidly recycled to the endosome after it arrives at the plasma membrane.  This leads to 
low maintenance on the cell surface, and helps HIV-1 evade the host immune system 
(Zhu et al., 2003).  The expression of gp120/gp41 complexes on the cell suface of 
infected cells can cause fusion of two or more cells resulting in the formation of 
multinucleated giant cells called syncytia (Yao et al., 1993).   
 The gp120 protein contains discontinuous segments five variable (V1-V5) 
regions, five constant (C1-C5) regions, and eighteen cysteine residues.  The CD4 
receptor-binding site is formed from the conserved C1, C3, and C4 domains of gp120 
(Lasky et al., 1987; Kowalski et al., 1987; Olshevsky et al., 1990).  The V3 loop is 
important for both membrane fusion and co-receptor (CXCR4 and/or CCR5) specificity 
(Cann et al., 1992; Chesebro et al., 1991; Freed et al., 1991; Hwang et al., 1991; 
O’Brien et al., 1990; Shioda et al., 1991).  The dominant epitopes are found on the V3 
loop and are recognized by neutralizing antibodies of the host immue system (Fouchier 
et al., 1992; Pollakis et al., 2004; Shioda et al., 1994).  After gp120 binds to CD4, gp120 
undergoes a high degree of re-folding allowing the V3 loop to bind either CXCR4 or 
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CCR5 through either a strong negative or strong positive charge, respectively (Doms 
and Peiper, 1997; Kwong et al., 2000; Moulard et al., 2000; Sullivan et al., 1998).  
Further conformational changes occur dissociating gp120 from gp41.  Then the gp41 
transmembrane glycoprotein mediates fusion of the viral lipid envelop with the host cell 
membrane.  The gp41 subunit is composed of three major domains; an extracellular 
domain (or ectodomain), transmembrane domain, and a C-terminal cytoplasmic domain.  
The gp41 protein anchors the viral envelope to the host cell membrane.  The 
extracellular domain contains the major fusion determinants used to catalyze the fusion 
of the viral and host cell lipid bilayers during viral entry (Bosch et al., 1989; Freed et al., 
1990; Freed et al., 1992).   
 
Vif  
 Vif is a basic, cytoplasmic, 23-kDa phosphoprotein expressed late in the 
retroviral life cycle.  This protein is highly conserved among all lentiviruses (except 
EIAV) and is essential for viral replication.  Vif is translated from a single spliced viral 
mRNA, whose expression is dependent on Rev (Garret et al., 1991; Schwartz et al., 
1991).  Vif is part of the cytoplasmic ribonucleoprotein (RNP) complex and is packaged 
into viral particles at low levels.  Packaging of Vif occurs through interactions with viral 
RNA, co-packaged cellular RNA, and the nucleocapsid domain of Pr55Gag (Kahn et al., 
2001; Zhang et al., 2000; Dettenhofer et al., 2000; Huvent et al., 1998; Liu et al., 1995; 
Karczewski et al., 1996).  
 Vif is required for the production of infectious virus in a cell-type specific manner.  
In cells termed non-permissive, viruses lacking a functional vif gene are restricted in 
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their ability to replicate and produce infectious virus, when compared to wild type virus 
(Courcoul et al., 1995; Fan and Peden, 1992; Fouchier et al., 1996; Gaddis et al., 2003; 
Goncalves et al., 1996; Hoglund et al., 1994; Simm et al., 1995; Simon and Malim, 
1996; Simon et al., 1998; Sova and Volsky, 1993; von Schwedler et al., 1993).   This 
lead to the identification of the cellular restriction factor called aplolipoprotein B mRNA-
editing catalytic polypeptide-like 3G (or APOBEC3G) (Sheehy et al., 2002).  In the 
absence of Vif, APOBEC3G is encapsidated into the virion and exerts its effects on the 
next target cell.  APOBEC3G induces massive cytidine deamination in the minus strand 
of viral DNA during reverse transcription producing an excessive number of G-to-A 
substitutions in the plus strand of DNA (Harris et al., 2003; Mangeat et al., 2003; Mariani 
et al., 2003; Suspene et al., 2004; Yu et al., 2004; Zhang et al., 2003).  The G-to-A 
substitutions occur in a gradient throughout the viral genome.  The most mutations are 
present in the Nef, and decrease towards the 5’UTR (Kijak et al., 2008; Koulinska et al., 
2003; Suspene et al., 2006; 2004; Yu et al., 2004).  However, Vif binds APOBEC3G and 
inhibits its packaging into the virion.  The N-terminus of Vif binds APOBEC3G recruiting 
Cul5/EloB/C/Rbx-1 E2 ubiquitin ligase subsequently leading to the polyubiquitination 
and proteosomal degradation of APOBEC3G (Conticello et al., 2003; Kobayashi et al., 
2005; Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu 
et al., 2003).  Vif binds the E3 ubiquitin ligase complex through two highly conserved 
domains, 144SLQ(Y/F)LA150 motif and the 108Hx5Cx17-18Cx3-5H139 domain.  The 
144SLQ(Y/F)LA150 motif binds elongin C, while the 108Hx5Cx17-18Cx3-5H139 domain binds 
Cullin 5 (Luo et al., 2005; Mehle et al., 2004; 2006; Yu et al., 2004).  This will be 
discussed in more depth below.   
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Nef 
 Nef is a small protein that is variable in length (between 200-215 amino acids) 
and devoid of enzymatic activity (O’Neill et al., 2006).  This protein is myristoylated at 
the N-terminus, which is required for its expression at the plasma membrane.  However, 
Nef is mainly localized to the paranuclear region of the infected cell with reduced 
expression at the plasma membrane.  Nef serves as an adaptor protein to divert host 
cell proteins to amplify viral replication and is a major determinant of pathogenicity 
(Arold et al., 2001; Geyer et al., 2001; Laurent-Crawford and Hovanessian, 1992; 
Niederman and Ratner, 1992).  In vitro, Nef has been determined to have four major 
functions: 1) downregulation of cell surface CD4 levels; 2) downregulation of cell 
surface major histocompatibility class I (MHCI) molecules; 3) mediation of cellular 
signaling and activation; 4) enhancement of viral particle infectivity by CD4 independent 
mechanisms (Aiken et al., 1996; 1997; 1998; Anderson et al., 1994; Arold et al., 2001; 
Aurora et al., 2000; Campbell et al., 2004; Chowers et al., 1994; Garcia et al., 1991; 
Greenburg et al., 1998; Lundquist et al., 2002; Luo et al., 1997;  Mangasarian et al., 
1997; Miller et al., 1994; Noviello et al., 2008; Pizzato et al., 2007; Renkema et al., 
1999; Schwartz et al., 1996; Simmons et al., 2001; Wei et al., 2005; Wonderlich et al., 
2008).  Nef is defined as a pathogenic factor, because nef-deficient viruses result in 
lower viral burdens and severity of disease in both humans and nonhuman primates 
(Coleman et al., 2001; Greene et al., 2004).   
 The most extensively characterized function of Nef is the down-regulation of CD4 
from the cell surface (Desrosiers et al., 1992; Garcia et al., 1991; Guy et al., 1987). This 
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involves the internalization of cell surface CD4 followed by the endosomal/lysosomal-
mediated degradation.  Nef binds the membrane proximal segment of the CD4 cytosolic 
domain and accumulates CD4 molecles into clathrin-coated pits at the cellular surface 
(Anderson et al., 1994; Garcia et al., 1991; Foti et al., 1997; Hua et al., 1997).  A 
canonical dileucine motif (160EXXXLL165) and the two acidic residues in a structurally 
flexible loop that extends from amino acids 140 to 180, (174(E/D)D175) are required for 
Nef binding to adaptor protein 2 (AP-2) (Grzesiek et al., 1997; Lindwasser et al., 200).  
This binding facilitates the formation of clathrin-coated pits resulting in the internalization 
of CD4 from the cell surface and subsequent lysosomal degradation (Lindwasser et al., 
2008).          
 Secondly, Nef allows infected cells to evade the destruction by cytotoxic T 
lymphocytes (CTLs) by inducing the downregulation of MHC-I molecules from the cell 
surface.  Nef forms a ternary complex between the cytoplasmic tail of MHC-I and 
adaptor protein-1 (AP-1) (Noviello et al., 2008; Wonderlich et al., 2008)).  AP-1 is a 
protein that directs proteins from the trans-Golgi network (TGN) to the endolysosomal 
pathways (Robinson and Bonifacino, 2001).  MHC-I molecules are normally 
phosphorylated and transported to the plasma membrane for antigen presentation; 
however, the ternary complex activates a tyrosine-sorting signal in the cytoplasmic 
cytoplasmic tail of MHC-I.  This allows the newly synthesized MHC-I molecules to be 
diverted from their transit to the plasma membrane to the lysosomes for degradation 
(Noviello et al., 2008; Roeth et al., 2006; Wonderlich et al., 2008).   Nef also has been 
shown to increase the rate of MHC-I down-regulation from the plasma membrane by 
interacting with the phosphofurin acidic cluster sorting protein 1 and/or 2 (PACS-1/2) 
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(Atkins et al., 2008; Noviello et al., 2008; Wonderlich et al., 2008).  However, much of 
this mechanism is still unknown.  For example, we do not know how this process leads 
to activation of the endocytic pathway, and if Nef is blocking the recycling of MHC-I back 
to the plasma membrane, or if Nef delivers the MHCI molecules to the lysosome for 
degradation (Foster and Garcia, 2008).   
 Nef regulates cellular activation through several kinases such as Pak2 and Hck 
(Arora et al., 2000; Briggs et al., 2000; Renkema et al., 1999; Walker et al., 1987).  
Although controversial, supporting data suggested that Nef regulates the actin 
cytoskeleton rearrangment (Fackler et al., 1999; Janardhan et al., 2004; Renkema et 
al., 2001; Rauch et al., 2008).  Nef forms a complex with Pak2 and induces its activation 
early in infection.  P21 activated kinases (PAK) are effectors that link Rho GTPases to 
cytoskeleton rearrangement and nuclear signaling (Agopian et al., 2006; Kirchhoff et al., 
2004; Pulkkinn et al., 2004; Rauch et al., 2008).  Nef also activates the cellular myeloid 
lineage specific Src family of tyrosine kinase, Hck.  This protein can bind to Nef in the 
absence of myristylation leading Nef to form dimer and trimers (Breuer et al., 2006).  
However, it is unknown how Nef dimerizes and activates Hck and how this activation 
enhances pathogenesis.   
 Single cycle infection assays are used to measure how Nef enhances infectivity 
(Campbell et al., 2004; Pizzato et al., 2007; Qi et al., 2007; Qi et al., 2008).  From these 
assays there are currently three models on Nef enhances infection efficiency for HIV-1 
virions without the down-regulation of the CD4 receptor. First, Campbell and colleagues 
showed that if the actin cytoskeleton in the target cell is disrupted the infectivity of the 
virus was able to overcome the nef-deficient virus (Campbell et al., 2004).  This shows 
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that the expression of Nef in the producer cell is able to overcome the cytoskeleton 
barrier of infection.  Secondly, Pizzato and colleagues suggested that an unknown 
cellular protein besides CD4 blocks the function of Env.  Nef downregulates the 
unknown protein in the producer cell, thereby blocking its incorporation into the virion 
and enhancing viral infectivity (Pizzato et al., 2007).  Finally, several studies have 
shown that Nef may protect the viral core from post-fusion degradation allowing reverse 
transcription to continue (Qi et al., 2007; Qi et al., 2008; Wei et al., 2005).   
 
Vpr/Vpx 
 The HIV-2 and SIV primate lentiviruses encode for a vpr gene and a paraolog of 
vpr known as vpx gene, while HIV-1 only encodes for a vpr gene (Campbell et al., 
1997).  Both of these proteins are important for the transport of the pre-integration 
complex (PIC) into the nucleus and inducing cell cycle arrest at the G2/M phase of the 
cell cycle (Lang et al., 1993; Shimura et al., 1999).  Both proteins have a supporting role 
during early infection and are selectively packaged into the virion.  The incorporation 
occurs througha dileucine (LXXLF) motif in the p6 domain of the Gag precursor protein, 
Pr55Gag (Accola et al., 1999; Bachand et al., 1999; Kondo et al., 1995; Lu et al., 1995; 
Paxton et al, 1993; Selig et al., 1999).  In addition, Vpr can regulate apoptosis and 
transactivate the viral promoter (Le Rouzic and Benichou, 2005; Planelles and 
Benichou, 2010).  However, Vpx is essential for viral growth in monocyte-derived 
macrophages (MDMs) and primary T lymphocytes, nuclear import of viral DNA, and is 
critical for reverse transcription in monocyte-derived dendritic and non-dividing cells by 
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promoting the accumulation of full-length DNA (Fletcher et al., 1996; Fujita et al., 2008; 
Goujon et al., 2007; Srivastava et al., 2008).   
 Vpr induces cell cycle arrest at the G2-to-M transition by activation of ataxia 
telangietasia-mutated and Rad-3-related kinase (ATR), which is a sensor for replication 
stress (Roshal et al., 2003).  Vpr also associates with damaged DNA-specific binding 
proteins 1 (DDB1) and Cullin 4-associated factor (DCAF)-1 (Angers et al., 2006; He et 
al., 2006; Higa et al., 2006; Jin et al., 2006).  This recruits the Cul4ADDB1 E3 ligase, 
which is involved in genome stability, DNA replication, and cell cycle arrest by activation 
of the G2 checkpoint (DeHart and Planelles, 2008; Huang and Chen, 2008).  Prolonged 
G2 cell cycle arrest may attribute to Vpr-induced apoptosis; therefore, Vpr-induced 
cytopathicity in macrophages could be due to the absence of ATR signaling 
(Zimmerman et al., 2006).  Also, Vpr inhibits T cell proliferation and modulates immune 
responses through interaction with proteins like the glucocorticoid receptor (Ayyayoo et 
al., 1997).  One of the immune modulatory functions of Vpr is to cause a dysregulation 
in selective co-stimmulatory molecules and cytokines in moncytes, macrophages, and 
dendritic cells (Granelli-Piperno et al., 2004; M et al., 2000; Majumder et al., 2005; 
Mirani et al., 2002; Muthumani et al., 2004; Smed-Sorensen et al., 2004).  
 The Vpr protein is present at the start of the replication cycle.  Vpr-deficient HIV-1 
shows a significant replication defect in primary macrophages, but not in T cells or 
laboratory cell lines (Balliet et al., 1994; Connor et al., 1995).  Vpr has been shown to 
enhance HIV-1 transcription in monocytic cells (Varin et al., 2005). This is due to a 
nuclear localization signal on Vpr that interacts with proteins associcated with the HIV-1 
PIC, such as human uracil-DNA glycosylase (hCGI), nucleoporin, importin alpha, and 
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exporin 1 (Bergamaschi et al., 2009; Chen et al., 2004; Jacquot et al., 2007; Nitahara-
Kasahara et al., 2007; Sherman et al., 2003).  Vpr is not essential for HIV-1 infection of 
macrophages, but depending on the lineage of SIV, is required for replication 
(Bergamaschi et al., 2009; Campbell et al., 1997; Fletcher et al., 1996; Ueno et al., 
2003).  This shows that the vpr genes have significantly diverged and that the 
importance of Vpr in macrophage infection differs between lentiviral lineages.   
 So far, Vpx is not implicated in cell cylce arrest and does not contain a nuclear 
localization signal to import the PIC complex into the nucleus (Fletcher et al., 1996; 
Kappes et al., 1993).   However, Vpx has been shown to be essential for SIVmac 
infection of monocytes and monocyte-derived dendritic cells (Gibs et al., 1995; Goujon 
et al., 2007; 2008; Wolfrum et al., 2007).  In pig-tailed macaques inoculated with 
SIVsmPBjΔvpx, the effect of Vpx deletion was dramatic on viral pathogenicity.  These 
macaques displayed delayed kinetics in viral replication and delayed disease 
manifestations (Gibbs et al., 1995; Hirsch et al., 1998).  Vpx does not minic Vpr as was 
previously suggested, because Vpx is required for infecting monocytes, non-diving 
macrophages, and monocyte-derived dendritic cells (Gibs et al., 1995; Goujon et al., 
2007; 2008; Wolfrum et al., 2007).  Deletion of vpr in these viruses, does not affect the 
requirement for Vpx in HIV-2/SIV infection (Gramberg et al., 2009; Kappes et al., 1993).  
However, similar to Vpr, Vpx uses the DCAF1 unbiquitin ligase to remove cellular 
restriction factors present in macrophages and dendritic cells (Kappes et al., 1993; 
Sharova et al., 2008; Srivastava et al., 2008).  While the ubiquitin ligase machinery has 
been identified, the restriction factor degraded is still unknown.   
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Tat/Rev 
 
 Tat is a transactivator protein that contributes to trans-activation of viral and 
cellular genes (Ju et al., 2009; Mahlknecht et al., 2008; Nekhai et al., 2007).  The HIV-1 
Tat protein is synthesized during the early and late stages of viral replication and is 
variable in length of 86-104 amino acids.  There are five functional domains in Tat, 
which include the N-terminus, the cysteine-rich region, the core, the basic, and the C-
terminal domains.  Also, there is a region known as the protein transduction domain that 
contains a rich-lysine and arginine region that allows Tat to cross the cell membrane. 
(Morris et al., 2001)  The extracellular form of Tat is efficient in cell membrane 
transduction, is released into the microenvironment by productively infected cells and, 
taken up by target cells in the surrounding environment (Ferrari et al., 2003; Zheng et 
al., 2005). Tat has several functions such as chromatin remodeling, phosphorylation of 
RNA polymerase II that is involved in the transcription of full-length viral mRNAs, 
transactivation of viral genes, and binding to nascent leader RNA known as trans-
activation responsive element RNA (TAR) (Ammosova et al., 2006; Richman et al., 
2009; Wong et al., 2005; Yedavalli et al., 2003).  Post-integration of the viral genome, 
the expression of the viral genome is controlled by the enhancer and promoter elements 
located in the (LTR) located at the 5’ end of the integrated genome (Rohr et al., 2003).  
To relieve the LTR, Tat interacts with several chromatin modifying complexes and 
histone modifying enzymes.  For example, Tat recruits histone acetyltransferases 
(HATs) such as CREB-binding protein (CBP/p300) complex to acetylate the 
nucleosomes on the HIV-1 promoter region relieving LTR repression.  This allows RNA 
polymerase II to efficiently transcribe viral genes (Deng et al., 2000; 2001; Pumfry et al., 
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2003).     By Tat changing the conformation of CBP/p300, the CBP/p300 complex is 
better able to bind the basal transcription factors such as the TATA-binding protein and 
transcription factor IIB (Dang et al., 2000; 2001).  In the absence of Tat or cellular 
activation signals, abortive short viral mRNA transcripts are produced due to the 
reduced efficiency with which RNA polymerase II binds the HIV-1 promoter (Pagans et 
al., 2005; Williams et al., 2006).   However, when Tat binds the TAR stem loop structure 
located at the 5’ end of all initiated viral transcripts, the P-TEFb complex composed of 
cellular cyclin T1 and CDK9 proteins is recruited (Williams et al., 2006).  This complex 
phosphorylates serine residues in the C-terminal domain (CTD) of RNA polymerase II 
leading to the synthesis of full-length HIV transcripts (Williams et al., 2006; Zhou et al., 
2003).  Tat also induces the phosphorylation of additional transcription factors including 
Sp1, CREB, the alpha subunit of eukaryotic initiation factor 2 (eIF2α), and NF-κB 
(Demarchi et al., 1998; Li et al., 2005; Rossi et al., 2006; Zauli et al., 2001).    
Tat has been shown to modulate the expression level of other cellular proteins 
such as cytokines, CCR5, IL-2, and CD25, while down regulating cellular proteins such 
as MHC I (Matsui et al., 1996; Mayol et al., 2007; Stettner et al., 2009; Zheng et al., 
2005).   Since Tat can be taken up by uninfected target cells, Tat is able up regulate 
cellular genes to induce additional effects such as the induction of apoptosis and 
immunosuppression (Bennasser and Bahraoui, 2002; Gupta et al., 2008; Ju et al., 2009; 
Poggi and Zocci, 2006; Zheng et al., 2005).   Tat can cross the blood brain barrier 
(BBB) and transverse cells such as neurons causing neurotoxicity, induce the release of 
tumor necrosis factor-α (TNF-α) from macrophages and astrocytes, IL-6 from 
astrocytes, and IL-1β from monocytes, causing apoptosis, which may provide an 
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explanation for the neurodegenerative effects of HIV-1 (Chang et al., 1997a; Chen et 
al., 1997; Nath et al., 1999; Cheng et al., 1998; Magnuson et al., 1995; Song et al., 
2003).   Tat also interacts with both non-polymerized subunits of microtubules and 
polymerized microtubules leading to the mitochondrial induction of apoptosis (de 
Mareuil et al., 2005; Giacca et al., 2005; Vendeville et al., 2004).  Due to this neuronal 
cytoskeleton rearrangement, neuropathogenesis associated with HIV-1 infection may 
occur (Drewes et al, 1998).   
Following integration of the provirus into the host-cell genome, the late phase of 
viral replication begins with transcription of the integrated proviral DNA and subsequent 
splicing and trafficking of viral RNAs (Grewe and Überla, 2010; Freed et al., 2001).  
Transcription from the LTR leads to the generation of unspliced incompletely spliced, 
and multiply spliced RNAs.  These major types of viral transcripts are 1) full length 
unspliced transcript encoding the Pr55Gag and Pr160GagPol precursors and the full length 
HIV-1 ~9-kb RNA genome; 2) singly spliced RNAs that encode for Vif, Vpr, Vpu, and 
Nef proteins; 3) multiply spliced RNAs that encode for Tat, Rev, and Nef proteins.  Rev 
is a 116 amino acid protein that allows mammalian cells to overcome the highly 
selective nuclear export of unspliced or partially spliced mRNAs (Cullen et al., 1998).  
The function of the Rev protein is mediated by two distinct domains: 1) an arginine-rich 
sequence that functions as both a nuclear localization signal (NLS) and an RNA-binding 
domain (RBD); and 2) a leucine-rich sequence located between amino acid residues 75 
to 85 that contains the nuclear export signal (NES) (Böhnlein et al., 1991; Daly et al., 
1989; Fischer et al., 1995; Hope et al., 1990; 1991; Kubota et al., 1989; Malim et al., 
1989; Malim and Cullen, 1991; Malim et al., 1991; Mermer et al., 1990; Meyer et al., 
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1996; Neville et al., 1997; Venkatesh et al., 1990; Weichselbraun et al., 1992; Wen et 
al., 1995; Zapp et al., 1991; Zapp and Green, 1989).   During the early stage of 
infection, HIV-1 full-length RNAs are expressed in the nucleus and gradually spliced to 
completion.  These spliced RNAs are exported from the nucleus using the cellular 
mRNA export pathway and lead to the synthesis of Tat, Nef, and Rev. Following 
translation, Tat and Rev are transported back into the nucleus using nuclear localization 
signals (NLS) to assist in viral transcription.  After enough Rev protein is expressed, 
nuclear export of both partially and unspliced transcripts occurs leading to the 
translation of all viral proteins (Cullen, 1998). 
Rev function is mediated by binding a cis-acting viral RNA stem-loop structure 
located in the env gene known as the Rev response element (RRE) (Malim et al., 1989).  
This interaction induces multimerization of Rev molecules to the RRE.  Ran-GTP bound 
exportin 1 binds to the NES of Rev forming a complex required for the docking and 
translocation through the nuclear pore into the cytoplasm (Fornerod et al., 1997; Neville 
et al., 1997; Stade et al., 1997).  Once the complex is translocated to the cytoplasm, the 
hydrolysis of Ran-GFP to Ran-GDP occurs inducing the release Rev from the complex.  
In the cytoplasm, Rev then binds importin-β and translocates back into the nucleus.  
Following translocation to the nucleus, the importin-β/Rev complex interacts with Ran-
GTP and disassembles to release Rev back into the nucleus (Henderson et a., 1997; 
Palmeri et al., 1998).   
 
Vpu 
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 Vpu is an 81 amino acid type I integral membrane protein.  Amino acid residues 
1-27 constitute the N-terminal membrane anchor followed by 54 residues that extend 
into the cytoplasm.  The cytoplasmic component consists of a highly conserved region 
spanning amino acid residues 47-58 that contain a pair of serine residues that are 
consitutively phosphorylated by casein kinase II (Schubert et al., 1994; Tiganos et al., 
1998).  The cytoplasmic domain of Vpu contains two α-helical structures comprised of 
amino acid residues 35-50 and 58-70 separated by a flexible segment containing two 
conserved serine residues that are phosphorylated (Federau et al., 1996; Henklein et 
al., 1993; Kochendoerfer et al., 2004; Wittlich et al., 2009; Wray et al., 1995; Zheng et 
al., 2003).  HIV-1 infected cells show that Vpu interacts with several host factors such 
as CD4, β-TrCP, and BST-2.  Also, homo-oligomerization of Vpu creates a pentameric 
complex to form cation-selective membrane pores (Ewart et al., 1996; Grice et al., 1997; 
Kruger and Fischer, 2009; 2010; Park et al., 2003; Schubert et al., 1996).  
 One function of Vpu is to induce the degradation of CD4.  The Env precursor 
gp160 blocks the trafficking of newly synthesized CD4 by binding and forming stable 
complexes that are retained in the endoplasmic reticulum (ER) (Bour et al., 1991; Crise 
et al., 1990; Jabbar and Nayak, 1990).  The cytoplasmic domain of Vpu interacts with 
the cytoplasmic domain of CD4 complexed with Env in the ER to target CD4 for 
proteosomal degradation (Bour et al., 1995; Margottin et al., 1996).  The two-conserved 
serine residues at amino acid positions 52 and 56 in the cytoplasmic domain of Vpu are 
phosphorylated and interact with the WD repeats of human beta Transducin-repeat 
Containing Protein (β-TrCP) (Margottin et al., 1998; Neer et al., 1994).  Human β-TrCP 
contains seven C-terminal WD repeats to mediate protein-protein interaction and an F-
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box domain that acts to connect target proteins to the ubiquitin-dependent proteolytic 
pathway (Bai et al., 1996; Neer et al., 1994).   
 A second function of Vpu is the regulation of virus release from HIV-1 infected 
cells (Strebel et al., 1988; Terwilliger et al., 1989).  There have been a number of 
different models that propose the regulation of virus release by Vpu.  First, virus release 
is regulated by the Vpu-associated ion channel activity.  When the transmembrane 
domain of Vpu is scrambled, the ion channel activity is inhibited resulting in the 
impairment of Vpu to regulate virus release but not CD4 degradation (Schubert et al., 
1996).  Secondly, Vpu may form heter-oligomeric complexes that interfere with the 
activity of TASK-1, a cellular ion channel (Hsu et al., 2004).  In the third model, the 
dependence on Vpu for virus release is cell-type specific (Varthakavi et al., 2003).  In 
addition to TASK-1, other host factors, such as BST-2, have been identified that are 
associated with inhibited virus reelase (Neil et al., 2008; Van Damme et al., 2008).   
BST-2 is a 180 amino acid type II transmembrane protein that was originally identified 
as a membrane protein in terminally differentiated human B cells of patients with 
multiple myeloma (Goto et al., 1994; Ohtomo et al., 1999; Ishikawa et al., 1995).   This 
protein consists of an N-terminal transmembrane domain and a C-terminal 
glycosylphosphatidylinositol (GPI) anchor that allows BST-2 to associate with lipid rafts 
at the cell surface and on internal membranes such as the Trans-Golgi Network (TGN) 
(Dube et al., 2009; Kupzig et al., 2003; Masuyama et al., 2009).  The ectodomain of 
BST-2 can form stable cysteine-linked dimmers that are critical for the inhibition of HIV-
1 release (Andrew et al., 2009; Perez-Caballero et al., 2009).  However, BST-2 positive 
cells that are infected with HIV-1ΔVpu accumulate virions at the cell surface.  The BST-
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2 N-terminal transmembrane domain and its C-terminal GPI anchor tethers together 
fully detached virions to the producer cell (Neil et al., 2008).  In wild type virus, BST-2 is 
redistributed from the plasma membrane into early endosomes through clathrin-
mediated endocytosis (Habermann et al., 2010; Neil et al., 2006; Mitchell et al., 2009; 
Rollason et al., 2007).  Vpu interacts with BST-2 in endosomes and the TGN to 
downregulate BST-2 from the cell surface increasing virus release (Douglas et al., 2009; 
Dube et al., 2009; Habermann et al., 2010; Le Tortorex and Neil, 2009; Mitchell et al., 
2009; Miyagi et al., 2009; Neil et al., 2008; Pardieu et al., 2010; Rollason et al., 2007; 
Sato et al., 2009; Schindler et al., 2010; Van Damme et al., 2008).   
 
 
Pathogenesis  
 HIV-1 is transmitted through sexual contact and by direct blood-to-blood contact.  
The blood-to-blood contact includes intravenous drug users, occupational accidental 
needle sticks, transfusions, and vertical mother-to-child perinatal transmission (Curran 
et al., 1988; Parazzini et al., 1995).  HIV-1 is the etiological agent of AIDS and results in 
a depletion of helper CD4+ T lymphocytes resulting in the loss of immune competence 
(Stevenson et al., 2003).  The slow continuous depletion of CD4+ lymphocytes during 
the infection results in damaged immune defense leading to the susceptibility to 
opportunistic infections that eventually leads to death.  The exact mechanism for the 
depletion of CD4+ lymphocytes is still unknown.  There are two working hypothesis to 
identify the mechanism by which HIV causes disease.  In the first hypothesis, it is 
thought that HIV causes a major depletion of CD4+ T lymphocytes by direct infection 
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and apoptosis.  The second hypothesis considers that HIV infection is indirectly 
impairing cell function by a possible aberrant reaction of the immune response to the 
infection (Stevenson et al., 2003).  A deeper understanding of viral replication, host 
response, reservoirs, and viral pathogenicity will help identify answers to these 
unanswered questions.   
 HIV infection can be divided into three phases:  acute primary infection, 
asymptomatic infection, and symptomatic infection and AIDS (Coffin et al., 1995).  
During the acute phase of infection, ~50% of the patients remain asymptomatic, while 
~50% develop flu-like symptoms such as as fever, headache, sore muscles and joints, 
stomachache, swollen lymph glands, and/or rash, during the first four weeks of 
infection.  During primary infection viral loads in the peripheral blood are high and the 
virus disseminates to many lymphoid and non-lymphoid tissues (Piatak et al., 1993).  
Following the acute phase, the asymptomatic carrier state begins and lasts between 10 
to 12 years in an untreated typical progressor patient.  During this stage, viral replication 
remains steady and there is a gradual decline in the number of circulating CD4+ T cells.  
Virus is persistently replicating in the primary and secondary lymph nodes and there is a 
rapid turn over of plasma virions and CD4+ T lymphocytes (Embertson et al., 1993; 
Pantaleo et al., 1993; Ho et al., 1995; Wei et al., 1995).  This stage is also known as 
clinical latency.  Eventually, the continuous damage to the immune system results in an 
increase in viral loads and life-threatening AIDS-defining diseases emerge (Sierra et al., 
2005).   When infected individuals establish clinical AIDS, the circulating CD4+ T 
lymphocytes decline to below 200 cells per microliter and/or the patient acquires an 
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AIDS-defining illness such as opportunistic infection(s), cancer(s), and/or HIV-related 
enecephalopathy (Coffin et al., 1995).   
 Between 5-10% of patients are classified as rapid progressors and develop AIDS 
within 3-4 years following infection with HIV-1.  These patients do not develop clinical 
latency, but continue to exhibit high viral loads and display a rapid decrease in the level 
of circulating CD4+ T lymphocytes (Arens et al., 1993; Bollinger et al., 1996; Demarest 
et al., 2001).  There are HIV-1 patients that exhibit high viral loads initially during 
primary infection and then continue to present with low viral burdens for an extended 
period of infection.    These individuals represent ~5% of the patients infected and are 
termed long-term non-progressors (LTNP).  The level of circulating CD4+ T 
lymphocytes remains stable in these patients, and these individuals remain 
asymptomatic.  These patients also display a strong qualitative and quantitative HIV-1 
specific cytotoxic T-lymphocyte (CTL) response (Migueles et al., 2002).  LTNP may 
result due to host/cellular restriction factors, attenuated HIV-1 due to mutations in nef 
(Δnef), or genetic polymorphisms that impair or abrogate expression of coreceptor 
proteins (CCR5Δ32) (Coffin et al., 1995; Deacon et al., 1995; Kirchhoff et al., 1995).   
 Additionally, HIV-1 invades the central nervous system early during infection and 
can cause persistent infection of the brain and inflammation (Shapshak et al., 2011).  
This infection can result in neurodegenerative disease known as neuroAIDS.  The 
severity of this disease can range from asymptomatic neurocognitive impairment (ANI), 
in a mild neurocognitive disorder (MND), or be full-blown HIV-associated dementia 
(HAD) in infected patients (Antinori et al., 2007; Shapshak et al., 2011).  These HIV-
associated neurocognitive disorders (HAND) are influenced by host and viral 
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characteristics, co-morbid factors, substance abuse, and HARRT therapy (Bhaskaran et 
al., 2008).  HAND is thought to occur by HIV-1 infected macrophages/monocytes 
transversing the tight junctions of the cerebral endothelial cells (CECs) of the blood 
brain barrier (BBB).  Once past the BBB, the monocytes differentiate into 
macrophages/microglia cells (Shapshak et al., 2011).  HIV-1 activates these 
macrophages/microglia and astrocyte cells causing the production of pro-inflammatory 
cytokines resulting in neuronal toxicity (Borjabad et al., 2009; Kaul et al., 2001; Minagar 
et al., 2004; Shapshak et al., 2004).  Unfortunately, few anti-retroviral drugs treat 
neuroAIDS effectively because they are unable to penetrate the BBB.  However, there 
are studies underway working to search for a way to either deliver a therapeutic drug to 
bypass the BBB or to create new therapeutics to treat these conditions (Shapshak et al., 
2011).  
 
Endogenous Retroelements 
 Genomic structural variations (SVs) are common in the human genome and 
occur through insertions, deletions, inversions, duplications, and translocations. Due to 
their mobility, abundance, and high sequence identity, transposable elements (TEs) are 
usually involved in creating genomic SVs (Konkel et al., 2010).  Retrotransposons are 
TEs that use an RNA intermediate, are reverse transcribed, and move within the 
genome through a copy-and-paste mechanism (Batzer et al., 2002; Ostertag et al., 
2001).  Based on the presence or absence of long terminal repeats (LTRs), 
retrotransposons can be divided into two groups: non-LTR retrotransposons or LTR-
retrotransposons (Konkel et al., 2010).    Besides the non-LTR elements listed, there 
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are inactive old non-LTR retrotransposons encompassing approximently 6% of the 
human genome (Lander et al., 2001).  LTR retrotransposons are the endogenous 
retroviruses and comprise approximently 8% of the human genome. However, there are 
no active LTR retrotransposones in the human genome today (Lander et al, 2001; Mills 
et al., 2007).   
 Non-LTR retrotransposons are comprised of three different families: long 
interspersed nuclear elements 1 (LINE1 or L1), Alu elements (a short interspersed 
element or SINE), and SVA (named after composite parts; SINE-R, VNTR (variable 
number of tandem repeats) (Cordaux et al., 2009; Belancio et al., 2008; Batzer et al., 
2002; Bennett et al., 2008; Lander et al., 2001).  L1s comprise about 17% (>500,000 
copies) of the human genome and display evidence of ongoing activity for over the past 
160 million years (Lander et al., 2001). Most L1 insertions are retrotranspositionally 
incompetent due to truncations and debilitating mutations; therefore, only ~80 to 100 
retrotrasnposition competent L1s have been identified in the human genome (Brouha et 
al., 2003; Lander et al., 2001).  L1s are known as autonomous retrotransposons that are 
currently mobilizing and at full-length are approximently 6-kb (Lander et al., 2001; 
Swergold et al., 1990).  The element consists of a 5’UTR containing an internal RNA 
polymerase II (RNAPII) promoter, two open reading frams (ORF 1 and ORF 2), and a 
3’UTR containing a polyadenylation signal ending with an oligo(dA)-rich tail of variable 
length (Figure 6) (Babushok et al., 2007; Swergold et al., 1990).  ORF1 encodes for a 
protein involved in RNA binding and ORF2 encodes for a protein that contains both 
endonuclease and reverse transcriptase activity (Feng et al., 1996; Jurka et al., 1997; 
Martin et al., 2003; Mathias et al., 1991).   
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 L1 retrotransposition duplication begins with RNA polymerase II transcription of 
the L1 gene locus from an internal promoter (Figure 6).  Initiation of transcription occurs 
at the 5’ end of the L1 element and the internal promoter generates autonomous 
duplicate copies at multiple locations in the genome (Lavie et al., 2004; Swergold et al., 
1990).  L1 RNA is then exported to the cytoplasm where ORF1 and ORF2 are 
translated.  ORF1 and ORF2 bind the L1 RNA transcript in a cis fashion and produce a 
ribonucleoprotein (RNP) complex that is transported back into the nucleus by an 
unknown mechanism (Lavie et al., 2004; Swergold et al., 1990; Wei et al., 2001).  The 
integration of L1 into the genome occurs through a process referred to as target-primed 
reverse transcription (TPRT) (Cost et al., 2002; Feng et al., 1996; Moran et al., 1996).  
The L1 endonuclease cleaves the first strand of target DNA, at 5’-TTTTAA-3’ consensus 
sites (Jurka et al., 1997).  The free 3’ hydroxyl generated by the DNA nick is used to 
prime the reverse transcription of L1 RNA by the L1 reverse transcriptase.  The second 
strand of the target DNA is cleaved and used to prime second strand synthesis by 
unidentified mechanisms.  It is thought that host repair systems are involved 
(Beauregard et al., 2008; Gasior et al., 2006; Gilbert et al., 2005; Ichiyanagi et al., 2007; 
Zingler et al., 2005).  Since there are frequent staggered breaks in the host DNA at the 
insertion site, the retrotransposon is flanked by short stretches of host DNA between 6-
20 base pairs in length and is referred to as target site duplications (TSD) (Feng et al., 
1996; Szak et al., 2002).   A variation of TPRT can also occur call “twin priming.” When 
inversions are formed, the second strand of DNA is cleaved during reverse transcription 
of the first strand.  The 3’OH of the second strand acts as a primer for the reverse 
transcription on the L1 RNA and the resolution of this second cDNA produces the 
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inversion (Kriegs et al., 2007; Bejerano et al., 2006).  Furthermore, it is thought that Alu 
and SVA retrotransposition occurs through the TPRT process using the L1 reverse 
trasncriptase machinery.  However, most of this process has remained elusive 
(Dewannieux et al., 2003; Ostertag et al., 2003; Wang et al., 2005).   
 There are greater than 1 million Alu copies in the human genome, making this 
element the most successful TE in the human genome.  This element is non-
autonomous and relies on the enzymatic machinery of L1 to complete retrotransposition 
(Wei et al., 2001; Weiner et al., 1986).  Alu elements are approximently 300 base pairs 
long and is dimeric in structure.  This element is formed by the fusion of two monomers 
originally derived from the 7SL RNA gene (Kriegs et al., 2007).  The two monomers of 
Alu are divided by an A-rich linker.  The 5’ region contains an internal RNA polymerase 
III, while the 3’ region contains a polyadenylation signal ending with an oligo(dA)-rich tail 
of a variable length (Figure 6) (Babushok et al., 2007; Swergold et al., 1990).  There is 
no termination signal for the RNA polymerase III, so the transcripts extend into the 
downstream flanking sequences until a terminator can be found (Comeaux et al., 2009; 
Shaikh et al., 1997).   
 SVA elements are less characterized with approximently 3,000 copies existing in 
the human genome (Ostertag et al., 2003; Wang et al., 2005).  This element is non-
autonomous and requires the enzymatic machinery of the L1 retrotransposon.  Similar 
to L1 elements, SVA elements are often truncated and terminate in a polyadenylation 
signal followed by a polyA tail (Ostertag et al., 2003; Wang et al., 2005).  SVA elements 
are approximently 2-kb in length and are composed of a hexamer repeat region, an Alu  
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Figure 6.  Schematic representation of the non-LTR retrotransposon structure.  
(A) The L1 element consists of a 5’UTR, two open reading frames (ORF1 and 
ORF2), and a 3’UTR.  The 5’UTR contains an internal RNA polymerase II promoter 
(gray box).  The element ends with a oligo(dA)-rich tail (AAA) preceded by a 
polyadenylation signal (pA).  (B) The Alu element consists of two related 
monomers separated by an A-rich linker (consensus sequence A5TACA6).  The 
left monomer consists of A and B boxes (gray boxes).  These boxes are 
transcriptional promoters for RNA polymerase III.  The 3’ end of the element 
contains an oligo(dA)-rich tail (AAA) that can be up to 100 base pairs long.  (C) 
The SVA element (from 5’ to 3’) consists of a (CCTCT)n hexamer repeat region, an 
Alu-like domain containing two antisense Alu fragments with additional 
sequences of unknown origin, a 35-50 base pair (VNTR) region derived from 
envelope polyprotein (env), and the 3’LTR of the human endogenous retrovirus 
(HERV)-K10.  The 3’ end of this element is an oligo(dA)-rich tail preceded by a 
polyadenylation signal similar to that observed in (A).  All three elements are 
flanked with target site duplications (not shown) that are generated post 
integration.      
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like region, a VNTR (variable number of tandem repeats), a HERV-K10-like region, and 
a polyadenylation signal ending with a oligo(dA)-rich tail of variable length (Figure 6) 
(Ostertag et al., 2003; Wang et al., 2005).  However, there is no internal promoter 
suggesting that promoter activity comes from flanking regions and that the element may 
be transcribed by RNA polymerase II (Ostertag et al., 2003; Wang et al., 2005).  
 LTR retrotransposons are very similar to exogenous retroviruses in structure.  
They contain two LTR’s at the 5’ and 3’ end of the element, slighty overlapping ORFs 
for gag, protease, and a pol gene, which encodes for the reverse transcriptase, 
endonuclease, integrase, and ribonuclease H (Kazazian et al., 2004; Voytas et al., 
2002).  LTR elements either lack or encode for a remnant of an env gene.  
Retrotransposition reverse transcription is essentially like retroviral reverse transcription, 
and the LTR retrotransposon RNA is made within the cytoplasm (Voytak et al., 2002). 
Some examples of LTR retrotransposons that are responsible for the majority of 
insertions are yeast Ty1 elements (Saccharomyces cerevisiae), IAP elements 
(intracisternal A-particles), MusD ETns (early transposons, and MaLR elements 
(mammalian LTR-retrotransposons). Most of these mobile elements are found in mice 
and are not present in humans, are essentially defective, and the reverse transcriptase 
source is still unknown (Kazazian et al., 2004k). However, IAPs and MusD elements are 
still highly mobile in the mouse genome (Maksakova et al., 2006).  It is important to note 
that unlike human, endogenous retroelements in the mouse genome are 5-fold more 
abundant than in the human genome (Maksakova et al., 2006).  In the human genome, 
although none of the HERVs are currently active, sequences can be recovered and 
reconstructed to study (Lee et al., 2007).   
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Disruption of coding or regulatory sequences due to deleterious insertions can 
occur due to non-LTR retrotransposons (Belancio et al., 2008a; Callinan et al., 2006; 
Chen et al., 2005; Deininger et al., 1999).   This can ultimately disrupt splice sites and 
cause exon skipping altering gene expression and increase the risk of certain diseases 
like cancer (Belancio et al., 2008b; Belancio et al., 2009; Chen et al., 2008; Chen et al., 
2006; Han et al., 2005; Landry et al., 2001; Perepelitsa-Belancio et al., 2003; Sobczak 
et al., 2002).    Recent research has shown that a family of cytidine deaminases, 
APOBEC3 (apolipoprotein B mRNA-editing enzyme catalytic- polypeptide like 3), are 
capable of either introducing mutations into retroelement DNA or inhibiting 
retrotransposition in the absence of editing (Chen et al., 2006; Esnault et al., 2005).  
This is due to these retroelements undergoing a reverse transcription process 
analogous to exogenous retroviruses like HIV-1.  These APOBEC3 proteins exude dual 
inhibitory effects on these endogenous retroviruses such as decreasing the number of 
transposed cDNA copies and extensive editing of the transposed copies (Esnault et al., 
2005; Esnault et al., 2006).  This material will be discussed in more detail later in the 
Introduction.   
 
SHIV/Macaque Model of Infection  
 Simian-human immunodeficiency virus (SHIV) is a chimeric virus consisting of 
HIV-1 tat, rev, vpu, and env genes in the genetic background of pathogenic SIVmac239 
(Figure 7).  The pathogenic SHIV model has allowed researchers to study the role of 
specific genes in HIV-1 using the SHIV/macaque model of infection.  Using this model, 
HIV-1 pathogenesis can be studied using non-human primates to evaluate mutations in  
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Figure 7.  Schematic representation of SHIV.  SIVmac239 genes are encoded in 
blue and HIV-1 genes are encoded in yellow.    
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HIV-1 env and vpu within the context of viral transmission, pathogenesis, and immune 
responses.  SHIVs are known to cause AIDS and productive central nervous system 
(CNS) infection in rhesus macaques (Joag et al., 1997; Raghavan et al., 1997).   
Originally, the SHIV constructed (SHIV-4) was able to infect both rhesus and pig-tailed 
macaques and cause a persistent infection.  However, these macaques did not develop 
a loss in circulating CD4+ T lymphocytes and did not develop an AIDS-like disease.  
SHIV-4 was passaged through a series of rhesus and pig-tailed macaques yielding 
pathogenic variants that developed a rapid loss of circulating CD4+ T lymphocytes, 
replicated to extremely high titers, and showed severe lymphoid depletion.  Within eight 
months to a year, these macaques developed AIDS, neurological and end-stage renal 
disease. Also, SHIV contains unique structural motifs in gp160 of HIV-1, which allows 
SHIV to use the co-receptor CXCR4 similar to HIV-1 infection in humans (Joag et al., 
1997; Karlsson et al., 1997; Liu et al., 1999; Shibata et al., 1997).  Our laboratory uses 
the pathogenic SHIV variants SHIVKU-1bMC33 and SHIVKU-2MC4, which have been shown to 
cause a rapid loss of CD4+ T lymphocytes eventually resulting in the development of 
AIDS six to eight months post-infection (Liu et al., 1999; Narayan et al., 1999; 
McCormick-Davis et al., 2000a).   
  
HIV-1 Vif Phenotype 
 The Vif protein is highly conserved among all lentiviruses, except for equine 
infectious anemia virus (EIAV), and is necessary for the production of infectious virus 
from CD4+ T cells and macrophages (Fisher et al., 1987; Strebel et al., 1987).  Viruses 
lacking a functional vif gene fail to mount a spreading infection in cells termed 
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“nonpermissive.” These nonpermissive cells include CD4+ T cells, macrophages, and 
some T cell leukemia lines, such as H9, HuT78, C8166, and MT2 cells (Gabuzda et al., 
1992; Sova et al., 1993; von Schwedler et al., 1993).  These nonpermissive cells 
support the normal production of HIV-1Δvif virions, but are unable to productively infect 
the next target cell (Gabuzda et al., 1992; Sova et al., 1993; von Schwedler et al., 
1993).  Conversely, Vif is dispensable for the production of infectious virus from cells 
termed “permissive (Gabuzda et al., 1992; von Schwedler et al., 1993).”  These 
permissive cells include T cell lines, such as Jurkat, SupT1, and CEM-SS cells, as well 
as nonhematopoietic cell lines, such as, HeLa, 293T, and COS cells (Gabuzda et al., 
1992; Sova et al., 1993; von Schwedler et al., 1993).  This particular “Vif phenotype” 
was found to be producer cell dependent, because experiments showed that 
transcomplementation of Vif in the producer cell was successful in rescuing viral 
infectivity (Strebel et al., 1987; von Schwedler et al., 1993).  However, expression of Vif 
in the target cell had no effect (Strebel et al., 1987).  Therefore, it was proposed that 
either Vif overcomes the effect of a negative factor in the nonpermissive cells or that 
permissive cells may express a host factor that influences viral infectivity.  
 
Identification of a Vif Sensitive Anti-HIV-1 Factor 
 Using subtractive hybridization techniques, Sheehy and colleagues showed that 
nonpermissive cells produced an endogenous inhibitor, CEM15 or Apobec3G, which 
prevented the infectious spread of HIV-1 in the absence of Vif (Sheehy et al., 2002).  
CEM-SS (nonpermissive) cells pseudotyped with VSV-G (vesicular stomatitis virus 
envelope protein) were infected with HIV-1ΔvifΔenv and incubated with CEM 
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(permissive) cells expressing HIV-1 Env (Sheehy et al., 2002).  Heterokaryons formed 
due to the fusion of CD4/CXCR4 receptors present on both nonpermissive and 
permissive cells.  When progeny virions (HIV-1Δvif) were incubated with CEM-SS cells, 
no spreading infection resulted and HIV-1Δvif replication was inhibited (Madani et al., 
1998; Simon et al, 1998; Sheehy et al., 2002).  However, when the Vif protein was re-
introduced into the virus, spreading infection resulted and the inhibition was relieved.  
Then using subtractive cloning, cDNA from the permissive (CEM) cell line was 
subtracted from the nonpermissive (CEM-SS) cell line to identify the cDNA clone 
CEM15.  This Vif-sensitive antiviral cytidine deaminase is now known as APOBEC3G 
(apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, or hA3G).  To 
validate its identity, cDNA from hA3G was transfected into permissive cells, and hA3G 
was sufficient to convert these cells into a permissive state without affecting the number 
of virions released (Sheehy et al., 2002).   
 
 APOBEC Family of Cytidine Deaminases 
 The APOBEC family of cytidine deaminases in human consists of activation-
induced deaminase (AID), APOBEC1, APOBEC2, APOBEC3A-H, and APOBEC4 
(Conticello et al., 2005; Jarmuz et al., 2002; OhAinle et al., 2006; Rogozin et al., 2005). 
These tissue restricted cytidine deaminases exhibit either RNA editing and/or DNA 
mutating activity by hydrolytic deamination of dC to dU (Harris et al., 2002; Teng et al., 
1993). The gene for AID is located on human chromosome 12 and is important for 
humoral immune and required in activated germinal center B cells during antibody 
affinity maturation (Muramatsu et al., 2000).  AID introduces dC to dU mutations in 
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single-stranded DNA substrates of specific sequence hotspots on the VDJ region of the 
immunoglobulin gene (Ig) by initiating somatic hypermutation (Bransteitter et al., 2003; 
Langlois et al., 2005; Neuberger et al., 2003; Pham et al., 2003).  Hypermutation of the 
Ig gene enhances the affinity with which the antibody binds to and neutralizes antigens.  
AID also initiates class switch recombination, enabling the expression of various 
antibody isotypes by deamination events that lead to DNA double-stranded breaks 
required for the switching of constant regions of the Ig gene (Schrader et al., 2009).   
Individuals who lack a functional AID suffer from severe recurrent inflammatory and 
autoimmune disorders, whereas individuals who have abnormal AID function suffer 
various large B cell lymphomas and non-Hodgkin’s lymphomas (Alce et al., 2004; Luo et 
al., 2004; Revy et al., 2000; Svarovskaia et al., 2004).   
 APOBEC1 (Apo1) is also located in tandem with AID on human chromosome 12 
and is primarily expressed in gastrointestinal tissue with a well-characterized role in lipid 
metabolism (Powell et al., 1987; Rogozin et al., 2005; Teng et al., 1993).  Apo1 is the 
central component of an RNA editosome complex that deaminates the cytidine-6,666 in 
apolipoprotein B (apoB) mRNA producing two isoforms of the apoB protein (Powell et 
al., 1987; Rogozin et al., 2005; Teng et al., 1993).  The full-length apoB100 protein 
mediates the transport of endogenously produced triglycerides and cholesterol in the 
blood (Powell et al., 1987; Yamanaka et al., 1995), and the truncated apoB48 protein 
regulates the absorption and transport of exogenous dietary lipids from the intestines to 
the tissues (Yamanaka et al., 1995).  Apo1 is the most extensively studied APOBEC 
protein and the only APOBEC protein that requires RNA as its substrate.  Over 
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expression of Apo1 in transgenic rabbits and mice led to both liver dysplasia and 
hepatocellular carcinomas (Yamanaka et al., 1995).   
 APOBEC2 (Apo2) is located on human chromosome 6 and is expressed 
specifically in skeletal muscle and heart (Jarmuz et al., 2002; Prochnow et al., 2007).  
Apo2 has proved to be the most enigmatic APOBEC to characterize given that its 
enzymatic activity is unrelated to its paralogs (Anant et al., 2001; Harris et al., 2002; 
Liao et al., 1999; Miki et al., 2005).  Similar to Apo2, APOBEC4 (Apo4), which is located 
on human chromosome 1, is very poorly understood.  Apo4 is primarily expressed in the 
testes, has low sequence similarity to the other AID/APOBEC proteins, and its function 
is unknown (Rogozin et al., 2005; Conticello et al., 2007).  The ancestry of Apo4 reveals 
possible connections to tRNA-editing enzymes that may provide clues as to the origin of 
the APOBEC family of cytidine deaminases (Conticello et al., 2007).   
 APOBEC3 (A3) genes are unique to mammals and were first identified as 
paralogs to Apo1 (Jarmuz et al., 2002).  There are a total of seven A3 genes in humans, 
four in felines, six in horse, two to three in artiodactyls, and a single gene in the mouse 
(Bogerd et al., 2008; Conticello et al., 2005; Conticello et al., 2008; LaRue et al., 2008; 
Munk et al., 2008).  All seven A3 genes in humans are tandemly arrayed on 
chromosome 22 and arose through gene duplication of a single-copy primordial gene 
(Conticello et al., 2008; Jarmuz et al., 2002).  These include APOBEC3A (A3A), 
APOBEC3B (A3B), APOBEC3C (A3C), APOBEC3D (A3D), APOBEC3F (A3F), 
APOBEC3G (A3G), and APOBEC3H (A3H) (Jarmuz et al., 2002).  The A3 genes in 
humans demonstrate a high degree of polymorphic variation; for example, Apobec3H, 
which suggests that these genes are under strong selective pressure (Munk et al., 
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2008; OhAinle et al., 2006; OhAinle et al., 2008; Sawyer et al., 2004; Takeda et al., 
2008; Zhang et al., 2004).  The A3 family of cytidine deaminases play an important role 
in the innate host immune response to inhibit a wide range of retroviruses, 
retrotransposons, hepadnaviruses, papillomavirus, foamy viruses, and parvoviruses 
(Abe et al., 2009; Baumert et al., 2007; Bonvin and Greeve, 2007; Bonvin et al., 2006; 
Chen et al., 2006; Henry et al., 2009; Jarmuz et al., 2002; Köck and Blum et al., 2008; 
Mahieux et al., 2005; Narvaiza et al., 2009; Noguchi et al., 2007; Paprotka et al., 2010; 
Sheehy et al., 2002; Strebel et al., 2005; Turelli et al., 2004; Vartanian et al., 2008; 
Zhang et al., 2008).  However, the majority of the research on A3 proteins has been on 
A3G and A3F, which display the most potent antiviral activity against HIV-1 and SIV.   
 
Structural Characteristics of APOBEC Cytidine Deaminases 
 All APOBEC cytidine deaminase family members contain a short α-helical 
domain followed by a catalytic domain (CD), a short linker peptide, and a 
pseudocatalytic domain (PCD) (Jarmuz et al., 2002).  Each catalytic domain is 
characterized by a highly conserved sequence required for cytidine deamination, C/H-X-
E-X23-28-P-C-X2-4-C.  The histidine and cysteine residues coordinate Zn2+, while the 
critical glutamate residue is involved in the proton shuttle (Betts et al., 1994; Iwatani et 
al., 2006; Jarmuz et al., 2002; Wedekind et al., 2003; Xie et al., 2004).  The catalytic 
domain of A3 proteins undergo the hydrolytic deamination at the C4 position of 2’-
deoxycytidine using the conserved amino acids described above.  The 2’-deoxycytidine 
is converted to 2’-deoxyuridine in the presence of water due to the removal of an amine 
group (Figure 8) (Rada et al., 2002).  While there is no high-resolution crystal structure, 
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several structural studies of the C-terminal cytidine deaminase domain (CDA; residues 
198-384) of A3G and the single domain of Apo2 have shown that the CDA core consists 
of five β strands flanked by α-helices on either side and appropriate connecting loops 
(Chen et al., 2008; Furukawa et al., 2009; Harjes et al., 2009; Holden et al., 2008; 
Prochnow et al., 2007; Zhang et al., 2007).  
 The members of the APOBEC family of cytidine deaminases contain either one 
or two CDA domains.  Apo1, AID, Apo2, A3A, A3C, A3H, and Apo4 contain only one 
CDA, while A3B, A3D, A3F, and A3G contain two CDAs (Figure 8).  The APOBEC 
proteins containing two CDAs, usually only have one domain that is catalytically active 
and required for species specificity, while the other CDA is involved in nucleic acid 
binding/sequence specificity, subcellular localization, and virion incorporation (Bogerd et 
al., 2007; Hache et al, 2005; Iwatani et al., 2006; Jonsson et al., 2006; Opi et al., 2006; 
Navarro et al., 2005; Newman et al., 2005).  However, A3B is an exception because 
one report found both CDAs to be catalytically active (Bogerd et al., 2007). 
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Figure 8.  APOBEC family of cytidine deaminases.  A) APOBEC family members 
contain wither one or two CDA domain.  The APOBEC proteins are aligned by 
their catalytically active CDA domain, depicted in purple, or their catalytically 
inactive CDA domain, depicted in red.  The specific APOBEC protein is shown on 
the left and the consensus sequence is shown at the bottom.  B) During 
deamination the 2’-deoxycytidine is converted 20 2’-deoxyuridine as a result of 
the removal of an amine group in the presence of water.  
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The N-terminus of double CDA A3 proteins mediate RNA binding, while the C-
terminus mediates sequence specific cytidine deamination of single-stranded DNA 
(Friew et al., 2009; Gooch and Cullen et al., 2008; Hache et al., 2005; Iwatani et al., 
2006; Li et al., 2004; Navarro et al., 2005).  When mutations are introduced into the N-
terminus of A3G (residues 124-127), the RNA-binding properties of A3G are impaired 
and A3G is no longer incorporated into budding virions (Burnett and Spearman, 2007; 
Huthoff et al., 2009; Huthoff and Malim, 2007; Navarro et al., 2005).  The double CDA 
A3 proteins are also capable of both homo- and heter-oligomerization, forming higher 
order multimers in cells that are stabilized by RNA (Bennett et al., 2008; Burnett et al., 
2007; Friew et al., 2009; Jarmuz et al., 2002; Navarro et al., 2005).  For example, 
APOBEC3G forms homo-multimers, which do not appear to be essential for its catalytic 
activity or virion incorporation, but allow A3G to be form multi-protein complexes of high 
molecular mass (HMM) (Opi et al., 2006).   
Since the deamination sequence is organized in a modular fashion at the 
APOBEC3 locus, the CDA domains are also characterized as either single or double Z-
domain proteins (Jarmuz et al., 2002; Liddament et al., 2004).  These Z-domains fall 
into three phylogenetic clusters depending on the conserved amino acid variations 
within the zinc-binding motif.  These clusters are designated as type Z1, Z2, or Z3.  This 
nomenclature is very useful in comparing cross-species and modeling the evolutionary 
history of the APOBEC family (Conticello et al., 2005; LaRue et al., 2008).   
 
Mechanism of Antiviral Activity by APOBEC3 Proteins 
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In nonpermissive cells (such as activated PBMC), HIV-1ΔVif effectively 
incorporates approximately 7 (± 4) molecules of A3G (Xu et al., 2007).  The A3G 
molecules are then effectively introduced into the target cell during the next round of 
infection and are sufficient to inhibit HIV-1 replication (Soros et al., 2007; Xu et al., 
2007).  In order for successful incorporation to occur, A3G directly interacts with the N-
terminal region of the nucleocapsid protein (NC) of the Gag polyprotein and viral 
genomic RNA (Luo et al., 2004; Schafer et al., 2004; Svarovskaia et al., 2004; Zennou 
et al., 2004).   Once inside the virion, A3G resides in the viral core, bound to the 
ribonucleoprotein (RNP) complex containing the viral genomic RNA, NC, integrase (IN), 
and Vpr proteins (Soros et al., 2007).  Recently, a studied showed the importance of 
amino acids Y124 and W127 of A3G in facilitating RNA binding and lipid raft 
association.  This study also showed that A3G associates with both lipid rafts and the 
genomic viral RNA to be effectively incorporated into the budding virion (Khan et al., 
2009).   
Following infection of the target cell, the minus strand of DNA is synthesized, and 
the RNA template is degraded by RNase H activity of the reverse transcriptase, which 
exposes the minus strand of DNA making it susceptible to A3G mediated degradation 
(Suspene et al., 2004; Yu et al., 2004).    A3G then binds the single stranded DNA 
randomly and processively “slides or jumps” for 100 nucleotides before it begins 
deamination in a predominantly 3’ to 5’ manner (Chelico et al., 2006).  The deamination 
by A3G produces excessive dC-to-dU substitutions in the minus strand of DNA (Figure 
9) (Suspene et al., 2004; Yu et al., 2004).  The mutated minus strand of DNA can be 
destroyed by two DNA base-excision repair enzymes: uracil DNA glycosylase 2 (UDG2) 
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or apurinic-apyrimidinic endonuclease (Schrofelbauer et al., 2005).  For example, the 
UNG recognizes and excises the cDNA uracils, leaving an abasic site.  This abasic site 
is cleaved by an endonucease such as APEX1, which would cleave the cDNA 
backbone (Harris et al., 2003a; 2003b; Yang et al., 2007).  These processes can lead to 
either strand breakage and impaired plus strand DNA synthesis or destruction of the 
minus strand of DNA (Figure 9) (Harris et al., 2003; Lecossier et al., 2003; Mangeat et 
al., 2003; Zhang et al., 2003).  However, further studies are needed to clarify the 
potential mechanisms by which viral cDNA is processed and degraded following A3G 
mediated deamination.  The few minus strands of DNA that are not degraded are 
synthesized into plus strand DNA where the dU promotes the misincorporation of dA 
resulting in G-to-A mutation (Harris et al., 2003; Mangeat et al., 2003; Mariani et al., 
2003; Zhang et al., 2003).  If these G-to-A substitutions exceed 10% of the dG residues 
in the viral genome, a phenomenon called hypermutation has occurred (Bishop et al., 
2004; Harris et al., 2003; Suspene et al., 2004; Yu et al., 2004).  These G-to-A 
substitutions occur throughout the viral genome and have been shown to produce a 
gradient from 3’ to 5’ in the minus strand of DNA (Kahn et al., 2007; Suspene et al., 
2006).  A gradient of hypermutation occurs depending on the length of time that the 
minus strand of remains single stranded.  This is predominantly from 3’ to 5’, with the 
most G-to-A substitutions residing in the Env (envelope) and Nef regions and then 
decreasing towards the 5’ UTR (Kijack et al, 2008; Koulinska et al., 2003; Suspene et 
al., 2004, Suspene et al., 2006; Yu et al., 2004).  Hypermutation can negate HIV-1 
infectivity by leading to alteration in the viral open reading frames, the incorporation of 
termination codons in viral genes, impairments in plus-strand synthesis, and defects in  
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Figure 9.  The antiviral activities of human A3G incorporated into HIV-1Δvif 
virions.  HA3G present in the cytoplasm of cells infected with HIV-1Δvif is readily 
incorporated into budding virions.  Following infection of the next target cell, 
hA3G is available to exert its antiviral effects on HIV-1 replication.  These 
inhibitory effects on HIV-1 replication can be deaminase-dependent and/or 
deaminase-independent.  1)  HA3G bound to viral RNA can physically impede the 
reverse transcriptase on the viral RNA template, thus resulting in a decrease in 
the number of reverse transcripts (deaminase-independent).  This form of 
inhibition is usually incomplete and minus-stranded viral DNA is generated acting 
as a target for the deaminase-dependent hA3G inhibition.  2) Extensive 
deamination of the minus-strand of viral DNA occurs halting HIV-1 replication by 
either an accumulation of dG-to-dA mutations in the subsequently synthesized 
plus-strand of viral DNA or because the minus-strand of DNA is destroyed by 
uracil DNA glycosylase (UDG) and apurinic-apyrimidinic endonuclease 
(deaminase-dependent).  3) Also, defects in the tRNALys3 primer cleavage can lead 
to the formation of viral DNA with aberrant ends.  This prevents the integration of 
the double-stranded viral DNA into the chromosome.  Figure adapted from Chiu 
and Greene, 2008.   
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integration (Figure 9) (Chiu et al., 2008).  This editing activity has strong antiretroviral 
effects and has been shown to block the replication of HIV-1, SIV, EIAV, and murine 
leukemia virus (MLV) (Delebecque et al., 2006; Harris et al., 2003; Mangeat et al., 2003; 
Mariani et al., 2003; Russell et al., 2005).   
A3 proteins leave a distinct footprint of the sequence context in which they 
typically mutate minus sense strand viral cDNA.  Since multiple A3 proteins are 
expressed in vivo, the sequence context helps assess which viral substrate is required 
for deamination.  For example, A3G preferentially mutates cytidine residues in the 
context of 5’-CC-3’ (minus strand) or 5’-GG-3’ (plus strand); whereas other A3 proteins 
most often mutate thymidine residues resulting in 5’-TC-3’ (minus strand) or 5’-GA-3’ 
(plus strand) (Bishop et al., 2004; Harris et al., 2003; Liddament et al., 2004; Mangeat et 
al., 2003; Wiegand et al., 2004; Yu et al., 2004; Zhang et al., 2003; Zheng et al., 2004).  
Also, by assessing these sequence contexts one can determine hypermutation hotspots 
or determine how hypermutation can be lethal to the virus.  For example, in the 
presence of A3G, a UGG codon encodes for a tryptophan and may be susceptible to 
the creation of either a UAG or even a UAA stop codon  (Watts et al., 2009). Depending 
on the base pair next in the sequence, an AUG start codon could be replaced with a 
wobble base ablating the initiating methionines required for protein translation.  This 
extensive mutation also has the ability to disrupt HIV-1 secondary RNA structures that 
are essential for the regulation of gene expression (Watts et al., 2009).   
It is important to note that a high frequency of G-to-A mutations were evident in 
HIV-1 sequences from patients before the discovery of A3 proteins (Janini et al., 2001; 
Vartanian et al., 1991; Vartanian et al., 1994).  These early studies showed that the 
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preferential sequence of the mutations for HIV-1 infected patients were in the context of 
5’-GA-3’ (plus strand) and to a lesser extent 5’-GG-3’ (plus strand) (Liddament et al., 
2004).  However, it remains unknown which A3 protein is responsible for these reported 
mutations (Gandhi et al., 2008; Ulenga et al., 2008).  So far, hypermutation does not 
appear to correlate with viral loads based off a cohort study of Senegalese female sex 
workers.  However, this study did find that the level of hypermutation is directly 
correlated to level of A3G mRNA expression.  This study found that patients with a 
lower viral set point have significantly higher levels of A3G mRNA (Ulenga et al., 2008).  
However, there is conflicting data on this topic.  Another study involving 28 Kenyan 
women showed no correlation between hypermutation and viral load or CD4+ T cell 
counts (Piantadosi et al., 2009).  Further studies are needed with larger cohorts to 
correlate indicators with both hypermutation and the expression of A3 proteins.  Since 
hypermutation is common in vivo, A3 proteins through hypermutation may be aiding in 
the evolution of HIV-1 drug-resistance (Berkhout et al., 2004; Haché et al., 2006; Pillai 
et al., 2008).  However, the data to support this topic is limited.   
Even though the antiviral activity of A3 proteins mainly relies on the cytidine 
deaminase activity, A3 proteins have also been shown to wield antiviral activity 
independent of cytidine deamination.  When mutations in the catalytic domain of A3G 
are introduced, deaminase activity is prevented but the mutants continue to exert 
antiviral activity against HIV-1 by reducing infectivity and the amount of HIV-1 cDNA 
produced in the target cell (Navarro et al., 2005; Newman et al., 2005).    A3G has 
deaminase-independent functions that interfere with primer tRNA annealing, primer 
tRNA progression, minus- and plus- strand transfer, and DNA elongation (Anderson and 
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Hope, 2008; Bishop et al., 2006; Guo et al., 2006; 2007; 2009; Holmes et al., 2007; 
Iwatani et al., 2007; Li et al., 2007; Luo et al., 2007; Mangeat et al., 2003; Mariani et al., 
2003; Mbisa et al., 2007).   A3G contained a docking site for the C-terminus of HIV-1 
integrase, which interferes with the preintegration complex (PIC) structure.  This inhibits 
the nuclear import of the PIC complex and impairs the integration of proviral DNA (Luo 
et al., 2007).   
A3 proteins have also been implicated in using deaminase independent functions 
to inhibit the replication of in retroviruses such as human T cell leukemia virus type-1 
(HTLV-1), hepatitis B virus (HBV), papillomaviruses and parvoviruses (Abe et al., 2009; 
Baumert et al., 2007; Bonvin and Greeve, 2007; Bonvin et al., 2006; Chen et al., 2006; 
Henry et al., 2009; Jarmuz et al., 2002; Köck and Blum, 2008; Mahieux et al., 2005; 
Narvaiza et al., 2009; Noguchi et al., 2007; Paprotka et al., 2010; Rosler et al., 2004; 
Sasada et al., 2005; Sheehy et al., 2002; Turelli et al., 2004; Vartanian et al., 2008; 
Zhang et al., 2008).  For example, human A3G is incorporated into HTLV-1 virions and 
exerts an antiviral effect.  No hypermutation is observed and it appears that A3G 
interferes with virus maturation through a deaminase-independent mechanism (Sasada 
et al., 2005).  HBV contains a reverse transcriptase that is required for the pregenomic 
RNA intermediates in the cytoplasm of cells producing virus. Human A3G inhibits HBV 
through a deaminase-independent mechanism during the early steps of viral reverse 
transcription and strand elongation inhibiting viral pregenome packaging (Nguyen et al., 
2007; Rosler et al., 2004; Turelli et al., 2004; Zhang et al., 2008).  Human A3A inhibits 
the replication of parvovirus adeno-associated virus (AAV) and the autonomous 
parvovirus minute virus of mice (MVM) (Narvaiza et al., 2009).  Both AAV and MVM are 
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single-stranded DNA viruses that do not contain a reverse transcriptase or any RNA 
substrates.  However, hA3A inhibits the replication of both these viruses through a 
direct interaction with viral DNA or the replication machinery.  Mutants that lack 
deaminase activity still retain the ability to inhibit these viruses through deaminase-
independent functions (Chen et al., 2006; Narvaiza et al., 2009).  Also, in the absence 
of hypermutation, A3A displays inhibitory activity against LINE-1 (long-interspersed 
nuclear element-1) and other retroelements (Bogerd et al., 2006a, 2006b; Hulme et al., 
2007; Niewiadomska et al., 2007; Muckenfuss et al., 2006).   
 
 
Antiviral Activity of the APOBEC3 Family of Cytidine Deaminases 
 In general, the evidence indicates that among activated Th1 CD4+ T cells, the 
expression of A3G and A3F are increased (Vetter et al., 2009).  This increase in 
expression results in an increase of A3G/F incorporation into virions and an overall 
lower infectivity of target cells (Koning et al., 2009).  This was found in most A3 proteins 
with the exception of A3A and to a lesser extent A3B in primary CD4+ T cells (Koning et 
al., 2009).  IFN-α and to a lesser extent IFN-γ treatment also result in a higher 
expression of A3 proteins and an increased resistance to HIV-1 infection (Peng et al., 
2007).  IFN-α has been found to increase the expression of A3 proteins and to a greater 
extent A3A in macrophages.  However A3B and A3C are possible exceptions to 
increased expression by IFN-α because they are part of the normal IFN response 
(Koning et al., 2009).  Immature dendritic cells are resistant to HIV-1 infection due to an 
increased expression in A3G and A3F; however, as dendritic cells mature, the high 
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expression levels of these proteins are reduced (Pion et al., 2006).  More work is still 
needed focusing on the expression of various A3 proteins by IFN.   
APOBEC3G has been extensively described above; therefore, this section will 
mainly focus on the other six members (A3A, A3B, A3B, A3D, A3F, and A3H) of the A3 
subfamily of single-stranded DNA cytidine deaminases.  Compiled data regarding the 
inhibition of HIV-1, SIVmac239, LTR retroelements, non-LTR retroelements, hepatitis B 
virus, or adeno-associated virus by various human A3 proteins is listed in Table I and 
Table II, respectively.  Of these A3 proteins, hA3B, hA3D, hA3G, and hA3F, have been 
shown to inhibit the replication of HIV-1Δvif, while hA3B, hA3C, hA3D, hA3G, and hA3F, 
have been shown to restrict SIVmac239Δvif  (Dang et al., 2006; 2008; Doehle et al., 
2005; Mariani et al., 2003; Wiegand et al., 2004; Yang et al., 2007; Yu et al., 2004a; 
2004b; Zennou and Bieniasz, 2006; Zheng et al., 2004).  Currently, more is becoming 
known about the rhesus A3 proteins.  It is known that HIV-1Δvif can be inhibited by 
rhA3G, rhA3F, rhA3B, and to a lesser extent rhA3H and rhA3D, while SIVmac239Δvif has 
been shown to be restricted by rhA3B, rhA3D, rhA3F, rhA3G, and rhA3H (Virgen and 
Haziioannou, 2007; Zennou and Bieniasz, 2006).    
 
APOBEC3A 
Human APOBEC3A (hA3A) is expressed in the keratinocytes, spleen, small 
intestine, PBLs (neutrophils, primary monocytes such as macrophages and dendritic 
cells), bone marrow, and lungs (Refsland et al., 2010; Thielen et al., 2010).  A3A is 
localized in both the cytoplasm and the nucleus and contains a single cytidine 
deaminase catalytic domain (Table I) (Goila-Gaur et al., 2007; Hultquist et al., 2011). 
	   76	  
This A3 protein does not have antiviral activity against either HIV-1 or HIV-1Δvif (Bogerd 
et al., 2006; Goila-Gaur et al., 2007).  When A3A is knocked down in monocytes, the 
susceptibility of the monocytes to HIV-1 infection increases and the spread of R5-tropic 
HIV-1 viruses are augmented (Berger et al., 2011; Peng et al., 2007).  It is thought that 
this antiviral effect occurs because a large pool of hA3A exists in the target cells, that 
decreases the viral DNA accumulation (Berger et al., 2011).  A3A is packaged into 
virions even in the presence of a functional Vif but does not associate with the viral 
nucleoprotein complex (NPC).  However, when constructed into a chimeric protein with 
A3G, where the N-terminus of A3G was fused to A3A, the A3G-A3A chimera was 
packaged into the HIV-1Δvif virions by associating with the viral NPC, displayed 
cytoplasmic localization similar to A3G, and restored its inhibitory effects on HIV-1Δvif 
(Goila-Gaur et al., 2007).   The target specificity sequence for hA3A has been identified 
as 5’-TC (minus strand) (Bulliard et al., 2011; Thielen et al., 2010).  Overexpression of 
A3A in vitro results in increased dC-to-dU (minus strand) mutations in the human 
papillomavirus (HPV) genome; however it is still unknown as to whether hA3A displays 
deaminase-dependent restriction against hepatitis B virus (HBV) (Vartanian et al., 
2008).   
Another important feature of hA3A is its ability to restrict foreign DNA, which can 
enter cells through multiple exogenous sources.  Recent research shows that the 
detection of foreign DNA and upregulation of IFN-α in phagocytes results in the 
degradation of foreign DNA by hA3A through cytidine deamination and a uracil-excision 
mechanism (Stenglein et al., 2010). While monocyte and in vitro cell culture genomic 
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DNA is unaffected, approximately 97% of cytidines in detected foreign DNA are 
deaminated (Stenglein et al., 2010).   
A3A can block endogenous LTR-retrotransposons such as IAP and MusD as well 
as non-LTR retroelements such as L1 and Alu (Table II) (Bogerd et al., 2006; Chen et 
al., 2006).  In A3A expressing cells, adeno-associated virus (AAV) producer cell 
replicating genomes are inhibited (Chen et al., 2006).  Twelve residues (amino acids 
H29, K30, N57, K60, R69, F75, W98, R128, Y130, D131, E217, and P247) have been 
identified at the core of A3A antiviral activity and are involved in the restriction of LINE-
1, AAV, and gene expression from foreign plasmid DNA. It is thought that these 
residues are responsible for forming the polynucleotide-accommodating groove of 
hA3A.  If these residues are mutated the inhibition of LINE-1, AAV, and the restriction of 
foreign DNA is prevented by deaminase-independent mechanisms (Bulliard et al., 2011; 
Chen et al., 2006; Madsen et al., 1999; Melo et al., 1998; Moran et al., 1996).  These 
mutants defective in editing lead to the accumulation of LINE-1 reverse transcripts, 
increasing level of viral replicative intermediates, and the expression of genes on 
foreign DNA (Bulliard et al., 2011; Chen et al., 2006).   
Viral protein X (Vpx) has been shown to bind hA3A (Berger et al., 2010).  Vpx is 
uniquely encoded in human immunodeficiency virus type 2 (HIV-2) and simian 
immunodeficiency virus (SIVmac/SIVsm) (Horton et al., 1994; Wolfrum et al., 2007).  This 
protein is crucial for in vitro infection of human macrophages and dendritic cells, but 
dispensable for infection of primary lymphocytes and laboratory cell lines (Cheng et al., 
2008; Fletcher et al., 1996; Sharova et al., 2008; Wolfrum et al., 2007).  SIVmac Vpx has 
been shown to partially bind and degrade hA3A during the early stages of infection 
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promoting the replication of SIVmac.  If a single-point mutation in Vpx at the histidine in 
amino acid position 82 is substituted for an alanine, Vpx is no longer able to bind and 
suppress hA3A abrogating the infection of monocytes  (Berger et al., 2010; Berger et 
al., 2011).   Another study fused viral protein R (Vpr) to hA3A to convert hA3A into an 
inhibitor of viral replication.  The Vpr protein of HIV-1 is needed to cause cell cycle 
arrest at the G2-to-M transition phase and to import the preintegration complexes (PIC) 
into the nucleus of cells (He et al., 1995; Jowett et al., 1995; Re et al., 1995; Rogel et 
al., 1995).  The constructed fusion protein, Vpr.A3A chimera, was readily incorporated 
into the viral core and potently restricted both HIV-1 and SIVmac in the presence of Vif 
(Aguiar et al., 2008).   
 
APOBEC3B 
Human APOBEC3B (hA3B) is expressed in the peripheral blood leukocytes, 
bone marrow, lung, and stem cells (Refsland et al., 2010).  A3B is not Vif sensitive and 
inhibits both HIV-1 and SIVmac239 in the presence of Vif, Table I  (Bishop et al., 2004; 
Doehle et al., 2005; Yu et al., 2004).  A3B contains two CDAs, as described above. 
Proteins that contain at double CDA display a separation of function between the 
domains.  For example, the N-terminal CDA is responsible for viral-RNA binding and is 
required for encapsidation, while the C-terminal CDA determines DNA deaminase 
activity and substrate specificity (Bishop et al., 2004; Haché et al., 2005; Iwatani et al.,  
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Table I.  Summary of both the expression and restriction profile by human 
APOBEC3 Proteins.  All references for this table are listed in the text.   
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Table II.  Summary of the restriction profile of LTR retorelements, non-LTR 
retroelements, and other viruses by human APOBEC3 Proteins.  All references 
used in this table can be found in the text.   
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2006; Liddament et al., 2004; Navarro et al., 2005; Newman et al., 2005; Wiegand et al., 
2004).  However, the C-terminal CDA of A3B is catalytically dominant and determines 
sequence specificity (5’-TC, minus strand), but the N-terminal CDA also elicits 
deaminase activity that is capable of mutating the viral genome (Bogerd et al., 2008).  
Human A3B has also been found to inihibit both LTR and non-LTR retroelements (Table 
II) (Boderg et al., 2006; Chen et al., 2006; Esnault et al., 2005; Musckenfuss et al., 
2006; Stenglein et al., 2006).  Mouse LTR retrotransposons, IAP and MusD elements 
are strongly inhibited by hA3B (Bogerd et al., 2006; Chen et al., 2006; Esnault et al., 
2005).     Secondly, hA3B strongly inhibits non-LTR retorelements such as LI and Alu 
(Bogerd et al., 2006; Chen et al., 2006; Muckenfuss et al., 2006; Stenglein et al., 2006).  
Using CDA mutants that lack deaminase activity, A3B still effectively inhibits L1 
retrotransposition by approximently 75% (Wissing et al., 2011). This may occur due to a 
highly homologous region in the CDA that directly interacts with L1 ORF2 (Turelli et al., 
2004).  A3B is predominantly localized to the nucleus, and in overexpression 
experiments performed in HeLa cells the nuclear localization of A3B is not essential for 
A3B to inhibit L1 retrotransposition (Hultquist et al., 2011; Pak et al., 2011).  Finally, in 
cotransfected hepatoma cell lines, hA3B used deaminase-independent functions to 
interfere with the replication of HBV (Okeoma et al., 2007).   This is due to hA3B having 
two splice variants in the human liver, which are both expressed, but only the longer 
variant is capable to inhibit HBV (Bonvin et al., 2006).   
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Interestingly, a small ~4-kb deletion in A3B is found in some patients with breast 
cancer (Komatsu et al., 2008).  Also, some patients display homozygous deletions of 
A3B, which can be associated with malignant tissues (Iskow et al., 2010).  There is also 
a common deletion polymorphism in the Oceanic population where 29.5 kb of genomic 
sequence spanning from the fifth exon of A3A to the eighth exon of A3B.  While A3B is 
deleted, A3A is produced and is a functional-full length A3A fusion protein with the 
3’UTR of A3B (Kidd et al., 2007).  At this time, it is unknown if this fusion protein is 
functional, restricts L1 retrotransposition, or what the potential role of this protein could 
be.      
 
APOBEC3C 
Human APOBEC3C (hA3C) is insensitive to IFN and expressed in the PBLs, 
thymus, spleen, lymph node, testis, ovary, small intestine, colon, liver, pancreas, heart, 
lung, and adipose tissue (Table I) (Refsland et al., 2010).   A3C contains one CDA and 
is localized to both the cytoplasm and the nucleus (Hultquist et al., 2011).   In contrast to 
A3B, the deaminase activity of A3C is poorly active against its sequence specific target, 
5’-TC (minus strand), and requires dimerization to exert its antiviral effect (Stauch et al., 
2009; Yu et al., 2004).  This A3 protein has potent antiviral activity against SIVmac239 
and to a much lesser extent HIV-1Δvif (Yu et al., 2004) (Table I).  Even though A3C is 
efficiently incorporated into the virions of these viruses, very few G-to-A (plus strand) 
mutations result (Yu et al., 2004).  If the N-terminal region (amino acid residues 2-47, 
before the CDA) of hA3C is deleted, than hA3C is insensitive to HIV-1 or SIVagm 
(African green monkey) Vif (Zhang et al., 2008).  This indicates that this region contains 
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an important determinant required for Vif-induced degradation.  When residue E106, 
located after the CDA, is mutated, hA3C is no longer sensitive to HIV-1 Vif (Smith et al., 
2010).   Also, the amino acid residue E289 in hA3C has been shown to be critical for 
HIV-1 Vif mediated degradation (Smith et al., 2010).   
When hA3C is overexpressed in vitro cell culture, hA3C mildly inhibits Non-LTR 
Retroelements such as L1 and Alu (Bogerd et al., 2006; Muckenfuss et al., 2006; 
Stenglein et al., 2006).  In contrast, hA3C effectively inhibits LTR retroelements such as 
IAP and MusD (Bogerd et al., 2006; Chen et al., 2006; Esnault et al., 2005) (Table II).  
In tissue culture, hA3C overexpression can reduce herpes simplex virus 1 (HSV-1) and 
Epstein-Barr herpesvirus (EBV) viral titers, decrease the particle/plaque forming unit 
ratio by approximately 10-fold, and hypermutate genomes (Suspène et al., 2011a). 
Human A3C has also been shown to mutate transfected human papillomavirus (HPV) 
and edit mitochondrial DNA (mtDNA) (Suspène et al., 2011b; Vartanian et al., 2008).  
Excessive hypermutation of the hepatitis B virus (HBV) genome has also been reported 
(Baumert et al., 2007; Köck et al., 2008).   
 
APOBEC3D 
Human APOBEC3D (hA3D; formally known as APOBEC3DE) is expressed in the 
PBLs, thymus, spleen, lymph node, ovary, liver, lung, adipose tissue, and more 
extensively than hA3F in nonpermissive cells (Dang et al., 2006; Refsland et al., 2010).  
This A3 protein is localized similar to A3C in both the cytoplasm and nucleus but 
contains two CDAs (Hultquist et al., 2011).  HA3D inhibits the replication of both HIV-
1Δvif and SIVmac239Δvif (Table I) (Dang et al., 2006).  This A3 protein is efficiently 
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incorporated into virions in the absence of Vif, which resulted in excessive G-to-A 
hypermutation.  A3D introduces 5’-CC, 5’-TC, and 5’-GC (minus strand shown) 
mutations into newly synthesized viral minus-strand DNA (Dang et al., 2006).  Using a 
GST-hA3D pull down assay in cells expressed with hA3G and hA3F, hA3D formed 
heteromultimers with both A3G and A3F which may enhance the antiretroviral effect 
(Dang et al., 2006; Wiegand et al., 2004).  Very little is known about the inhibition of 
hA3D on other viruses, LTR retrotransposons, or non-LTR retrotransposons.  Therefore, 
more studies are needed to determine the extent to which hA3D exerts its antiviral 
activities.     
 
APOBEC3F 
Human APOBEC3F (hA3F) is expressed in the PBLs, thymus, spleen, lymph 
node, testis, ovary, uterus, brain, lung, colon, kidney, and pancreas (Refsland et al., 
2010).  The cellular localization of hA3F is cytoplasmic (Table I) (Hultquist et al., 2011).  
HA3F is the second most potent inhibitor of HIV-1Δvif, but is produced at lower levels in 
natural target cells of HIV-1, is partially resistant to Vif, and is less potent than hA3G 
(Koning et al., 2009; Liddament et al., 2004; Simon et al., 2005; Xu et al., 2004; 
Wiegand et al., 2004; Zennou and Bieniasz, 2006).  Mutations in binding domain of Vif 
that prevent interaction with hA3G increase the sensitivity of Vif to hA3F (Russell et al., 
2009).  This protein has two catalytically active cytidine deaminase domains; however, 
unlike A3G, the deaminase activity in the C-terminal CDA is not required for inhibition of 
HIV-1Δvif. Catalytically inactive mutants of A3F are just as potent inhibitors of viral 
infectivity causing reductions in the accumulation of viral reverse transcripts (Holmes et 
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al., 2007).  Therefore, A3F-mediated inhibition of HIV-1Δvif infectivity primarily occurs 
through a deaminase-independent mechanism (Holmes et al., 2007).   
A3F has been isolated from purified HBV capsids and can inhibit the replication 
of HBV in the absence of hypermutation (Noguchi et al., 2005; Rosler et al., 2005; 
Suspene et al., 2005; Wiegand et al., 2004). However, using 3D-PCR, G-to-A 
hypermutated HBV genomes (context 5’-TC, minus strand) have been found in the 
serum of patients with chronic HBV at low frequencies (Haché et al., 2005; Suspene et 
al., 2005).  Furthermore, A3F has been shown to inhibit both LTR retroelements such as 
IAP, MusD, and Ty1 (Boderd et al., 2006; Chen et al., 2006; Dutko et al., 2005; 
Schumacher et al., 2005).  This A3 protein is also a potent inhibitor of L1 
retrotransposition in the absence of hypermutation (Table II) (Muckenfuss et al., 2006; 
Stenglein et al., 2006).    
 
APOBEC3H 
Human APOBEC3H (hA3H) is expressed in the PBLs, thymus, testis, ovary, 
brain, small intestine, colon, and keratinocytes (Table I) (Refsland et al., 2010). This A3 
protein has cytonuclear localization and is poorly expressed in vivo (Doehle et al., 2005; 
Hultquist et al., 2011; Kidd et al., 2007).  A3H contains one cytidine deaminase catalytic 
domain (CDA); therefore, A3H lacks the second CDA that mediates RNA binding, 
homodimerization, and virion incorporation (Gooch et al., 2008; Navarro et al., 2005).  
However, the CDA of hA3H can inihibit the replication of both non-LTR retrotransposons 
such as L1 and Alu (Holmes et al., 2007; OhAinle et al., 2008).   Interestingly, hA3H has 
been reported to hypermutate the genomes of both HBV and HPV (Table II) (Lecossier 
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et al., 2003). Thus far, hA3H is composed of five single nucleotide polymorphisms 
(SNP) (amino acid residues N15Δ, R18L, G105R, K121D, and E178D) and seven 
haplotypes (I-VII) (Harari et al., 2008; Wang et al., 2011).  These various SNP mutations 
are readily found as variations in the different haplotypes. A3H mRNA can be detected; 
however, the protein expression of A3H has not been observed (Li et al., 2010; OhAinle 
et al., 2006).  The reason for an absence of protein expression can be explained by a 
premature termination codon (PTC) in the fifth exon of the human A3H gene.  If the PTC 
is repaired, high levels of hA3H protein are observed in cell culture (Dang et al., 2008). 
When the N15Δ or G105R mutations are present, there is a dramatic decrease in the 
expression of A3H (OhAinle et al., 2008).  Only haplotype II (hapII) of hA3H, which does 
not have the N15Δ and/or G105R mutations, can be stably expressed.  Hap II was 
originally identified as being the most common haplotype among the African-American 
population (OhAinle et al., 2008). More recently, Hap V was detected frequently in 
African-American, Caribbean, and Chinese populations whereas Hap VII was identified 
in only Euorpean Caucasian populations (Wang et al., 2011).  Both hap V and hap VII 
have been shown to incorporate into HIV-1 virions using the 112YYXW115 motif instead of 
the CDA like various other A3 proteins such as hA3G.  Also, both of these haplotypes 
inhibit HIV-1 replication.  However, it appears that all the various haplotypes of human 
A3H are resistant to HIV-1 Vif; therefore, further research needs to be conducted to 
determine the antiviral activites of hA3H on HIV-1 replciation (Wang et al., 2011).   
Humans, chimpanzees, and the rhesus macaque (Macaca mulatta) have 
undergone extensive positive selection and locus expansion, but appear to share similar 
locus architectures.  While the A3 proteins in humans have been excessively studied, 
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less is known about the A3 proteins in the rhesus macaque (macaca mulata).  Rhesus 
A3B, C, D, F, G, and H have been identified, while rhA3A has yet to be identified 
(Hultquist et al., 2011; Virgen et al., 2007).   RhA3D, rhA3F rhA3G, and rhA3H all 
contribute to the antiviral restriction of HIV-1Δvif and are targeted for degradation by 
SIVmac239 (Hultquist et al., 2011, Virgen et al., 2007; Zennou and Bieniasz, 2006).  
These homologous A3 proteins of both human and the rhesus macaque have 
comparable steady-state localization as well as both HIV-1 and SIVmac restriction 
abilities such as hypermutation in the absence of Vif (Hultquist et al., 2011; Virgen et al., 
2007).  However, futher studies will be needed to identify rhA3A, assess the expression 
patterns of these proteins in vivo, and determine their significance in the rhesus 
macaque.   
 
Vif-APOBEC3 Paradigm 
 Vif reduces the encapsidation of A3G into virions by 99% either directly inhibiting 
the incorporation of A3G or more importantly by depleting the cellular stores of A3G 
(Kao et al., 2003; Mariani et al., 2003; Marin et al., 2003; Mehle et al., 2004; Sheehy et 
al., 2003; Stopak et al., 2003).  This ensures that the progeny virions will be highly 
infectious.  Vif uses multiple protein-protein interactions to ensure that the antiviral 
effects of A3G are inhibited. The N-terminus of Vif is required for interaction with 
genomic RNA and to bind/interact with various regions of the A3 proteins, which will be 
discussed in detail below, while the C-terminus of Vif is essential to recruiting an active 
E3-ubiquitin ligase complex.   
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Sequence analysis from different lentiviral Vif proteins display several highly 
conserved domains in the C-terminus of Vif that are required for the assembly of the Vif-
CBF-β-Cullin 5/Elongin B/Elongin C/ Nedd8/Ring box-1 E3 ubiquitin ligase complex. Vif 
accomplishes this by binding A3 and then a substrate recognition subunit of the 
Cul5/EloB/C complex targeting A3 for polyubiquitination and subsequent degradation by 
the 26S proteosome (Figures 10 and 11) (Conticello et al., 2003; Jäger et al., 2011; 
Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003; Yu et al., 
2004).  These domains in HIV-1 Vif are the 108HCCH139 motif, 144SLQ(Y/F)LA150 domain, 
E88WRRKK93 and the P161PLP164 domain.   
 The highly conserved zinc binding domain of HIV-1 Vif is referred to as the 
HCCH domain and is located between amino acid residues (108-139) (Figure 12).  The 
108H-X5-C—X17-18-C-X3-5-H139 domain is indispensable for Vif function and thought to 
maintain a structural conformation of Histines and cysteines flanked by hydrophobic 
residues that coordinate zinc to form the Cul 5 binding site (Luo et al., 2005; Mehle et 
al., 2006; Xiao et al., 2006; Xiao et al., 2007).  Zinc binding to the HCCH motif is both 
specific and reversible producing conformational changes leading to protein aggregate 
formation (Paul et al., 2006).   These high order protein assemblies alter protein 
conformation to expose possible protein-protein interaction sites (Giri and Maynard, 
2009; Paul et al., 2006).  Upon further investigation using fluorescence and CD 
spectroscopy, the binding of the HCCH domain to zinc confirmed that zinc binding 
increases tertiary packing supporting the theory that zinc binding and protein 
conformation are coupled tightly (34). Chelation of zinc by cell-permeable N, N, Nʹ′, Nʹ′-
tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN) results in the loss of Vif function  
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Figure 10.  Proteosomal degradation of human A3G by HIV-1 Vif.  1) HIV-1 Vif 
binds to hA3G and recruits the E3 ubiquitin ligase complex leading to the 
ubiquitination and subsequent proteosomal degradation of hA3G.  2) HIV-1 Vif 
can impair the translation of hA3G mRNA.  3) HIV-1 Vif can physically bind hA3G 
excluding it from the virion and sequestering hA3G away from the sites of viral 
assembly.  Figure adapted from Chiu and Greene, 2008.   
 
 
 
 
 
 
 
 
	   92	  
 
 
 
 
 
 
	   93	  
 
 
 
 
 
 
 
Figure 11.  Vif induced polyubiquitination of A3G through the recruitment of the 
CBF-β-Cul5-EloB/C-Rbx 1 E3 ubiquitin ligase complex and the specific amino acid 
motifs that mediate protein-protein interactions.   
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Figure 12.  The HCCH and BC box domains of Vif are highly conserved in primate 
lentiviruses.  The HCCH domain is indicated in orange and the BC box domain is 
depicted in blue.    
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leading to an increase in antiviral activity by A3G (Xiao et al., 2007).  Mutation of either 
cysteine residue or spacing within the HCCH motif results in the inability of Vif to target 
A3G for proteosomal degradation (Paul et al., 2007; Xiao et al., 2006). This is due to a 
conformational change in the HCCH motif that prevents the exposure of possible 
protein-protein interaction sites (Giri and Maynard, 2009; Paul et al., 2006).  Upon 
further investigation using fluorescence and CD spectroscopy, the binding of the HCCH 
domain to zinc confirmed that zinc binding increases tertiary packing supporting the 
theory that zinc binding and protein conformation are coupled tightly (34). Chelation of 
zinc by cell-permeable N, N, Nʹ′, Nʹ′-tetrakis-(2-pyridylmethyl)ethylenediamine (TPEN) 
results in the loss of Vif function leading to an increase in antiviral activity by A3G (Xiao 
et al., 2007).  Mutation of either cysteine residue or spacing within the HCCH motif 
results in the inability of Vif to target A3G for proteosomal degradation (Paul et al., 2007; 
Xiao et al., 2006).  Therefore, it would be interesting to see how mutations in the HCCH 
domain affect HIV-1 pathogenesis in vivo.   
 Another highly conserved domain crucial for the function of Vif is the 
144SLQ(Y/F)LA150 motif which binds the cullin adapter protein EloBC through a BC-box 
motif (Figure 12) (Yu et al., 2003).  The BC-box of the suppressors of cytokine signaling 
(SOCS) proteins is a loop helix motif with the consensus sequence 
((A/P/T/S)1L2xxx(C/A/S)6xxx(A/V/L/I)10) that also exists in other cellular proteins known 
to interact with EloBC (Kamura et al., 1998).  The serine at amino acid position 144 is 
regulated by phosphorylation thus negatively regulating the binding of Vif to EloC.  If this 
serine is mutated to an alanine, phosphorylation is prevented, but this mutant still 
efficiently depletes cellular stores of A3G.  However, the virions that are produced are 
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severely reduced in infectivity (Mehle et al., 2004). While Vif binds EloBC heterodimer 
with high affinity, it does not fit the consensus sequence perfectly.  The BC-box of Vif is 
unstructured in its unbound state; however, this motif binds EloC through two α-helicies 
and becomes structured.  Once EloC is bound, the P161PLP164 domain (described 
below) interacts with the amino acid residues 101-104 of EloB (Bergeron et al., 2010).  
These two binding steps are essential for the Vif-EloBC interaction and recruit the E3 
ligase.  If either EloB or C are deleted or mutated, the Vif-EloBC interaction is lost 
(Mehle et al., 2004; Yu et al., 2001; Yu et al., 2003).   More studies are needed to look 
at the in vivo pathogenesis by making site-directed mutations in the SLQ(Y/F)LA 
domain of Vif.   
The central hydrophobic domain E88WRRKK93 and the conserved P161PLP164 
domain of HIV-1 Vif are important for the steady-state levels of Vif and for interactions 
with tyrosine kinases (Donahue et al., 2008; Fujita et al., 2003; 2004).  Mutation of 
either of these sites results in decreased Vif-Vif multimerization, dimished Vif 
expression, reduced A3G binding, and a loss of viral infectivity (Fujita et al., 2003; 2004; 
Kataropoulou et al., 2009; Yang et al., 2001; Yang et al., 2003).  Furthermore, if the 
PPLP motif is mutated or deleted, HIV-1 in the presence of Vif is unable to exclude A3G 
from the virion.  This dominant negative effect leads to a decrease in virion infectivity 
(Walker et al., 2010).    Although the role of the PPLP domain not completely clear, it 
has been shown that the PPLP domain may help promote the dimerization of VIf in the 
absence of Cul 5, that it directly interacts with Cul 5, and that it is essential for Vif 
function (Simon et al., 1999; Yang et al., 2001; Yang et al., 2003).   
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Structural Determinants of Vif that Interact with APOBEC3  
 As disscussed above, HIV-1 and HIV-2 were transmitted to humans by different 
zoonotic transmission events (Sharp et al., 2001).  Briefly, SIVcpz (chimpanzee, Pan 
troglodytes) was the precursor for HIV-1 and SIVsm (sooty mangabey, Cerocebus) was 
the source of HIV-2, which are both related but very distinct SIVs that naturally infect 
nonhuman primates (Sharp et al., 2001).  These zoonotic infections seem to occur 
when the host cell does not strongly resist lentiviral infection with post-entry restriction 
factors, such as TRIM5α or A3G (Cullen et al., 2006; Stremlau et al., 2004).  The Vif-
A3G interaction is an important factor in species-specificity between HIV and various 
SIVs.  Zoonotic infections only persist when the lentiviral Vif protein can bind to and 
induce the degradation of A3G (Cullen et al., 2006; Mariani et al., 2003).  For example, 
HIV-1 and SIVcpz Vif can bind and degrade human A3G but not African green monkey 
A3G rendering humans resistant to infection by SIVagm.  On the contrary, SIVagm 
cannot bind and degrade HIV-1 or SIVcpz Vif (Cullen et al., 2006; Mariani et al., 2003).  
The direct interaction between A3G and Vif are dependent on amino acids 128-130 in 
A3G (Huthoff and Malim, 2007; Russell et al., 2009).  Previous research has determined 
that species-specificity is determined by a single amino acid in human A3G, D128, and 
Africa green monkey A3G, K128 (Bogerd et al., 2004; Mangeat et al., 2004; 
Schrofelbauer et al., 2004; Xu et al., 2004) and amino acids 14-17 on HIV-1 Vif 
(Schrofelbauer et al., 2006).  In human A3G if the aspartic acid is replaced with a lysine, 
hA3G becomes sensitive to SIVagm Vif and insensitive to HIV-1 Vif (Bogerd et al., 
2004; Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004).  Also, if the 
D14RMR17 motif in HIV-1 Vif is replaced with either the S14ERQ17 or S14EMQ17 residues 
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in SIVagm VIf, the HIV-1 Vif protein is now able to interact with both A3G from African 
green monkeys and rhesus macaques (Schrofelbauer et al., 2006).  These species-
specific limitations of Vif form a means to prevent or minimize the number of successful 
zoonotic transmissions of various primate lentiviruses.       
 Regions implicated ability of Vif to bind and interact with A3 proteins have been 
mapped to the N-terminal region of HIV-1 Vif (Figure 13).  The amino acid residues 
involved are arranged in a non-linear fashion thereby indicating that multiple surfaces 
are involved in this interaction.  The exact binding domain in HIV-1 Vif consists of 
several discontinuous subdomains (Goila-Gaur et al., 2008, Marin et al., 2003; Mehle et 
al., 2007; Russell et al., 2007; Russell et al., 2009; Schrofelbauer et al., 2006; Simon et 
al., 2005; Tian et al., 2006).  For example, using site-directed mutagenesis, hydrophilic 
motifs 40YRHHY44 and 23SLVK26 were found to be essential for the restriction of A3G or 
A3G and A3F, respectively (Chen et al., 2009; Dang et al., 2009; Marin et al., 2003; 
Russell et al., 2007; Russell et al., 2009; Yamashita et al., 2008; Zhang et al., 2008) 
The hydrophobic patch, 69YWxL72 was shown to suppress A3G, A3F, and A3B and the 
55VxIPLx4L64 motif is important for binding A3G (Walker 18, 50; He et al., 2008; Pery al., 
2009).  These residues 55-72 are sufficient alone for A3G binding and the charged 
residues in this region (R56, R61, and R63) are dispensable for A3G degradation (He et 
al., 2008; Mehle et al., 2007).  The 12QVDRMR17 motif is important for interaction with 
A3F and A3C (Mehle et al., 2007; Russell et al., 2007).  The 81LGxGxxIxW89 domain 
has been found to bind and regulate both A3G and A3F neutralizing activities.  The L81 
and G82 regulates the binding of Vif to A3F, while G84, I87, and W89 regulate 
interaction with both A3G and A3F (Dang et al., 2010).  Both the 74TGERxW79 and 
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171EDRWN175 domains specifically bind and neutralize A3F (Dang et al., 2010; Russell 
et al., 2007).   
Although there is only approximately 50% homology between HIV-1 Vif and 
SIVmac239, very few domains in the N-terminus of HIV-1 Vif are partially conserved in 
SIVmac239 Vif (Dang et al., 2009; He et al., 2008; Pery et al., 2009).  These domains are 
listed in Figure 13.  Identifying these domains on SIVmac239 Vif is essential for using 
the rhesus macaque as a model to study viral pathogenesis.  Even though the 
interaction surfaces on Vif are structurally complicated, it is important to understand and 
identify these domains to determine the mechanism by which Vif recognizes A3 
proteins.   
 
APOBEC3 and Vif as Therapeutic Targets 
 Since a protective vaccine is not available, the Merck vaccine trial proved 
unsuccessful, and the resistance to HARRT therapy occurs, we need new and more 
effective antiviral drugs for the management of HIV-1 infection (Barouch et al., 2008; 
Robb et al., 2008).  Some scientists are now looking into using the Vif-A3 protein 
interactions as targets for antiviral drug development.  This is possible because several 
studies have implied that interference with the Vif-A3 interaction strongly suppress HIV-
1 viral replication in nonpermisive cells (Gabuzda et al., 1992; Fisher et al., 1987; 
Strebel et al., 1987; von Schwedler et al., 1993).   
In order to use APOBEC3 proteins as therapeutics, the significant quantities of 
APOBEC3 needs to be incorporated/packaged into the HIV-1 virion.  Using this  
 
	   102	  
 
 
 
 
 
 
Figure 13.  The domains of HIV-1 and SIVmac239 Vif that have been implicated in 
binding A3 proteins.  Shown are representations of both the N-terminus of HIV-1 
(top) and SIVmac239 (bottom) Vif from amino acids 1 to 174 as indicated below the 
protein.  Labeled in the boxes are specific amino acid motifs that are required to 
interact with the designated A3 proteins listed above the proteins.   
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scenario, even HIV-1 virions would contain increased amounts of A3 effectively 
overwhelming the normal Vif function thus preventing the genomic RNA from becoming 
a replication-competent provirus in the target cell (Albin et al., 2010; Jern et al., 2009; 
Mulder et al., 2008).  The amount of risk associated with increasing A3G expression 
and causing mutagenic activity would need to be smaller than the ability of A3G to exert 
its antiviral activities.  In order to increase encapsidation of A3G into HIV-1 virions and 
prevent the degradation of A3G, two different approaches can be employed:  1.)  
Directly increasing incorporation of A3G by increasing the expression of A3G, or 2.)  
Indirectly increasing A3G incorporation by preventing proteosomal degradation of A3G 
(Albin et al., 2010).   
 In order to directly increase the expression of A3G thus increasing the 
incorporation, IFN-α treatment is possible.  Induction of A3 proteins in macrophages by 
IFN-α treatment is effective in restricting the infectivity of HIV-1 (Peng et al., 2006).  By 
doing this, we may be able to selectively increase A3G expression and aid the immune 
system in controlling HIV-1 infection.  This treatment could also enhance other small 
molecules that occur naturally to aid the immune system or inhibit viral replication.  
However, IFN-α treatment induces many non-specific cellular effects making it difficult 
to rule out the A3 antiviral activity.  Another side effect of this treatment could also be 
the hypermutation of the human genome because A3 expression levels would 
overwhelm the cellular regulatory mechanisms leading to the development of certain 
cancers (Harris et al., 2002; Yamanaka et al., 1995).   
 Another direct approach could also be to selectively target A3 proteins to the viral 
core in HIV-1 virions.  For example; if A3G is fused to a fragment of Vpr, A3G is 
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efficiently incorporated into HIV-1 virions in the presence of Vif (Aguiar et al., 2008).  
Also, fusing A3A to Vpr resulted in enhanced antiviral activity in the target cell.  This is 
important because normally A3A does not restrict HIV-1 or reach the viral core; 
however, when fused to Vpr, the A3A-Vpr protein is specifically targeted to the viral core 
and potently restricts HIV-1 (Aguiar et al., 2008).   
 An indirect approach would be to increase incorporation of the A3 protein and to 
prevent its proteosomal degradation.  For example, in one study a membrane-
permeable zinc chelator, TPEN was used to prevent the formation of the E3 ubiquitin 
ligase by inhibiting the Vif-Cullin 5 binding thus preventing the degradation of A3G (Xiao 
et al., 2007).  However, TPEN in vitro has been shown to induce apoptosis in human 
cells by inhibiting other cellular functions, which would make this chelator undesirable 
(Martin et al., 1991; Cao et al., 2005).  Also, proline-rich peptides containing the PPLP 
motif have been used to prevent the oligomerization of Vif in nonpermissive cells and 
inhibit the replication of HIV-1 (Miller et al., 2007; Yang et al., 2003).  Peptide inhibitors, 
such as these, provide useful information on protein-protein interactions, but are not 
desirable as antiviral drugs due to their low stability and poor bioavailability (Adessi et 
al., 2002).   
 In order to indirectly increase incorporation of A3 proteins into HIV-1 virions, the 
interacting domains of both Vif and A3 need to be elucidated.  Currently, in vitro Vif-A3G 
binding assays are underway using a fluorescence resonance energy transfer (FRET) 
assay to measure the interactions between GST-Vif and a biotinylated A3G peptide.  
High-throughput screening is being used to identify potential candidate molecules that 
may target the Vif-A3G interaction (Mehle et al., 2007).   
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 Another indirect approach may be to create a molecule that directly binds A3 and 
inhibits the binding of HIV-1 Vif (Harris et al., 2004).  Also, it could be theoretically 
possible to create a molecule that could be used to inhibit the interaction of HIV-1 Vif 
with either A3 proteins or the proteosomal machinery.  For example, RN-18 (containing 
a 2-(4-nitophenylthio-N-phenylbenzamide) moiety) is a small-molecule antagonist of 
HIV-1 Vif that inhibits the interaction between A3-Vif (Nathans et al., 2008). RN-18 
increases the expression levels of A3G, A3F, A3C as well as the incorporation of A3G 
into the virion, but it does not affect the binding of HIV-1 Vif to A3G or A3F.  The 
inhibitor does increase the proteosomal degradation of Vif in the presence of A3G, A3F, 
or A3C.  Also, RN-18 did not display cytotoxic effects at a concentration of 50-100 µM 
(Nathans et al., 2008). However, this inhibitor is a recent development and is not yet 
ready for clinical trials.  While there has been promising success in designing small 
molecule inhibitors, more research is needed to visualize the structural interaction 
between A3 and Vif to design efficient interaction inhibitors.   
 The final approach may be the use of gene therapy.  However, further advances 
in both safety and efficacy of both cell therapy and gene delivery must be overcome.  As 
mentioned above, the Vif-A3 interaction is species-specific.  If human A3G aspartate 
128 is substituted with the lysine found in both the rhesus macaque and the African 
green monkey A3G, the human A3G would become resistant to Vif-mediated 
proteosomal degradation (Mariani et al., 2003).  The human D128K A3G mutation 
would protect hA3G from binding HIV-1 Vif (Bogerd et al., 2004; Huthoff et al., 2007; Li 
et al., 2008; Mangeat et al., 2004; Schröfelbauer et al., 2004).  Theoretically this would 
lead to increased packaging of A3G into the HIV-1 virion by preventing its interaction 
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with Vif thus leading to the restriction of HIV-1.  To date, there are no known 
occurrences of this allele circulating in the human population; therefore, therapeutic 
gene delivery would be necessary.  Another method would be to fuse A3G to ubiquitin-
associated domain 2 (UBA2), a stabilization signal known to protect proteins from 
proteosomal degradation (Li et al., 2008).  This fusion only has a partial effect on 
restriction of HIV-1 and is only partially restricted to Vif-mediated degradation (Li et al., 
2008).  This modifcation along with others may someday provide a tactic in engineering 
T cells to be resistant to HIV-1 infection.   
  
Goals of the study 
 All primate lentiviruses encode for a Vif protein, which is necessary for HIV-1 
replication in primary CD4+ T cells and macrophages (Fan and Peden, 1992; Gabuzda 
et al., 1992; Blanc et al., 1993; Sakai et al., 1993; von Schwedler et al., 1993; Borman 
et al., 1995).   The Vif protein interacts with apolipoprotein B mRNA-editing enzyme 
catalytic peptide-like 3 (APOBEC3; A3) proteins promoting their accelerated 
degradation by the 26S proteosome (Sheehy et al., 2002). Sequence analysis of Vif 
proteins from different lentiviruses revealed that there are two highly conserved 
domains in the carboxyl terminus that are required for the recruitment of the Vif-CBF-β-
Cul5/Elongin B/C/Rbx-1 E3 ubiquitin ligase complex (Hultquist et al., 2012; Luo et al., 
2005; Mehle et al., 2004; 2006; Yu et al., 2004).  These domains are the viral BC box, 
SLQ(Y/F)LA, and the Zn2+ (H-X5-C-X17-18-C-X3-5-H; HCCH) binding domains.  Previous 
cell culture studies have shown that the introduction of amino acid substitutions in the 
SLQ(Y/F)LA motif resulted in decreased binding of Vif to Elongin C, while substitutions 
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in the HCCH domain prevented interactions with Cullin 5 in the Vif-CBF-β-Cul5/Elongin 
B/C/Rbx-1 E3 ubiquitin ligase complex (Luo et al., 2005; Mehle et al., 2004a; 2004b; 
2006; Stopak et al., 2003; Yu et al., 2203; 2004).    
 In our first study we were interested in determining the importance of the highly 
conserved SLQYLA motif in viral pathogenesis using the SHIV/macaque model of 
infection.  Two amino acid substitutions were introduced into the SLQYLA (AAQYLA) 
domain of the SIV Vif protein. Prior to our rhesus macaque study, the resulting virus, 
SHIVVifAAQYLA, was assessed in both non-permissive (CEM) and permissive (CEM-SS) 
cells to examine the replication of these mutant viruses relative to parental SHIV.  We 
found that, while SHIVVifAAQYLA replicated with similar kinetics to SHIVKU-1bMC33 in CEM-
SS cells, it did not replicate in CEM cells.  We were also interested in determining if 
human A3G is incorporated into SHIVVifAAQYLA and showed that human A3G was readily 
incorporated into SHIVVifAAQYLA virions but not SHIVKU-1bMC33. To assess the replication 
and persistence of SHIVVifAAQYLA in vivo, SHIVVifAAQYLA was inoculated into three rhesus 
macaques where various viral and immunological parameters were followed for six 
months.  All three macaques inoculated with SHIVVifAAQYLA developed a transient 
decrease in circulating CD4+ T cells one week post-inoculation that rebounded to pre-
inoculation levels by four weeks post-inoculation.  These macaques also had plasma 
viral loads that were 100-fold lower than macaques inoculated with SHIVKU-1bMC33, 
developed no histological lesions in lymphoid tissues, and had a decreased distribution 
of replicating virus in visceral tissues.  The engineered Vif mutations were stable during 
the first three weeks post-inoculation, but by four weeks post-inoculation the S147A 
amino acid substitution changed to a threonine in two of the three macaques.  At 
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necropsy, plasma was analyzed for the presence of immunoprecipitating antibodies, 
and all three macaques developed immunoprecipitating antibodies although one 
macaque developed significantly less.  Sequence analysis of vif, vpu, env, and nef from 
the thymus, mesenteric, axillary, and inguinal lymph nodes, revealed an increased 
amount of G-to-A substitutions in the dinucleotide context of 5’-TC (minus strand) in 
these genes amplified from macaques inoculated with SHIVVifAAQYLA.  To determine if 
pathogenic virus was present in plasma from macaques inoculated with SHIVVifAAQYLA at 
the time of necropsy, plasma was pooled from two of the three macaques and 
inoculated into a naïve macaque (macaque I95).  Macaque I95 was assessed for 
various viral parameters such as circulating CD4+ T cell levels, virus burden, 
imuunoprecipitating antibodies, and the detection of replicating virus in both PBMC and 
visceral tissues.  We showed that this macaque maintained circulating CD4+ T cell 
levels, no viral loads, and no immunoprecipitating antibodies.  Viral DNA sequences 
(the gag gene) could be detected in PBMC through out the duration of infection; 
however, viral RNA sequences could not.  At necropsy, viral DNA and RNA could be 
detected in the liver, kidney, spleen, tonsil, axillary lymph node, and small intestine 
(ileum).  This study indicated that a certain level of infectious viral replication was 
occurring in macaques inoculated with SHIVVifAAQYLA and that the pooled plasma 
contained only low levels of infectious virus that was efficiently controlled by macaque 
I95.   
In our second study we used the SHIV/macaque model of infection to compare 
the replication and pathogenicity of SHIVs that express a Vif protein in which the entire 
SLQYLA (SHIVVif5A) or HCCH (SHIVVifHCCH(-)) domains were substituted with alanine 
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residues.  We were interested in extending our previous studies to determine if these 
highly conserved domains were critical to Vif function in vivo.  Prior to our rhesus 
macaque study, we were interested in determining whether SHIVVif5A and SHIVVifHCCH(-) 
were effectively inhibited by rhesus A3G/F.  We performed assays to examine the 
replication of these mutants in both non-permissive (C8166, PBMC) and permissive 
(SupT1) cells.  We also determined if SHIVVif5A and SHIVVifHCCH(-) in the presence of 
rhesus A3G/F incorporated into virions, remained stably expressed in cells, restricted 
virus replication, and if these viruses were capable of introducing significant G-to-A 
substitutions into the nef gene of the SHIV genome in vitro.  We found that both 
SHIVVif5A and SHIVVifHCCH(-) did not replicate in non-permissive cells but replicated 
efficiently in permissive cells.   We also showed that rhesus A3G/F was readily 
incorporated into SHIVVif5A and SHIVVifHCCH(-) virions, remained stably expressed in the 
cell, severely restricted viral replication, and induced a significant number of G-to-A 
substitutions in nef similar to SHIVVifStop (SHIV expressing a Vif protein with two stop 
codons introduced at amino acid residues 28 and 29).   To assess the replication 
and persistence of these viruses in vivo, each virus was inoculated into three rhesus 
macaques where various viral and immunological parameters were followed for six 
months.  All macaques maintained a stable level of circulating CD4+ T cells, low viral 
burdens, maintained engineered mutations, yielded no histological lesions, and 
developed immunoprecipitating antibodies by 12 weeks post-inoculation.  However, the 
production of viral RNA only persisted in macaques inoculated with SHIVVifHCCH(-).  
Sequence analysis of nef and vpu from the small intestine (ileum), thymus, and the 
spleen showed extensive G-to-A substitutions in nef genes isolated from macaques 
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inoculated with SHIVVifHCCH(-).  Macaques inoculated with SHIVVif5A effectively controlled 
the virus three weeks post-inoculation and no viral sequences could be amplified from 
tissue DNA.  These studies showed that the SLQYLA and HCCH domains are critical 
for viral pathogenesis in vivo and that there may exist APOBEC3 negative reservoirs in 
the rhesus macaque that allow for low levels of viral replication and persistence but not 
disease.  Therefore, from these first two studies we inferred that mutations targeted to 
one or more functional conserved domains within the Vif protein may limit viral 
replication and generate an effective immune response leading to the “self-inactivation” 
of the virus by the activities of various APOBEC3 proteins resulting in a possible live-
attenuated vaccine candidate.   
 While the human APOBEC3 repertoire has been extensively studied, the full 
complement of these proteins in the rhesus macaque remains unknown. Sequencing of 
the rhesus macaque genome has led to the identification of the rhesus homologues 
A3B, A3C, A3D, A3F, A3G, and A3H.  In the final study, we were interested in 
identifying and characterizing the human A3A (hA3A) homologue in the rhesus 
macaque (rhA3A).   Using cDNA from Concanavalin-A-activated rhesus macaque 
PBMCs, we were able to detect and clone rhesus A3A.  Using the cloned rhesus A3A 
sequence we were able to determine that both the human and rhesus Apobec3 genes 
are orthologous. We show that rhA3A is highly expressed in activated CD4+ T cells, 
widely expressed in both the visceral and central nervous system tissues of the rhesus 
macaque, maintains nucleocytoplasmic localization, does not inhibit virus release, does 
not restrict foreign DNA, and is degraded in the presence of the human 
immunodeficiency virus (HIV-1) and simian-human immunodeficiency virus (SHIV) 
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genomes in a Vif-dependent manner.    Our results also indicate that rhA3A reduced the 
level of infectious SHIVΔvif by approximately 20-fold and HIV-1Δvif by 3-fold.  Human 
and monkey A3A amino acid sequences are 81% homologous and can be distinguished 
by a three amino acid indel (insertion and/or deletion) located between residues 27-30. 
When these residues were deleted from rhA3A (rhA3AΔSVR), the antiviral activity of 
rhA3A was abolished suggesting that these residues are critical for lentivirus inhibition.  
Select APOBEC3 proteins are incorporated into the virion and can inhibit reverse 
transcription and/or induce G-to-A hypermutation in nascent reverse transcripts in the 
next target cell. Previous studies revealed that rhA3G is incorporated into SHIVΔvif 
virions and exerts its antiviral activity in target cells by an increase in cytidine 
deamination of newly synthesized minus-strand viral DNA from cytosines to uracils, 
leading to G-to-A substitutions (plus strand) in the viral genome.  We were able to 
detect the incorporation of rhA3A into SHIVΔvif and to a lesser extent in SHIV virions; 
however, we were unable to detect the incorporation of rhA3A into either HIV-1 or HIV-
1Δvif virions.  Even though rhA3A is incorporated into SHIVΔvif virions and potently 
restricts SHIVΔvif similar to rhA3G, rhA3A produced an approximately 5-fold decrease 
in the number of G-to-A mutations compared to rhA3G. Since previous research 
showed that human A3A inhibits the replication of adeno-associated virus 2 (AAV-2), 
intracisternal A particles (IAP), and long interspersed nuclear element 1 (L1), we were 
interested in determining if rhesus A3A could inhibit AAV-2 replication and L1 
retrotransposition (Bogerd et al., 2006a; 2006b; Chen et al., 2006; Muckenfuss et al., 
2006).  We found that rhesus A3A could not inhibit AAV-2 replication or L1 
retrotransposition.  The data from this study suggests for the first time that a primate 
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A3A protein can inhibit lentiviral replication but not AAV-2 replication or L1 
retrotransposition.   
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VI.        Chapter Two: Mutations in the SLQYLA Motif of Vif in the Simian-Human  
             Virus Results in a Less Pathogenic Virus in Rhesus Macaques 
 
Abstract 
 The simian-human immunodeficiency virus (SHIV)/macaque model for human 
immunodeficiency virus type 1 (HIV-1) has become a useful tool to assess the role of 
accessory genes like virion infectivity factor (Vif), in lentiviral pathogenesis.  In this 
study, we introduced two amino acid changes in the highly conserved SLQYLA domain 
(to AAQYLA) of the SIV Vif protein.  The resulting virus SHIVVifAAQYLA, was used to infect 
three macaques, which were followed for over six months.  Plasma viral loads and 
circulating CD4+ T cell levels were assessed during the course of infection.  The three 
macaques inoculated with SHIVVifAAQYLA did not develop significant CD4+ T cell loss over 
the course of their infection, had plasma viral loads that were over 100-fold lower than 
macaques inoculated with parental SHIVKU-1bMC33, and developed no histological lesions 
in lymphoid tissues.   DNA and RT-PCR analysis revealed that only a select number of 
tissues were infected with this virus.  Sequence analysis indicates that the site-directed 
changes were stable during the first three weeks after inoculation but thereafter the 
S147A amino acid substitution changed to a threonine in two of the three macaques.  
However, the L148A substitution remained stable in the vif amplified from the PBMC of 
all three macaques.  Sequence analysis of vif, vpu, env, and nef genes revealed G-to-A 
substitutions in the genes amplified from macaques inoculated with SHIVVifAAQYLA, which 
were higher than in a macaque inoculated with parental SHIVKU-1bMC33.  We found that 
the majority (>85%) of the G-to-A substitutions were in the context of 5’-TC (minus 
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strand) and not 5’-CC, suggestive that one or more the rhesus APOBEC3 proteins may 
be responsible for the observed mutational patterns. Finally, macaques inoculated with 
SHIVVifAAQYLA developed immunoprecipitating antibody responses against the virus.  The 
results from this study provide the first in vivo evidence of the importance of the 
conserved SLQYLA domain in viral pathogenesis and show that targeted mutations in 
vif can lead to a persistent infection with G-to-A (plus strand) changes accumulating in 
the viral genome. 
 
Introduction 
Human immunodeficiency virus type 1 (HIV-1) as well as other lentiviruses 
encode for a Vif protein, which has been shown to be essential for HIV-1 replication in 
certain cell types.   The Vif protein of HIV-1 was first shown to interact with 
apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G; 
hA3G) (Sheehy et al., 2002).  This protein was found to be incorporated into the virus 
and provide cells with an innate intracellular anti-retroviral activity that is associated with 
hypermutation of the viral genome through cytidine deamination (Harris et al., 2003; 
Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003).  This hA3G-induced 
cytidine deamination results in cytidine to uridine changes during minus strand DNA 
synthesis triggering the DNA repair pathways that lead to the degradation of viral 
transcripts (Harris et al., 2003; Mangeat et al., 2003; Mariani et al., 2003; Yu et al., 
2004; Zhang et al., 2003).  Several groups subsequently showed that the Vif protein can 
prevent hypermutation by binding to hA3G and targeting this protein for degradation via 
the proteasome  (Conticello et al., 2003; Kao et al., 2004; Mariani et al., 2003; Marin et 
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al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003; 
2004).  In addition to A3G, humans have six other A3 genes: hA3A, hA3B, hA3C,  
hA3DE,  hA3F, and hA3H (Jarmuz et al., 2002).  The members of this family either have 
one (hA3A, hA3C, and hA3H) or two (hA3B, hA3DE, hA3F and hA3G) Zn+2 coordinating 
deaminase domains organized as H-x1-E-x25-31-C-x 2-4-C  (with x being a non-conserved 
position) (Chiu and Greene, 2008).   Other APOBEC3 family members such as hA3B, 
hA3DE, hA3F, and hA3H have also been shown to also inhibit the replication of HIV-
1Δvif  (Dang et al., 2007; Doehle et al., 2005; Wiegand et al., 2004; Yang et al., 2007; 
Yu et al., 2004; Zheng et al., 2004).   Moreover, SIVmac239Δvif is potently restricted by 
hA3G, hA3F, and hA3H and to a lesser extent by hA3B, hA3C, and hA3DE (Dang et al., 
2007; 2008; Mariani et al., 2003; Virgen et al., 2007; Yu et al., 2004).  While fewer 
studies have been performed on the APOBEC3 family proteins from macaques, two 
studies have shown that rhesus macaque A3G and A3F inhibit the replication of 
SIVmacΔvif (Zennou et al., 2006; Virgen et al., 2007). 
As mentioned, previous studies have shown that Vif inhibits the antiviral activity 
of APOBEC3 proteins by targeting A3 proteins for proteosomal degradation through a 
CBF-β-Vif-Cul5/ElonginB/C/Rbx-1 E3-dependent ubiquitin ligase (Jäger et al., 2011; 
Kobayashi et al., 2005; Mehle et al., 2004; Shao et al., 2010; Stanley et al., 2008; Yu et 
al., 2004).  Vif binds the Cullin 5 complex through a highly conserved BC-box region 
known as the 144SLQ(Y/F)LA149 domain (Yu et al., 2003).  The BC-box of Vif is a loop-
helix motif with a consensus sequence ((A/P/T/S)1L2xxx(C/A/S)6xxx(A/V/L/I)10) that has 
also been identified in other cellular proteins that are known to interact with elongin B/C 
(Kamura et al., 2004; Luo et al., 2005).  Through this motif, Vif has a high affinity for 
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elongin B/C (Mehle et al., 2004).    Mutation or deletion of the SLQ(Y/F)LA motif disrupts 
the proteosomal targeting and degradation of A3 proteins, and prevents the production 
of infectious HIV-1 virions (Kobayashi et al., 2005; Mehle et al., 2004a; 2004b; Shao et 
al., 2010; Simon et al., 1999; Stanley et al., 2008; Yu et al., 2004).  While this domain 
has been extensively studied in vitro, no studies have assessed the role of this domain 
using a non-human primate model of HIV-1 pathogenesis.   
In this study, we constructed a simian-human immunodeficiency virus (SHIV) 
with amino acid changes in the highly conserved SLQYLA (SHIVVifAAQYLA) domain and 
assessed it for pathogenesis in macaques.  Mutation of this motif resulted in lower viral 
loads, stabilization of circulating CD4+ T cell levels, immunoprecipitating antibodies, and 
the accumulation of G-to-A substitutions in secondary lymphoid tissues.  Our results 
show for the first time that the SLQYLA domain has determinants that contribute to the 
pathogenicity of SHIV in macaques and that mutations in this particular domain result in 
the accumulation of G-to-A mutations in the viral genome.  
 
Results 
Replication of SHIVVifAAQYLA in APOBEC3G (A3G) positive and negative cell lines 
 We performed assays to examine the replication of parental SHIVKU-1bMC33 and 
SHIVVifAAQYLA in A3G/F positive (CEM) and negative (CEM-SS) cell lines.  Cells were 
infected with each of the two viruses and the levels of p27 Gag released into the culture 
medium were quantified using a commercial antigen capture assay.  SHIVVifAAQYLA 
replication in CEM-SS cells with similar kinetics to SHIVKU-1bMC33 (Figure 14A).  
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However, SHIVVifAAQYLA released less than 0.5% p27 compared to the parental SHIVKU-
1bMC33 in CEM cells (Figure 14B).   
 
Human APOBEC3G is incorporated into SHIVVifAAQYLA virions 
 Since SHIVVifAAQYLA released significantly less p27 than SHIVKU-1bMC33 in CEM 
(A3G/F positive) cells, we determined if human A3G was incorporated into maturing 
virus particles leading to the restriction of SHIVVifAAQYLA replication.  293 cells were 
transfected with HA-hA3G and the complete genomes of either SHIVVifAAQYLA or SHIVKU-
1bMC33.  At 48 hours post-transfection, the culture medium was collected, clarified, and 
the virus partially purified and concentrated by ultracentrifugation.  The amount of p27 
was determined and a western blot was run to detect for the presence or absence of 
hA3G.  The results shown in Figure 15 indicate that hA3G was incorporated into 
SHIVVifAAQYLA virus particles but excluded from SHIVKU-1bMC33.   
 
Disease in macaques inoculated with SHIVVifAAQYLA 
 We inoculated three macaques with SHIVVifAAQYLA (RAK10, RCS10, and RPL10).  
These macaques developed a transient decrease in the level of circulating CD4+ T cells 
at one week post-inoculation (Figure 16B).  However, by four weeks post-inoculation the 
level of circulating CD4+ T cells rebounded to near pre-inoculation levels (Figure 16B).    
These macaques maintained high levels of circulating CD4+ T cells throughout the 
course of their infection.  All three macaques were euthanized at 28 weeks post-
inoculation.  At necropsy, macaques inoculated with  
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Figure 14.  Replication of SHIVKU-1bMC33 and SHIVVifAAQYLA in APOBEC3G positive 
(CEM) and negative (CEM-SS) cell lines.  CEM and CEM-SS cells were inoculated 
with equal amounts of each virus and levels of p27 in the culture supernatants 
determined at various time points post-inoculation.  (Panel A)  Replication of 
SHIVKU-1bMC33 and SHIVVifAAQYLA in CEM-SS cells.  (Panel B)  SHIVKU-1bMC33 and 
SHIVVifAAQYLA in CEM cells. (  ) SHIVKU-1bMC33; (  )  SHIVVifAAQYLA.   
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Figure 15.  Human APOBEC3G is incorporated into SHIVVifAAQYLA virions.   293 
cells were transfected with a plasmid that expresses the genome of either SHIVKU-
1bMC33 or SHIVVifAAQYLA and a vector expressing HA-hA3G.  At 48 hours, the culture 
medium was collected, clarified, and concentrated by ultracentrifugation through 
a 20/60% sucrose (w/v) gradient.  Equivalent levels of p27 from each sample was 
resuspended in 2x sample reducing buffer, boiled, and proteins separated by 
SDS-PAGE.  The presence of hA3G was detected by Western blot using an 
antibody directed against the HA-tag.  Lane 1.  Human A3G protein in pelleted 
supernatant from cells transfected with empty vectors.  Lane 2-4.  Human A3G 
detected in virus from cells transfected with the vector expressing hA3G and 
SHIVKU-1bMC33 (Lane 2), SHIVVifAAQYLA (Lane 3), or the positive control SHIVΔVif 
(Lane 4).      
 
 
 
 
 
	   122	  
 
 
 
 
 
 
 
 
	   
 
 
	   123	  
 
 
 
 
 
 
 
 
Figure 16.  Circulating CD4+ T cell levels in macaques inoculated with SHIVKU-
1bMC33 and SHIVVifAAQYLA.  (Panel A)  The levels of circulating CD4+ T cells in five 
macaques inoculated with SHIVKU-1bMC33 (2000,  ; CM4G,  ; CM4K, ; RRH10, ).  
(Panel B)  The levels of circulating CD4+ T cells in three macaques inoculated 
with SHIVVifAAQYLA (RAK10,  ; RCS10, ; RPL10, ).   
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SHIVVifAAQYLA had circulating CD4+ T cell counts of 2427, 1656, and 3021, respectively.  
This contrasts with macaques inoculated with SHIVKU-1bMC33 (Figure 16A).  Analysis of 
plasma viral loads in macaques inoculated with SHIVVifAAQYLA revealed that during the 
early peak (1 to 3 weeks) of viremia, the mean load was 8.52 x 104 copies per ml 
(Figure 17A), approximately 100-fold less than macaques inoculated with parental 
SHIVKU-1bMC33 (Figure 17B).  Following the first month of infection, the plasma viral loads 
in macaque RPL10 declined faster than macaques RAK10 and RCS10 (Figure 17A).   
 
Stability of the vif gene mutations during the course of infection and at necropsy  
 We assessed the stability of the engineered mutations in the vif gene during the 
course of infection.  DNA was extracted from PBMC samples at various times post-
inoculation and from lymphoid tissues at necropsy.  The vif sequences were amplified, 
directly sequenced and compared to the input vif sequence of SHIVVifAAQYLA.  The vif 
mutations were stable from one to three weeks post-inoculation for all three 
SHIVVifAAQYLA infected macaques (Figure 18).  However, four weeks post-inoculation the 
S147A amino acid substitution changed to a threonine in two of the macaques, RPL10 
and RAK10.  Interestingly, this amino acid substitution was mediated by a G-to-A 
mutation.  DNA from lymphoid organs obtained at necropsy from RAK10 and RPL10 
also showed the A147T mutation whereas macaque RCS10 maintained the S147A 
amino acid substitution (Figure 18).  The L148A substitution was found to be stable 
during the course of infection for all three macaques and in the lymphoid organs 
analyzed at necropsy.  There were no mutations in this region of vif from RRH10, which 
was inoculated with SHIVKU-1bMC33 (Figure 18).   
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Figure 17.  Plasma viral loads in macaques inoculated with SHIVVifAAQYLA and 
SHIVKU-1bMC33.  (Panel A)  Plasma viral loads in three macaques inoculated with 
SHIVVifAAQYLA (RAK10,  ; RCS10,  ; RPL10, ).  (Panel B)  Plasma viral loads in 
four macaques (2000,  ; CEM4G, ; CEM4K,  ; and RRH10, ) following 
inoculation with SHIVKU-1bMC33.       
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Figure 18.  Analysis of the vif gene for the stability of the engineered mutations.  
DNA was isolated from PBMC at 1, 3, 4, 8, 12, and 28 weeks post-inoculation and 
from lymphoid tissues (thymus, mesenteric lymph node and inguinal lymph node) 
at necropsy.  The vif gene was amplified and directly sequence.  Shown at the top 
are the sequences for both parental SHIVKU-1bMC33 and SHIVVifAAQYLA.  Amino acids 
depicted in red indicate the A147T mutation and the amino acids shown in blue 
indicate the maintained S147A amino acid substitution.   
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Macaques inoculated with SHIVVifAAQYLA developed antibody responses against 
SHIV 
 At necropsy, we analyzed the plasma for the presence of immunoprecipitating 
antibodies against SHIVKU-1bMC33.  All three macaques developed immunoprecipitating 
antibody responses against SHIVKU-1bMC33, although macaque RCS10 developed 
significantly lower antibody response compared to the other two macaques (Figure 19).  
In contrast, a macaque inoculated with parental SHIVKU-1bMC33 (RRH10) did not develop 
antibodies to the virus, which is common for macaques that develop severe CD4+ T cell 
loss during the acute phase (<4 weeks) following inoculation with pathogenic X4 SHIV 
(Figure 19).   
 
Histological examination of tissues 
 Tissues from macaques were examined for the presence of histological lesions 
consistent with pathogenic X4 SHIV infection (Stephens et al., 2002).  Histological 
examination of tissues from macaque RRH10, which was inoculated with SHIVKU-1bMC33, 
revealed severe lymphoid depletion in both the thymus and lymph nodes and mild 
lymphoid depletion in the spleen (Figure 20).  The lymphoid depletion observed in the 
macaques is consistent of that observed following inoculation with the parental SHIVKU-
1bMC33 (Stephens et al., 2002).  The macaques inoculated with SHIVVifAAQYLA did not 
exhibit lesions in any of the 13 visceral organs and CNS.  Micrographs of sections from 
the thymus, mesenteric lymph node, and spleen from macaque RAK10 are shown along 
with micrographs of histological sections from an uninfected macaque in Figure 20.   
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Figure 19.  Macaques inoculated with SHIVVifAAQYLA developed antibody responses 
against SHIV.  C8166 cells were inoculated with SHIVKU-1bMC33 for 5 days, starved 
in methionine/cysteine-free media and radiolabeled overnight with 35S-
methionine/cysteine.  The culture medium was harvested and used in 
immunoprecipitation reactions with plasma from RAK10, RCS10, RPL10 and 
RRH10 as described in the Experimental Methods.  The immunoprecipitates were 
washed with 1x RIPA buffer, boiled in 2x sample reducing buffer and proteins 
separated on 10% SDS-PAGE gels.  (Lane 1)  SHIV proteins immunoprecipitated 
using supernatant from an uninfected culture.  (Lane 2)  SHIV proteins 
immunoprecipitated from a positive control plasma sample.  (Lane 3)  SHIV 
proteins immunoprecipitated using RAK10 plasma.  (Lane 4)  SHIV proteins 
immunoprecipitated using RCS10 plasma.  (Lane 5).  SHIV proteins 
immunoprecipitated using RPL10 plasma.  (Lane 6)  SHIV proteins 
immunoprecipitated using RRH10 plasma.  The molecular weight standards are 
displayed on the left and specific SHIV proteins are shown on the right.   
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Figure 20. Histopathology associated with SHIVVifAAQYLA infection of macaques.  
Hematoxylin and eosin stains of section from the thymus (A-C), mesenteric lymph 
node (Panels D-F) and spleen (Panels G-I) from a SHIVVifAAQYLA inoculated 
macaque RAK10 (Panels A, D, and G), an uninfected macaque (Panels B, E and H) 
and a SHIVKU-1bMC33 infected macaque RRH10 (Panels C, F, and I).   
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Macaques inoculated with SHIVVifAAQYLA had decreased tissue distribution of 
replicating virus 
 Since the plasma viral loads were decreased in comparison to macaques 
inoculated with parental SHIVKU-1bMC33, we were interested in determining if this effect 
was due to the infection of select cell populations in one or more organs, which may not 
express rhesus A3G.  First, we analyzed DNA isolated from 13 visceral organs from 
SHIVVifAAQYLA macaques for the presence of viral gag sequences by nested DNA PCR.  
We found that 12 of the 13 visceral organs from a SHIVKU-1bMC33 inoculated macaque 
(RRH10) were positive for viral gag sequences in DNA samples (Figure 21).  For 
macaques inoculated with SHIVVifAAQYLA, we found that 6 of the 13, 8 of the 13, and 12 
of the 13 organs from macaques RAK10, RCS10 and RPL10, respectively, were 
positive for viral gag sequences by nested DNA PCR (Figure 21).  The majority of the 
organs that were gag positive were lymphoid organs.  We next assessed RNA isolated 
from these tissues for the presence of viral gag RNA sequences using RT-PCR.  The 
results of this analysis are shown in Figure 22.  We found that 5 of 13, 6 of 13, and 9 of 
13 visceral organs from macaques RAK10, RCS10 and RPL10 were positive for viral 
gag RNA sequences, respectively.  A macaque inoculated with SHIVKU-1bMC33 (RRH10) 
had 11 of the 13 organs positive for the presence of gag RNA sequences.  Taken 
together, these results indicate that the SHIVVifAAQYLA infection was less widespread in 2 
or the 3 macaques compared to a macaque inoculated with parental SHIVKU-1bMC33.   
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Figure 21.  Macaques inoculated with SHIVVifAAQYLA had a decreased tissue 
distribution of proviral DNA.  DNA was isolated from different organs as indicated 
at necropsy and amplified using nested DNA PCR and oligonucleotides specific 
for gag.  Samples were run on a 1.5% agarose gel, stained with ethidium bromide, 
and photographed.  Shown are the results of the nested DNA PCR reaction using 
DNA from macaques RRH10 (Panel A), RAK10 (Panel B), RCS10 (Panel C) and 
RPL10 (Panel D).  The tissues DNAs analyzed are noted above each lane and the 
100 base pair marker is indicated on the right.  The positive control was gag 
amplified from lymph node tissue obtained from macaque 50O that died of 
neuroAIDS (McCormick-Davis et al., 2000) and the negative control was spleen 
tissue DNA from an uninfected macaque.  
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Figure 22.  Macaques inoculated with SHIVVifAAQYLA had a decreased tissue 
distribution of viral RNA.  RNA was isolated from 13 different visceral organs 
obtained at necropsy. The RNA was DNase I treated to remove residual DNA and 
used in a nested RT-PCR reaction with oligonucleotides specific for gag.  
Samples were run on a 1.5% agarose gel, stained with ethidium bromide and 
photographed.  The results are shown as follows:  Macaques RRH10 (Panel A), 
RAK10 (Panel B), RCS10 (Panel C) and RPL10 (Panel D).  The tissue RNAs 
analyzed are noted above each lane.  The positive control was amplified from  
lymph node tissue obtained from macaque 50O that died of neuroAIDS 
(McCormick-Davis et al., 2000).  The negative control was spleen RNA isolated 
from an uninfected macaque.  The 100 bp marker is indicated on the right.   
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Sequence changes in vif, vpu, env and nef in primary and secondary lymphoid 
organs at necropsy 
 Previous research has shown that HIV-1Δvif incorporates select A3 proteins into 
viral particles leading to cytosine deamination in the minus strand during DNA synthesis 
(Sheehy et al., 2002; Bishop et al., 2004). Hypermutation in HIV-1 reverse transcripts 
display a high frequency of G-to-A substitutions in the plus strand of DNA resulting in 
inhibition of virus replication (Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 
2003).  We examined the extent of G-to-A mutations in viral DNA amplified from one 
primary lymphoid organ (thymus) and several secondary lymphoid organs (mesenteric, 
axillary, and inguinal lymph nodes) from three macaques inoculated with SHIVVifAAQYLA 
and one macaque inoculated with SHIVKU-1bMC33 (RRH10).  We analyzed sequences 
from the vif, vpu, env, and nef genes.  The results of the sequence analysis are shown 
in Table III.  These analyses showed that: a) with the exception of env, the thymus 
consistently had the lowest percentage of G-to-A substitutions; b) not all lymphoid 
organs had significant G-to-A substitutions; and c) greater than 85% of the G-to-A 
mutations were in the context of TC and not CC.  The sequence of vpu amplified from 
the lymphoid tissues of macaque RPL10 is shown as an example in Figure 23.  
Macaque RRH10 had the fewest G-to-A substitutions in all of the lymphoid organs, 
which is similar to other macaques inoculated with SHIVKU-1bMC33 (unpublished 
observations).  The percentage of mutations was approximately <0.2-0.41% of the 
nucleotides analyzed for macaque RRH10.  The highest percentage of G-to-A 
substitutions was found in the nef gene of macaque RCS10 inoculated with 
SHIVVifAAQYLA (5.0%).   
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Table III.  Results of viral DNA sequence analysis from visceral tissues at 
necropsy 
 
 
 
 
 
 
 
 
	   142	  
 
 
 
 
 
 
 
	   143	  
 
 
 
 
 
 
 
 
 
 
Figure 23.  Sequence of the vpu gene amplified from lymphoid tissues of 
macaque RPL10.  Shown on the top line is the input sequence of vpu from 
SHIVKU-1bMC33.  The (.) represents identity with the nucleotide sequence shown 
above. The underlined sequences represent the context in which the G-to-A 
substitutions occurred.    
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Pooled plasma from two macaques inoculated with SHIVVifAAQYLA contained low 
levels of infectious virus when transfused into a naïve macaque 
 In order to determine if infectious virus was present in plasma that was not 
detected in our infectivity assays, plasma from macaques RAK10 and RPL10 was 
pooled and intravenously inoculated into a naïve macaque, I95.  We were able to detect 
viral gag sequences in DNA isolated from PBMC at 0, 1, 2, 3, 4, 5, 6, and 20 weeks 
post-inoculation (Figure 25).  We also assessed plasmas from macaque I95 for viral 
loads using real-time PCR from weeks 0 to 20.  We were unable to detect viral burdens 
in macaque I95.  The level of circulating CD4+ T cells did not decrease from the pre-
inoculation levels (Figure 24).  We were unable to detect antibodies in the plasma from 
this macaque at week 9 (data not shown).  At 20 weeks post-inoculation, macaque I95 
was sacrificed.  DNA was isolated from PBMC at various time points throughout the 
duration of infections and from 10 visceral organs and used in a nested PCR to detect 
viral gag sequences.  Viral gag sequences were amplified from all 10 visceral organs 
examined (Figure 26).  We also isolated RNA from the same organs for use in RT-PCR 
to detect viral gag RNA sequences.  The viral RNA was detected in six organs (liver, 
kidney, axillary lymph node, small intestine (ileum), spleen, and tonsil) (Figure 27).  This 
indicates that some level of viral replication was ongoing although we were unable to 
isolate infectious virus on CEM-SS and SupT1 cells (data not shown).  Taken together, 
these results indicate that pooled plasma contained only low levels of infectious virus 
that were controlled by the immune system of macaque I95.   
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Figure 24.  Viral loads and circulating CD4+ T cell levels in macaque I95 that was 
intravenously inoculated with pooled plasma from macaques RAK10 and RPL10 
obtained at necropsy.  Blood was obtained at 0 (just prior to inoculation), 1, 2, 3, 
4, 5, 6 and 20 weeks after inoculation.  Results of the real-time PCR for viral gag 
sequences from plasma samples (  ; scale to left) and circulating CD4+ T cell 
levels (  ; scale to right).    
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Figure 25.  Presence of viral DNA sequences in PBMC from macaque 195.  PBMC 
were purified over Ficoll-Hypaque gradients and total cellular DNA was isolated.  
DNA was used in a nested DNA PCR for viral gag.  (Lane 1)  100 base pair marker.  
(Lane 2)  Positive control, week 1 PBMC DNA from macaque RRH10 (inoculated 
with SHIVKU-1bMC33.  (Lane 3-10)  Represent gag sequences amplified from PBMC 
isolated from I95 at 0, 1, 2, 3, 4, 5, 6, and 20 weeks post-inoculation, respectively.    
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Figure 26.  Distribution of viral DNA gag sequences in tissues from macaque I95.  
At necropsy tissues were harvested, DNA isolated and a nested PCR for gag run.  
(Lane 1)  Positive control, lymph node tissue DNA from macaque 50O that died of 
neuroAIDS (McCormick-Davis et al., 2000).  (Lane 2)  Negative control, spleen 
tissue DNA from an uninfected macaque.  (Lane 3)  Liver.  (Lane 4)  Lung.  (Lane 
5)  Kidney.  (Lane 6)  Mesenteric lymph node.  (Lane 7)  Axillary lymph node.  
(Lane 8)  Ingunial lymph node.  (Lane 9)  Small intestine (ileum).  (Lane 10)  
Spleen.  (Lane 11)  Thymus.  (Lane 12)  Tonsil.  (Lane 13)  100 base pair marker.   
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Figure 27.  Distribution of viral RNA gag sequences in tissues from macaque I95.  
At necropsy, tissues were harvested for total RNA and a nested RT-PCR for gag 
was run.  (Lane 1) 100 base pair marker. (Lane 2) Positive control, lymph node 
tissue RNA from macaque 50O that died of neuroAIDS (McCormick-Davis et al., 
2000). (Lane 3) Negative control, spleen tissue DNA from an uninfected macaque. 
(Lane 4) Liver. (Lane 5) Lung. (Lane 6) Kidney. (Lane 7) Mesenteric lymph node. 
(Lane 8) Axillary lymph node. (Lane 9) Inguinal lymph node. (Lane 10) Small 
intestine (ileum). (Lane 11) Spleen. (Lane 12) Thymus. (Lane 13) Tonsil.  
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Discussion 
 The results presented in this publication are the first to evaluate the role of 
domain-specific mutations in the BC box domain of the vif gene using a non-human 
primate model of HIV-1/AIDS.  Previous studies have shown that the BC box domain of 
HIV-1 Vif (SLQYLALAAL) interacts with elongin C, which contains the consensus 
sequence (A, P, S, T)1L2xxx(C, A, S)6xxx(A, I, L, V)10 with the leucine at position 2 being 
invariant (Luo et al., 2005; Mehle et al., 2004).  The invariant leucine at position 2 of the 
BC box domain is critical because mutation of this amino acid to an alanine prevents the 
interaction between Vif and elongin C preventing assembly of the E3 ubiquitin Ligase 
complex (Kobayashi et al., 2005; Yu et al., 2003; Yu et al., 2004a, 2004b, 2004c).  
Since the S147 and L148 amino acid residues of the SLQYLALAAL domain are highly 
conserved among primate lentivirus Vif proteins, we chose to mutate these amino acid 
residues to alanine residues.  The results from this study indicate that macaques 
inoculated with SHIVVifAAQYLA developed no significant loss of circulating CD4+ T cells 
and had a 100-fold lower plasma viral loads during the acute phase of infection, when 
compared to macaques inoculated with SHIVKU-1bMC33.  Additionally, our analyses 
revealed fewer tissues positive for viral gag DNA and RNA sequences in 2 of the 3 
macaques inoculated with SHIVVifAAQYLA, suggesting that SHIVVifAAQYLA was controlled by 
the host.  This could be due to the presence of susceptible cells expressing one or more 
of the A3 proteins that could restrict a virus containing mutations such as these.  The 
presence of plasma viral loads in these macaques indicates that virus may have 
persisted in populations of cells that either did not express A3 proteins or expressed 
these proteins at very low levels.   
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 Thus, a major question that emerged was, “Are the viruses produced from these 
cellular reservoirs infectious, replication competent viruses?”  In order to detect small 
amounts of virus that we were unable to see in our infectious centers assay (data not 
shown), we inoculated a naïve macaque, I95, with plasma pooled from 2 of the 3 
macaques inoculated with SHIVVifAAQYLA.  Macaque I95 revealed the presence of virus in 
PBMCs between weeks 1 to 20 and in 10 tissues (liver, lung, kidney, mesenteric lymph 
node, axillary lymph node, inguinal lymph node, ileum, spleen, thymus, and tonsil) 
examined at necropsy, although the plasma viral loads were below the limits of 
detection (Figure 25).  These results suggested that plasma from the SHIVVifAAQYLA 
inoculated macaques had infectious virus, but the macaques readily controlled the virus.     
 While none of the three macaques inoculated with SHIVVifAAQYLA exhibited 
histological lesions, there were two incongruent observations.  First, macaque RPL10 
had the lowest viral loads but also had the most widespread visceral tissue distribution 
of viral gag sequences.  While the reason for this result is unclear, it could be explained 
by a greater viral distribution during the early stage of infection.  Second, macaques 
RCS10 developed less immunoprecipitating antibodies compared with macaques 
RAK10 and RPL10.  Although the answer to this question is currently unknown, if could 
relate to the inability of RCS10 to select for the A147T amino acid substitution.  Perhaps 
the A147T substitution permitted more replication in macaques RAK10 and RPL10 
providing a better antigenic stimulus.  It should also be noted that SHIVVifTAQYLA from 
RAK10 and RPL10 could not be isolated.  Therefore, we do not know if a virus with the 
146TAQYLALAAL155 motif is capable of causing CD4+ T cell loss, histological lesions or 
high viral burdens.   
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 Our sequence analysis indicated that not all viral genes amplified from the 
lymphoid tissues contained G-to-A substitutions above background levels.  For the three 
macaques inoculated with SHIVVifAAQYLA, a total of four lymph tissues (thymus, 
mesenteric, axillary, and inguinal lymph nodes) and four viral genes (vif, vpu, env, and 
nef) were assessed (Table III).  Approximately half (25) of the 48 sequences contained 
G-to-A substitutions that were above 1.2% with the majority of the substitutions being in 
the context of 5’-TC. Potential reasons for this may include that the aliquot of tissue 
examined may have contained archived virus from the initial round of infection, the 
viruses amplified were from a cell type that did not express A3G, or that the domain-
specific mutations may have crippled but not completely abolished the antiviral activity 
of Vif.  Alternatively, it is possible that both deaminase-dependent and deaminase-
independent mechanisms of restriction may be present to decrease the replication of 
SHIVVifAAQYLA in macaques.  The context of the G-to-A substitutions identified in viral 
sequences can provide insight into which A3 members are involved in cytidine 
deamination.  For instance, human A3G is known to cause cytidine deamination with a 
base preference of 5’-CC, while A3F, A3H and A3A have a preference for 5’-TC (Beale 
et al., 2004; Langolis et al., 2005; Liddament et al., 2004; Thielen et al., 2010).  
However, A3D has a preference for 5’-T/A-T/A-C-G/T and A3B and A3C favor both 5’-
TC and 5’-CC (Dang et al., 2007; Doehle et al., 2005; Yu et al., 2004).  This indicates 
that most likely an A3 protein other than A3G is causing the majority of the mutations 
we observed. 
Attenuated viruses have been used to prevent many viral diseases in humans 
(smallpox, poliovirus, measles, mumps, rubella, chickenpox etc.).  It is known that live, 
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attenuated virus vaccines generally result in better immune responses (both humoral 
and cell mediated) that are longer lived when compared to killed virus vaccines.  
However, the major drawback of attenuated virus vaccines is that live viruses are 
genetic elements and replication can introduce mutations that result in reversion of the 
attenuated phenotype to a pathogenic phenotype.  The prime example of this is the live 
attenuated poliovirus vaccine (Kew et al., 2005).  The major concern for the use of 
attenuated lentiviruses has been that it involved the removal of “non-essential” viral 
genes such as vpr, vpx, nef or vpu, which could allow for low level virus replication and 
the accumulation of compensatory mutations in other  gene and potentially a reversion 
to a pathogenic phenotype.    The work by Daniel and colleagues (1992) showed that 
deletion of the nef from the pathogenic SIVmac239 resulted in an attenuated virus that 
resisted challenge against pathogenic parental virus.   However, the hope that an 
attenuated vaccine approach was soon diminished by the studies showing that 
inoculation of a SIVmac239 derivative with deletions in vpr, nef and the negative 
regulatory element (NRE) could cause AIDS in neonatal macaques (Baba et al., 1995).  
This was followed with a study showing that the same virus could cause disease in both 
neonatal and adult macaques (Baba et al., 1999).    Despite these setbacks, the 
vaccines against SIV (or HIV-1) infection that have shown the most promise have been 
those that have deleted or inactivated one or more genes of the virus (Koff et al., 2006).   
In contrast to Vpr, Vpx, Vpu and Nef, the Vif protein is required for replication in CD4+ T 
cells and macrophages, the two major cell populations that HIV-1 infects productively 
(Chiu and Greene, 2008).    This suggests that mutations that target one or more 
conserved (and functional) domains within Vif may permit limited replication and 
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generation of effective immune responses against the virus prior to “self inactivation” 
through the activities of various APOBEC3 family members and may represent a novel 
means to attenuate lentiviruses for candidate vaccines.     
 
Experimental Methods 
 
Cells, Plasmids, and Viruses 
 The CEM and CEM-SS lymphocyte cell lines obtained from the NIH AIDS 
Research and Reagents Program were used for the production of viral stocks, the 
measure of infectivity and the cytopathicity of the viruses used in this study (Salter et al., 
1985; Foley et al., 1965; Nara et al., 1987; Nara et al., 1988).  CEM, CEM-SS, and 
C8166 cell lines were maintained in RPMI-1640 supplemented with 10 mM Hepes 
buffer pH 7.3, 10% fetal bovine serum (R10FBS), 5 µg/mL gentamicin, and 1% 
penicillin/streptomycin.  The derivation of SHIVKU-1bMC33 has been previously described 
(McCormick-Davis et al., 2000; Stephens et al., 2002).   
 
Proviral DNA Plasmid Construction 
 For the construction of SHIVVifAAQYLA, a PacI/SphI fragment (nucleotides 4609 to 
5901) from the p5’SHIV-4 was subcloned into the pGEM3Zf (+) vector.  The serine at 
amino acid position 147 of Vif was substituted to an alanine using oligonucleotides (only 
sense strand shown) 5’-AAGTACCAGGTACCAGCCCTACAGTACTTA-3’ and the 
Quick-Change Mutagenesis Kit (Stratagene) according to the manufacturer’s 
instructions.  The resulting plasmid, pGEM3Zf (+)-PacI/SphI VifAAQYLA, was used to 
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change the leucine at amino acid position 148 of Vif to an alanine using oligonucleotides 
(sense strand shown) 5’-ACCAGGTACCAGCCGCACAGTACTTAGCAC-3’ and the 
Quick-Change Mutagenesis Kit (Stratagene) according to the manufacturer’s 
instructions.  The resulting plasmid, pGEM3Zf (+)-VifAAQYLA, was purified and digested 
with PacI/SphI.    The isolated fragment was purified and subcloned into p5’SHIV-4 to 
generate p5’SHIVVifAAQYLA.  The proviral plasmid DNA was sequenced to determine if 
the desired mutations were introduced as expected.  To generate virus, p5’SHIVVifAAQYLA 
and p3’SHIV were digested with SphI and the two plasmids were ligated together with 
T4 DNA Ligase (Promega).  The resulting ligation was transfected into CEM-SS cells as 
previously described (Stephens et al., 2002; Hout et al., 2005; 2006).  Stocks of SHIVKU-
1bMC33 and SHIVVifAAQYLA were harvested, tittered onto CEM-SS cells to determine the 
TCID50/mL and stored at -86°C.   
 
Replication of SHIVVifAAQYLA in both non-permissive and permissive cell lines 
 The replication of SHIVVifAAQYLA was assessed in CEM (A3G/F positive) and 
CEM-SS (A3G/F negative) cell lines.  One million cells were infected with equivalent 
levels (50 ng) of parental SHIVKU-1bMC33 or SHIVVifAAQYLA for 4 h at 37°C.  The cells were 
centrifuged and washed 3 times to remove the inoculum and incubated in fresh medium 
at 37°C for 9 days.  Aliquots of culture supernatants were obtained at 0, 1, 3, 5, 7 and 9 
days post-inoculation.   The level of p27 was assessed using a commercially available 
p27 antigen capture assay kits (Zeptometrix).   
 
Virion Incorporation Assay 
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 Plasmids containing the genomes of viruses SHIVKU-1bMC33 and SHIVVifAAQYLA 
were co-transfected with human HA-APOBEC3G (HA-hA3G) into 293 cells using 
polyethylenimine transfection reagent (PEI; ExGen-500, Fermentas) along with a 
plasmid expressing HA-hA3G.  At 48 hours, virus containing supernatants were 
harvested and clarified by low speed centrifugation.  The clarified supernatant was then 
subjected to ultracentrifugation to pellet the virus (SW41 rotor 247,000 xg, 1 h).  The 
pellet was resuspended in 1x PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4⋅2H2O, 
1.76 mM KH2PO4; pH 7.4).  An aliquot was saved to determine the p27 content by a 
commercially available antigen capture assay (Zeptometrix).  The remaining sample 
was boiled in 2x sample reducing buffer (125 mM Tris pH 6.8, 4% SDS, 10% glycerol, 
0.006% bromophenol blue, 1% β-mercaptoethanol) and boiled for 5 minutes.  
Equivalent amounts of p27 were loaded on a 12% SDS-PAGE gel and transferred to 
PVDF membrane.  HA-hA3G proteins were detected by Western blotting using an 
antibody directed against the HA tag (HA-probe, Santa Cruz) of HA3G.  The blot was 
stripped in 1x stripping buffer (62.5 mM Tris-HCl, pH6.8 and 2% SDS in 1x PBS, pH 
7.4) and reprobed using a rabbit polyclonal antibody specific for p27.   
 
Macaques analyzed in this study 
 Five 1-1.5 year old pig-tailed macaques (Macaca nemestrina:  2000; CM4G; 
CM4K; RRH10) were intravenously inoculated with 1 ml of undiluted SHIVKU-1bMC33 
containing 104 TCID50 per ml (titered in CEM cells).  Three additional pig-tailed 
macaques (RPL10; RCS10; RAK10) were inoculated with 104 TCID50 SHIVVifAAQYLA 
(tittered in CEM-SS cells).  Twenty-four weeks post-inoculation, 2 ml of plasma was 
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pooled from macaques RPL10 and RAK10 and used to inoculate a naïve macaque, I95.  
The animals were all housed in the AAALAC-approved animal facility at the University 
of Kansas Medical Center.  Blood was collected weekly for the first 4 weeks, then at 2-
week intervals for the next month, and thereafter at monthly intervals.   
 
Circulating CD4+ T cells 
 The levels of circulating CD4+ T cells was assessed at 0, 1, 2, 3, 4, 6, 8, 12, 16, 
20, 24, 28 weeks post-inoculation using FACs (Bectin Dickinson) analysis.  T cell 
subsets were labeled with OKT4 (CD4; Ortho Diagnostics Systems, Inc.), SP34 (CD3; 
Pharmigen), or FN18 (CD3; Biosource International) monoclonal antibodies.  The 
number of circulating CD4+ T cells were determined per µl.  As a control for FACS 
analysis, T cell subsets from an uninfected macaque were always performed.   
 
Processing of tissue samples at necropsy 
 At the time of euthanasia (28 weeks for those macaques inoculated with 
SHIVVifAAQYLA and 20 weeks for macaque I95), all animals in this study were 
anesthetized by administration of 10-mg/kg ketamine (IM) followed by intravenous 
administration of sodium Phenobarbital at 20-30 mg/kg.  A laparotomy was performed 
and the animal exsanguinated by aortic canulation and perfused with one liter of cold 
Ringer’s saline.  All aspects of the animal studies were performed according to the 
institutional guidelines for animal care and use at the University of Kansas Medical 
Center.  Lymphoid and non-lymphoid tissues (brain, heart, lungs, liver, kidney, 
pancreas, salivary glands, liver, spleen, thymus, small intestine, colon, tonsils, and 
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mesenteric, inguinal and axillary lymph nodes) were harvested in HBSS (HBSS; 0.137 
M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM 
MgSO4, 4.2 mM NaHCO3) and aliquots of tissues were either fixed for histological 
analysis or snap frozen for DNA and RNA assays.  Cells were isolated from the thymus, 
spleen, and mesenteric lymph node and used in an infectious centers assay to 
determine if infectious virus is present at the time of necropsy.   
 
Histology 
 Tissues obtained from necropsy listed above were fixed in 10% neutral buffered- 
formalin, subdivided into smaller blocks, and processed for paraffin embedding.  Five 
µm sections were stained with eosin and hematoxylin.  The histological samples were 
examined for morphological abnormalities and lesions consistent with pathogenic X4 
SHIV infection (Stephens et al., 2002).   
 
Plasma viral loads 
 Plasma viral RNA loads were determined on RNA extracted from 0.5 ml of 
EDTA-treated plasma.  Virus was pelleted using ultracentrifugation (Beckman SW55Ti, 
110,000 x g, 2 h) and RNA extracted using the Qiagen viral RNA kit (Qiagen).  RNA 
samples were analyzed by real-time RT-PCR using gag primers and a 5’FAM and 
3’TAMRA labeled Taqman probe that was homologous to the SIV gag gene as 
previously described (Hofmann-Lehmann et al., 2000).  Standard curves were prepared 
using a series of 12 ten-fold dilutions of viral RNA of known concentration.  The 
sensitivity of the assay was 100 RNA equivalents per ml.  Samples were analyzed in 
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triplicate and the number or RNA equivalents were calculated per ml of plasma.  The 
limit of detection was 100 copies.   
 
Analysis of tissues for viral DNA and RNA  
 DNA was extracted from the visceral organs listed above as previously described 
(Hill et al., 2008) and used in nested PCR to amplify SIV gag sequence.  The 240 base 
pair amplified product was visualized through a 1.5% agarose gel stained with ethidium 
bromide.  Viral RNA, which is indicative of actively replicating virus, was extracted from 
approximately 30 mg of each visceral or CNS tissue using the RNAEasy kit (Qiagen) 
and the manufacturer’s instructions.  RNA samples were digested with DNase I for 30 
minutes and run on agarose formaldehyde gels to check for the presence of 
contaminating DNA.  RT-PCR amplification of the extracted RNA was performed using 
the Titan One RT-PCR kit (Roche) and the manufacturer’s instructions.  Each reaction 
used one microgram of total RNA and was amplified using oligonucleotide primers 
specific for the SIVmac239 gag gene.  Each RT PCR reaction contained 50 ng of RNA, 
0.1 mM dNTP mix, 5 mM DTT solution, 5U RNase inhibitor, 0.4 µM of each primer, 5X 
RT-PCR buffer, and 1U of Enzyme mix.  The oligonucleotides used for the first round of 
amplification were 5’-CGTCATCTGGTGCATTCACG-3’ (sense) and 5’-
CTGATTAATGTCATAGGGGGTGC-3’ (antisense), which are complementary to bases 
1343-1362 and 1636-1658, respectively.   The nested primers used were 5’-
CACGCAGAAGAGAAAGTGAAACAC-3’ (sense) and 5’-
GGTGCAACCTTCTGACAGTGC-3’ (antisense), which are correspond to bases 1359-
1382 and 1620-40, respectively.  The reactions were performed with an Applied 
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Systems 2720 Thermal Cycler using the following thermal profile:  42C for 30 min, 1 
cycle; 94C for 2 min, 1 cycle; 94C for 30 s, 55C for 30 s, 68C for 45 s, 10 cycles; 94C 
for 30 s, 55C for 30 s, and 68C for 2 min; 25 cycles.  One microliter of the initial reaction 
mixture was then added to a nested PCR mixture containing gag primers and performed 
with the following thermal profile: 95C for 10 min, 1 cycle; 30 s, 55C for 30 s, and 68C 
for 2 min; 35 cycles.  The amplified gag fragment is 281 base pairs.  β-actin was 
amplified from all of the tissue RNA samples as a control to verify the RNA integrity.   
 
DNA sequence analysis of vif, vpu, nef, and env 
 In order to assess the sequence of viral genes, PBMC and tissue DNA was 
extracted using the QIAamp DNA mini kit (Qiagen) according to the manufacturer’s 
instructions.  One µg of isolated genomic DNA was used in a nested DNA polymerase 
chain reaction using rTaq (Takara) following the manufacturer’s instructions and specific 
nucleotides listed in Table IV.   Each PCR reaction contained 1x PCR buffer (Mg2+-free), 
4 mM MgCl2, 0.25 mM of each deoxynucleotide triphosphate, 500 nM of each primer, 
and 1U of rTaq DNA polymerase.  The PCR reactions were performed using an Applied 
Systems 2720 Thermal Cycler with the following thermal profile: 95°C for 2 min; 1 cycle; 
95°C for 30 s, 48°C for 30 s, 65°C for 2 min, 35 cycles; 65°C for 7 min. The PCR 
products were pooled from three separate reactions and separated by electrophoresis 
on a 1.5% agarose gel, isolated, and directly sequenced.  Cycled sequencing reactions 
were constructed using the BigDye Terminator Cycle Sequencing Ready Reaction kit 
with AmpliTaq DNA Polymerase, FS (PE Applied Biosystems).  Sequence detection  
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Table IV.  Oligonucleotides used in rTaq PCR to amplify SHIV genes.  
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was conducted with an Applied Biosystems 377 Prism XL automated DNA sequencer 
and visualized using the ABI Editview program. A total of 466, 246, 490, and 400 
nucleotides from vif, vpu, env, and nef genes, respectively, were analyzed and 
compared to the sequence of SHIVKU-1bMC33 using the SE Central Software package.   
 
Immunoprecipitation assays 
 To determine if macaques developed antibodies to SHIV proteins following 
inoculation, the plasma obtained at necropsy was used in immunoprecipitation assays.  
C8166 cells were inoculated with approximately 104 TCID50 of SHIVKU-1bMC33 for 4 days.  
The cells were then incubated in methionine/cysteine-free media for 2 h and 
radiolabeled with 500 µCi of 35S-methionine/cysteine for 15 hours.  The cells were lysed 
in 1 ml of 1x RIPA buffer (50 mM Tris-HCl, pH7.5; 50 mM NaCl, 0.5% deoxycholate; 
0.2% SDS; 10 mM EDTA) and nuclei were removed by centrifugation.  The cell lysates 
were incubated overnight at 4°C with 10 µl of plasma from each macaque and protein-A 
Sepharose beads (Sigma).  The immunoprecipitates bound to the beads were washed 
3x in 1x RIPA, resuspended in 75 µl of 2x sample reducing buffer (125 mM Tris-HCl pH 
6.8; 4% SDS, 10% glycerol. 0.06% bromophenol blue, 1% β-mercaptoethanol), and 
boiled for 5 min.  Proteins were separated on a 10% SDS-PAGE gel and proteins 
visualized by autoradiography.  Controls included pooled prebleed plasma from 
macaques RAK10, RCS10, and RPL10 (negative control) and plasma from macaques 
that had been previously inoculated with non-pathogenic SHIV-4 (positive control).   
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VII.  Chapter 3:  Replication and persistence of simian-human immunodeficiency 
viruses in rhesus macaques expressing Vif proteins with mutations in the 
SLQYLA and HCCH domains 
 
Abstract 
 
The Vif protein of primate lentiviruses interacts with APOBEC3 proteins, which 
results in shunting of the APOBEC3-Vif complex to the proteosome for degradation.  
Using the simian-human immunodeficiency virus (SHIV)/macaque model, we compared 
the replication and pathogenicity of SHIVs that express a Vif protein in which the entire 
SLQ(Y/F)LA (SHIVVif5A) or HCCH (SHIVVifHCCH(-)) domains were substituted with alanine 
residues.  Each virus was inoculated into three macaques and various viral and 
immunological parameters followed for six months. All macaques maintained stable 
circulating CD4+ T cells, developed low viral loads, maintained the engineered 
mutations, yielded no histological lesions, and developed immunoprecipitating 
antibodies early post-inoculation. Sequence analysis of nef and vpu from three lymphoid 
tissues revealed a high percentage of G-to-A-substitutions. Our results show that while 
the presence of HCCH and SLQ(Y/F)LA domains are critical in vivo, there may exist 
APOBEC3 negative reservoirs that allow for low levels of viral replication and 
persistence but not disease.  
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Introduction 
Mammals have evolved cellular restriction factors such as apolipoprotein B 
mRNA editing enzyme catalytic peptide-like 3G (APOBEC3G; hA3G) to inhibit the 
replication of retroviruses. However, retroviruses, such as human immunodeficiency 
virus type-1 (HIV-1), have also developed mechanisms to counter defend these 
restriction factors by subverting the host’s proteosomal degradation pathway.  For 
instance, the HIV-1 Vif protein has been shown to interact with A3G promoting its 
accelerated degradation by the 26S proteosome (Sheehy et al., 2003). APOBEC3G is a 
cytidine deaminase that, if packaged into HIV-1Δvif/SIVmac239Δvif virions, induces 
cytidine deamination of newly synthesized minus-strand viral DNA from cytosines to 
uracils, leading to G to A transitions in plus strand synthesis and inhibition of viral 
replication (Jarmuz et al., 2002; Harris et al., 2003; Mariani et al., 2003; Mangeat et al., 
2003; Sheehy et al., 2003; Virgen et al., 2007; Yu et al., 2004; Zennou et al., 2006). 
Previous in vitro studies have shown that SIVmac239Δvif has been shown to be 
restricted by hA3G, hA3F, hA3H and to a lesser extent hA3B, hA3C, hA3D (Dang et al., 
2006; Dang et al., 2008; Mariani etal., 2003; Yu et al., 2004b; Zennou et al., 2006).  The 
HIV-1 Vif has limited activity against rhesus and African green monkey A3 proteins 
while Vif from SIVmac239 and SIVagm have broader specificities.  While less is presently 
known about the rhesus A3 proteins, it is known that HIV-1Δvif can be inhibited by 
rhA3G, rhA3F, rhA3B, and to a lesser extent rhA3H and rhA3DE (Virgen et al., 2007).   
SIVmac239Δvif has been shown to be restricted by rhA3G, rhA3F, rhA3C, rhA3B and 
rhA3DE, and to a lesser extent rhA3H (Virgen et al., 2007; Zennou et al., 2006).   
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Sequence analysis of Vif proteins from different lentiviruses reveals that there are 
two highly conserved domains in the carboxyl terminus of Vif required for the assembly 
of the Vif-CBF-β-Cul5/ElonginB/C/Rbx1 E3 ubiquitin ligase complex, the BC box 
144SLQ(Y/F)LAL150 and Zn++ binding (HCCH; H108-X5-C114-X17-18-C133-X3-5-H139) motifs 
(Jäger et al., 2011; Kile et al., 2002; Luo et al., 2005; Mehle et al., 2004; Mehle et al., 
2006; Paul et al., 2006; Yu et al., 2003; Yu et al., 2003).  As described in the 
Introduction, the 144SLQ(Y/F)LAL150 motif sequence resembles a conserved motif 
identified in the BC box of the suppressors of cytokine signaling (SOCS) proteins and 
mediates high affinity binding of Vif to elongin C (Luo et al., 2005; Mehle et al., 2004a; 
Mehle et al., 2004b; Mehle et al., 2006; Stopak et al., 2003; Yu et al., 2003; Yu et al., 
2004c). Located upstream of the BC box is the HCCH motif, which was found to 
mediate interaction with Cullin-5.  Previous studies have shown that substitution of 
either critical cysteine residue prevents the binding of Zn++ thus affecting the proper 
folding of the protein (Paul et al., 2006; Xiao et al., 207).  Following the binding of N-
terminus of Vif to the N-terminus of A3G, both the SLQ(Y/F)LAL and HCCH motifs 
enable Vif to recruit the Cul5/ElonginB/C/Rbx1 E3 ubiquitin ligase complex to accelerate 
the polyubiquitination and subsequent 26S proteosomal degradation (Conticello et al., 
2003; Marin et al., 2003; Mehle et al., 2004; Stopak et al., 2003; Yu et al., 2003; Yu et 
al., 2004).   
In this study, we constructed simian-human immunodeficiency viruses (SHIVs) in 
which five amino acids in the SLQYLA motif (SHIVVif5A) and four amino acids of the 
HCCH (SHIVVifHCCH(-)) domain were changed to alanine residues.   Our results indicate 
that rhA3G and rhA3F was efficiently incorporated into both SHIVVif5A and SHIVVifHCCH(-) 
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virions.  However, rhA3F was stable in the presence of wild type and mutant Vif viruses, 
while only mutant Vif viruses efficiently degraded rhA3G. In vitro, rhesus A3G (rhA3G) 
was more effective at cytidine deamination than rhesus A3F (rhA3F).  Macaques 
inoculated with mutant Vif viruses maintained stable circulating CD4+ T cells, developed 
low viral loads, and developed immunoprecipitating antibodies.  Sequence analysis of 
both nef and vpu from the thymus, spleen, and small intestine (ileum) of SHIVVifHCCH(-) 
inoculated macaques displayed a high percentage of G-to-A substitutions. Our results 
show that both the HCCH and SLQYLA domains were critical to Vif function in vivo but 
that production of viral RNA only persisted in the macaques inoculated with the 
SHIVVifHCCH(-).  
 
 
Results 
 
Replication of SHIVVif5A and SHIVVifHCCH(-) in A3 positive and negative cell lines 
 We performed assays to examine the replication of parental SHIVKU-2MC4, 
SHIVVif5A, SHIVVifHCCH(-), SHIVViAAQYLA and SHIVVifStop in hA3G/F positive (C8166) and 
negative (SupT1) cell lines as well as rhesus PBMC (rhA3G/F).  The sequence of the 
Vif mutants that were analyzed in this study are shown in Figure 28.  We included 
SHIVVifAAQYLA in these growth curve studies for comparison.  The replication of 
SHIVVifAAQYLA has been previously reported in both tissue culture and rhesus macaques 
(Schmitt et al., 2009).  Cells were inoculated with equivalent amounts (25 ng of p27) of 
each virus and the levels of p27 (Gag) released into the culture medium were quantified 
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using a commercial antigen capture assay.  All four mutant viruses (SHIVVif5A, 
SHIVVifHCCH(-), SHIVVifAAQYLA and SHIVVifStop) replicated in SupT1 cells to similar levels as 
parental SHIVKU-2MC4 by day 15 post-inoculation, although the kinetics of replication 
were slower (Figure 29).  However, inoculation of SHIVVif5A, SHIVVifHCCH(-), SHIVVifAAQYLA 
and SHIVVifStop into hA3G/F positive C8166 cell cultures resulted in less than 0.01% of 
the p27 released compared to parental SHIVKU-2MC4 (Figure 29).   
 
Both SHIVVif5A and SHIVVifHCCH(-) incorporate rhA3G and rhA3F into virus particles  
The above results suggested that hA3G and hA3F or rhA3G and rhA3F might 
be incorporated into maturing virus particles resulting in restriction of replication.  As 
we are most interested in an rhA3G and rhA3F, we transfected 293 cells with plasmids 
expressing an HA-tagged rhA3G or a V5-tagged rhA3F and the complete genomes of 
either SHIVVif5A, SHIVVifHCCH(-), SHIVVifSTOP, or parental SHIVKU-2MC4.  At 48 hours post-
transfection, the culture medium was collected, clarified, and the virus partially purified 
and concentrated by ultracentrifugation.   The amount of p27 was determined followed 
by Western blot analysis to detect for the presence or absence of rhA3G or rhA3F.  
The results shown in Figure 30 indicate that rhA3G was incorporated into SHIVVif5A, 
SHIVVifHCCH(-), and SHIVVifSTOP virus particles but was excluded from SHIVKU-2MC4 
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Figure 28.  The sequence of wild type SIVmac230 Vif and the two mutants assessed 
in this study.   
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Figure 29.  Replication of SHIVKU-2MC4, SHIVVifHCCH(-), SHIVVif5A, and SHIVVifStop in 
C8166 cells (hA3G/F positive), SupT1 cells (hA3G/F negative) and rhesus 
macaque PBMC.  Cells were inoculated with equal amounts of each virus (25 ng 
of p27) and the levels of p27 in the culture supernatants was assessed at various 
time points post-inoculation.  Panel A.  Replication of viruses in C8166 cells. 
Panel B.  Replication of viruses in C8166 cells.  Panel C.  Replication of viruses in 
activated rhesus macaque PBMC.  ( ) SHIVKU-2MC4, ( ) SHIVVifHCCH(-),  (  ) SHIVVif5A, 
and (  ) SHIVVifStop.	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Figure 30.  The incorporation of rhA3G and rhA3F into virus particles.  293 cells 
were co-transfected with a plasmid that expresses the genome of either SHIVKU-
2MC4, SHIVVif5A, SHIVVifHCCH(-) or SHIVVifStop and a vector expressing HA-rhA3G or V5-
rhA3F.  At 48 hours, the culture medium was collected, clarified by low speed 
centrifugation and concentrated by ultracentrifugation through a 20/60 (w/v) step 
gradient.  Equivalent levels of p27 from each sample were resuspended in sample 
reducing buffer, boiled and the proteins were separated by 10% SDS-PAGE.  The 
presence of either rhA3G or rhA3F was detected through western blot analysis 
using an antibody directed by against the HA-tag or V5-tag, respectively.  Panel 
A.  Results of the rhA3G incorporation into virus particles.  Lane 1. RhA3G 
proteins detected in lysate from cells transfected with the vector expressing HA-
rhA3G alone.  Lane 2-5.  RhA3G proteins detected in virus from cells transfected 
with a vector expressing HA-rhA3G and SHIVKU-2MC4 (Lane 2), SHIVVif5A (Lane 3), 
SHIVVifHCCH(-), (Lane 4) and SHIVVifStop (Lane 5).  Lane 6.  RhA3G proteins in pelleted 
supernatant from cells transfected with empty expression vectors. Panel B.   The 
blot in Panel A was stripped and reprobed with an antibody against the p27 
protein.  Panel C.  Results of the rhA3G incorporation of rhA3F into virus 
particles.  Lane 1. RhA3F proteins detected in a lysate from cell transfected with a 
vector expressing rhA3F alone.  Lane 2-5.  RhA3F proteins detected in virus from 
cells transfected with a vector expressing rhA3F and SHIVKU-2MC4 (Lane 2), 
SHIVVif5A (Lane 3), SHIVVifHCCH(-), (Lane 4) and SHIVVifStop (Lane 5).  Lane 6.  RhA3F 
proteins in pelleted supernatant from cells transfected with empty expression 
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vectors.  Panel D.  The blot in Panel C was stripped and reprobed with an 
antibody against the p27 protein.                
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particles.  However, we found that the rhA3F protein was incorporated into all four 
viruses (Figure 30).  These results indicate that rhA3G was selectively incorporated only 
into the Vif mutants while rhA3F was incorporated into all viruses.  The inability of 
SIVmac239 Vif to degrade and prevent the incorporation of rhA3F has been previously 
reported (Virgen et al., 2007).   
 
Rhesus A3F is stable in the presence of SIVmac239 Vif 
Since we observed that rhA3F was incorporated into virus particles, we 
determined the stability of rhA3F and rhA3G in the presence of the viral genome.  293 
cells were co-transfected with vectors expressing rhA3G or rhA3F and the genomes of 
SHIVKU-2MC4, SHIVVif5A, SHIVVifHCCH(-), or SHIVVifSTOP.  Our results indicate that in the 
presence of the SHIVKU-2MC4 genome, rhA3G was not stable whereas it was detected in 
the presence of the SHIVVif5A, SHIVVifHCCH(-) or SHIVVifSTOP  (Figure 31).   We also found 
that rhA3F appeared to be stable in the presence of both SHIVKU-2MC4 and also 
SHIVVif5A, SHIVVifHCCH(-), or SHIVVifSTOP genomes.  However, it should be noted that we 
consistently found higher levels of rhA3F in the presence of the SHIVVifSTOP genome, 
indicating fundamental differences between the targeting site-directed Vif mutants and 
the absence of the Vif protein.  The results obtained with rhA3F correlate well with the 
above experiment showing that rhA3F was incorporated into virus particles.  
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Figure 31.  Stability of the rhA3G and rhA3F proteins in the presence of the 
various vif mutant viral genomes.  Plasmids expressing the genomes of either 
SHIVKU-2MC4, SHIVVif5A, SHIVVifHCCH(-) or SHIVVifStop were co-transfected into 293 cells 
with a vector expressing either HA-rhA3G or V5-rhA3F.  At 24 hours post-
transfection, cells were lysed and proteins were precipitated using methanol.  
Proteins were separated on a 10% SDS-PAGE gel and probed using an antibody 
directed against either the HA or V5-tag.  All samples were normalized to the 
amount of β-actin protein.  Panel A.  Stability of rhA3G in the presence of SHIVKU-
2MC4 (Lane 2), SHIVVifStop (Lane 3), SHIVVif5A (Lane 4) or SHIVVifHCCH(-) (Lane 5) was 
assessed.  Lanes 1 and 6 were used as positive (HA-rhA3G only, Lane 1) and 
negative (pcDNA3.1(+) only, Lane 6) controls.  Panel B.  The stability of rhA3F in 
the presence of SHIVKU-2MC4 (Lane 2), SHIVVifStop (Lane 3), SHIVVif5A (Lane 4) or 
SHIVVifHCCH(-) (Lane 5) was assessed.     Lanes 1 and 6 were used as a negative 
(pcDNA3.1(+) only, Lane 1) or positive (V5-rhA3F only, Lane 6) controls.  Similar 
results were acquired at 48 hours as well (data not shown).  Panel B and C.  The 
blot in Panel A and B were stripped and reprobed with an antibody against β-actin 
protein.   
 
 
 
 
 
	   181	  
 
 
 
 
 
 
 
 
 
 
	   182	  
SHIVVifHCCH(-), SHIVVifSTOP, or SHIVKU-2MC4 and a plasmid expressing either an HA-tagged 
rhA3G, V5-tagged rhA3F or the empty vector.   At 48 hours, the virus containing 
supernatant was collected, clarified by centrifugation, and the p27 levels quantified.   
Equivalent levels of p27 from each virus stock were used to titrate infectious virus by a 
series of 10-fold dilutions onto TZM.bl cells.   At 48 hours, the cells were stained for β-
galactosidase activity (β-galactosidase is under the control of the LTR and expression of 
Tat from the incoming virus) and the number of TCID50 determined.  If rhA3G or rhA3F 
was packaged into the virions, the virus should be hypermutated resulting in the 
expression of a non-functional Tat.   As shown in Figure 32, SHIVKU-2MC4 replicated to 
approximately the same levels in the presence or absence (empty vector) of rhA3G while 
the titers of SHIVVifHCCH(-) , SHIVVif5A and SHIVVifSTOP were 100 to 1000 fold less than the 
unmodified virus (SHIVKU-2MC4).  With rhA3F, our results indicate that SHIVKU-2MC4, 
SHIVVifHCCH(-) and  SHIVVif5A had an approximate 10-fold decrease in titers and 
SHIVVifSTOP had greater than a 1000-fold decrease in titer (Figure 32).  The results with 
rhA3F also emphasize the differences in site-directed mutations in SHIVVifHCCH(-), 
SHIVVif5A and the severely truncated  Vif in SHIVVifSTOP.  
 
Rhesus A3G but not rhA3F causes significant G-to-A mutations in the nef gene of 
the SHIV genome 
The results above indicated that significant levels of rhA3F were incorporated 
into virions and rhA3F was stable in cells expressing the wild type genome.  We 
compared the level of G-to-A mutations of the SHIV genome in the presence of either 
rhA3G or rhA3F.  The results are shown in Figure 33 and Table V.  Using viral genomes 
to express the Vif protein, we observed minimal G-to-A changes in SHIVKU-2MC4 nef  in  
	   183	  
 
 
 
 
 
 
Figure 32.  The incorporation of rhA3G results in less infectious virus.  293 cells 
were co-transfected with full-length vectors expressing SHIVKU-2MC4, SHIVVifHCCH(-), 
SHIVVif5A and SHIVVifStop and plasmids expressing either rhA3G of rhA3F.  As a 
control each full-length genome was co-transfected with the empty vector, 
pcDNA3.1(+), only.  At 48 hours, the culture medium was harvested, assessed for 
p27, and the amount of infectious virus titrated on TZM.bl cells as described in 
the Material and Methods section.  Shown are the infectious titers in the absence 
or presence of either rhA3G (Panel A) or rhA3F (Panel B).   
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Table V.  Results of the hypermutation assay of nef amplified by rhA3G and rhA3F 
in the presence of wild type and mutant Vif proteins.   
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Figure 33.  RhA3G but not rhA3F induced G-to-A substitutions in single colony 
sequences obtained from SIVmac239 nef.  Full-length genomes of wild type and vif 
mutant viruses were co-transfected with vectors expressing either rhA3G or rhA3F 
into 293 cells.  At 48 hours post-transfection, the culture medium was collected, 
clarified by low speed centrifugation, DNase I-treated and used to infect TZM.bl 
cells.  A 325 base pair fragment of SIVmac239 nef was amplified from DNA at 24 
hours post-infection and assessed for G-to-A substitutions.  Panel A. A graph 
depicting the cumulative number of mutations from the 15 independent clones per 
virus assessed in the presence of rhA3G.  Each bar is shaded according to the 
proportion of G-to-A substitutions that occurred in the context of GA (red), GG 
(yellow), GT (cyan), GC (gray), or non G-to-A (black).   Panel B.  A graph depicting 
the cumulative number of mutations from the 15 independent clones per virus 
assessed in the presence of rhA3G.  Each bar is shaded according to the 
proportion of G-to-A substitutions that occurred in the context of GA (red), GG 
(yellow), GT (cyan), GC (gray), or non G-to-A (black).  Panel C.  A graph depicting 
the cumulative number of mutations from the 15 independent clones per virus 
assessed in the presence of rhA3F.           
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the presence of either rhA3G or rhA3F.  In the presence of rhA3G, we found that  
SHIVVif5A, SHIVVifHCCH(-) or SHIVVifSTOP nef had an increase in the number of G-to-A 
changes (from 2 to 24-29) or approximately 0.5% of the bases sequenced (Table V).  
However, in the presence of rhA3F, we observed that SHIVVif5A, SHIVVifHCCH(-), and  
SHIVVifSTOP nef had a similar level of G-to-A changes compared to SHIVKU-2MC4  (Table 
V).   The results with the rhA3F suggest that incorporation of rhA3F does not result in 
significant G-to-A substitutions in nef.   
 
Assessment of SHIVVifHCCH(-) replication in macaques 
We inoculated three macaques with 104 TCID50 of SHIVVifHCCH(-).  Prior to 
inoculation, macaques AS34, AS51, and AV18 had circulating CD4+ cell levels of 1,509, 
1,109, and 400 cells per µl, respectively.  These three macaques maintained levels of 
circulating CD4+ T cells at pre-inoculation levels or higher throughout the course of the 
six-month infection (Figure 34).    All three macaques were euthanized at 26-28 weeks 
post-inoculation in excellent condition.   At necropsy, AS34, AS51, and AV18 had 
circulating CD4+ T cell levels of 2,124, 1,338, and 1,298 cells/µl, respectively.  This 
contrasts with macaques inoculated with parental SHIVKU-2MC4, which developed a 
severe loss of circulating CD4+ T cells within 3-4 weeks post-inoculation (Figure 34).   
Analysis of the plasma viral loads revealed a mean viral load of 4.15 x103 copies per ml 
at one week post-inoculation (Figure 35), which is approximately 10,000-fold less than 
the macaques inoculated with parental SHIVKU-2MC4 (Figure 35).  Following the first 
week of infection, the plasma viral loads in macaques AS34, AS51, and AV18 were at 
or just above the limits of detection.   At necropsy, viral loads in all three macaques 
were  
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Figure 34.  Circulating CD4+ T cell levels in macaques inoculated with SHIVVifHCCH(-
), SHIVVif5A, and SHIVKU-2MC4.  Panel A.  The levels of circulating CD4+ T cells in 
three macaques (AS34, ; AS51, ; and AV18, ) following inoculation with 
SHIVVifHCCH(-).  Panel B.  The levels of circulating CD4+ T cells in three macaques 
(CX54, ; ER65, ; and I92, ) following inoculation with SHIVVif5A.  Panel C.  The 
levels of circulating CD4+ T cells in three macaques (44O, ; 44N, ; 35N, ) 
following inoculation with SHIVKU-2MC4.     
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Figure 35.  Plasma viral loads in macaques inoculated with SHIVVifHCCH(-), SHIVVif5A, 
and SHIVKU-2MC4 as determined by real-time quantitative PCR.  Panel A.  Plasma vial 
loads in three macaques (AS34, ; AS51, ; and AV18, ) following inoculation 
with SHIVVifHCCH(-).  Panel B.  Plasma viral loads in three macaques (CX54, ; ER65, 
; and I92, ) following inoculation with SHIVVif5A.  Panel C.  Plasma viral loads in 
three macaques (44O, ; 44N, ; 35N, ) following inoculation with SHIVKU-2MC4.     
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undetectable.  These results indicate that SHIVVifHCCH(-) transiently replicated in these 
macaques prior to control of the infection.   
 
Assessment of SHIVVif5A replication in macaques 
We also assessed the ability of SHIVVif5A to replicate in three macaques (CX54, 
ER65, and I92).   Prior to inoculation, macaques CX54, ER65, and I92 had circulating 
CD4+ T cell levels of 777, 844, and 1,451 cells per µl, respectively (Figure 34).  These 
macaques, similar to those inoculated with SHIVVifHCCH(-), maintained circulating CD4+ T 
cell levels near the pre-inoculation levels throughout the course of the 6 month infection.   
All three macaques were euthanized at 26 weeks post-inoculation in excellent condition.   
At necropsy, CX54, ER65, and I92 had circulating CD4+ T cell levels of 513, 853, and  
1192 cells per µl,  respectively (Figure 34).   This also contrasts with macaques 
inoculated with parental SHIVKU-2MC4 (Figure 34).  Analysis of the plasma viral loads of 
the macaques inoculated with SHIVVif5A revealed a mean viral load of 1.3 x103 copies 
per ml at one week post-inoculation (Figure 35).   Following the first week of infection, 
the plasma viral loads in macaques CX54, ER65, and I92 fell to undetectable levels.   
 
Mutations in vif amplified from isolated DNA of PBMC during the course of 
infection 
We assessed the stability of the engineered mutations in the vif gene from DNA 
isolated PBMC throughout the course of infection.   The vif sequence was amplified, 
directly sequenced and compared to the input vif sequence of SHIVVif5A or SHIVVifHCCH(-).  
We observed that the engineered mutations were stable throughout the course of the 
six month infection for macaques inoculated with SHIVVifHCCH(-).  We performed bulk  
	   198	  
 
 
 
 
 
 
Figure 36.  Analysis of vif sequences amplified from DNA isolated from PBMC at 
various times post-inoculation.   Panel A.  Quantitative representation of 
mutations induced in bulk sequences obtained from a 450 base pair fragment of 
SHIVVifHCCH(-) Vif.  Each vertical bar represents the total number of G-to-A 
substitutions.  Each bar is shaded according to the proportion of G-to-A 
substitutions that occurred in the context of GA (red), GG (yellow), GT (cyan), or 
non G-to-A (black).  Panel B.  A 450 base pair fragment of the SIV Vif was 
amplified using DNA isolated from macaque PBMC inoculated with SHIVVifHCCH(-).  
Mutations from bulk sequence analysis from each macaque are shown.  Each 
mutation is denoted by a vertical line that is color coded with respect to the 
dinucleotide context: GA (red), GG (yellow), GT (cyan), GC (gray) and non-G-to-A 
substitutions (black).     
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sequencing of the vif amplified at 1, 2, 3, 4, 6, and 16 weeks.  As shown in Figure  36, 
the number of G-to-A mutations in the amplified vif gene increased with time in two 
(AS51, AV18) of the three macaques while the third macaque (AS34) appeared to have 
the largest number of G-to-A mutations at 3 weeks post-inoculation.   As we had 
reported earlier, the majority of the G-to-A mutations were in the context of the 5'-TC 
rather than 5'-CC (Schmitt et al., 2009).   We were able to amplify part of the vif 
sequence at 1 week from PBMC DNA isolated from macaques inoculated with SHIVVif5A 
(CX54, ER65, I92).   The sequence analysis also revealed that these vif mutations were 
stable at one week post-inoculation (data not shown).   However, from 4 weeks until 
necropsy, we were unable to amplify the vif gene, which correlates with the undetectable 
plasma viral loads in these macaques after week 1 post-inoculation.     
 
Macaques inoculated with SHIVVif5A and SHIVVifHCCH(-) developed anti-viral antibody 
responses early after inoculation 
We analyzed the plasma from infected macaques at 12 weeks and at necropsy 
(26-28 weeks) for the presence of immunoprecipitating antibody responses.  At 12 
weeks post-inoculation, all three macaques inoculated with SHIVVif5A had developed 
antibody responses to p27 but only macaque ER65 developed antibody responses to 
the Env glycoprotein (Figure 37).  For macaques inoculated with SHIVVifHCCH(-), all three 
macaques developed antibodies to p27 and the Env glycoprotein (Figure 37).  At 
necropsy, we could not detect the presence of immunoprecipitating antibodies from 
macaques inoculated with either SHIVVif5A or SHIVVifHCCH(-) (Figure 37).  A macaque 
inoculated with parental SHIVKU-2MC4 (44O) did not develop antibodies to the virus at 
either time point, which is common for macaques that develop severe CD4+ T cell loss  
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Figure 37.  Macaques inoculated with SHIVVifHCCH(-) and SHIVVif5A developed 
antibody responses against each virus early after inoculation.  C8166 cells were 
inoculated with SHIVKU-2MC4 for 5 days, starved in methionine/cysteine-free DMEM, 
and then radio labeled overnight with 35S-methionine/cysteine.  The culture 
medium was harvested and used in immunoprecipitation reactions with plasma 
from AS34, AS51, AV18, CX54, ER65, and I92 as described in the Materials and 
Methods section.  The immunoprecipitates were washed with 1 x RIPA buffer and 
boiled in 2x sample reducing buffer. The proteins were then separated on a 12%-
SDS-PAGE gel and visualized using auto radiographic techniques.  Panel A.  SHIV 
proteins immunoprecipitated with plasma obtained at week 12 post-inoculation. 
Panel B.  SHIV proteins immunoprecipitated with plasma obtained at necropsy. 
(Lanes 1-3) SHIVVifHCCH(-) proteins immunoprecipitated using plasma  from either 
AS34 (Lane 1), AS51 (Lane 2), or AV18 (Lane 3), respectively.  (Lanes 4-6) 
SHIVVif5A proteins immunoprecipitated using plasma from either CX54 (Lane 4), 
ER65 (Lane 5), or I92 (Lane 6), respectively.  (Lane 7) SHIV proteins 
immunoprecipitated using plasma from an uninfected macaque.  (Lane 8) SHIV 
proteins immunoprecipitated from a positive control plasma sample.  The 
molecular weight standards are shown on the left.   
 
 
	   203	  
 
 
 
 
 
	   204	  
during the acute phase (<4 weeks) following inoculation with a pathogenic X4 SHIV (data 
not shown).   
 
Histological examination of tissues and viral loads in visceral organs of 
macaques inoculated with SHIVVif5A and SHIVVifHCCH(-)
Tissues from infected macaques were examined for the presence of lesions 
consistent with this pathogenic X4 SHIV (Joag et al., 1998).  Macaques inoculated with 
either SHIVVif5A or SHIVVifHCCH(-) did not exhibit histological lesions in any of the 13 
visceral organs examined or in the CNS (data not shown).  As the plasma viral loads 
were significantly less than macaques inoculated with SHIVKU-2MC4, we assessed the 
tissue distribution of these two viruses in macaques.   RNA was isolated from 13 
visceral organs from macaques inoculated with SHIVVif5A and SHIVVifHCCH(-), DNase I 
treated, and copy numbers determined by real time quantitative RT-PCR. The number 
of copies is expressed per 106 copies of GADPH.  The results obtained from macaques 
inoculated with SHIVVifHCCH(-) are shown in Figure 38.  We found that macaque AS34 
had eight tissues (kidney, lung, pancreas, axillary lymph node, inguinal lymph node, 
spleen, thymus and tonsil) greater than 1,000 copies per 106 copies of GAPDH (Figure 
38).   Macaque AS51 was found to have two tissues (lung and small intestine) with 
greater than 1,000 copies per 106 copies of GAPDH, and macaque AV18 had six 
tissues (lung, pancreas, axillary lymph node, inguinal lymph node, mesenteric lymph 
node and spleen) with greater than 1,000 copies per 106 copies of GAPDH (Figure 38).  
Interestingly, the lung had the highest viral copy number in each macaque.  In contrast, 
we were unable to quantify viral RNA from tissues of macaques that were inoculated  
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Figure 38.  Comparison of viral copy numbers in the visceral tissues of macaques 
inoculated with SHIVKU-2MC4, SHIVVifHCCH(-), and SHIVVif5A.  RNA was isolated from 
different visceral organs of macaques inoculated with either SHIVVifHCCH(-) or 
SHIVVif5A.  The RNA was DNase I treated to remove residual DNA and used in real 
time quantitative RT-PCR using oligonucleotide primers specific for SIV gag as 
described in the Materials and Methods.  The levels of viral RNA are shown per 
106 copies of GAPDH RNA.  Panel A.  The results of the real time quantitative RT-
PCR using RNA isolated from tissues of macaque 44O, which was inoculated with 
SHIVKU-2MC4.  Panels B-D. The results of the real time quantitative RT-PCR using 
RNA isolated from the tissues of macaques AS34 (Panel B), AS51 (Panel C), and 
AV18 (Panel D), which were inoculated with SHIVVifHCCH(-).    Panels E-G.  The 
results of the real time quantitative RT-PCR using RNA isolated from tissues of 
macaques CX54 (Panel E), ER65 (Panel F), and I92 (Panel G), which were 
inoculated with SHIVVif5A.   
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with SHIVVif5A (data not shown).   Macaques inoculated with parental SHIVKU-2MC4, 44O 
and 44N, had high copy numbers of virus in various tissues (Figure 38).  Taken together, 
these results indicate that both SHIVVifHCCH(-) and SHIVVif5A infections were significantly 
less widespread compared to macaques inoculated with parental  SHIVKU-2MC4.   
 
G-to-A mutations in nef and vpu amplified from DNA of primary and secondary 
lymph organs 
  A well documented feature of HIV-1Δvif infection is the incorporation of select 
APOBEC3 proteins into viral particles leading to cytosine deamination during minus 
strand DNA synthesis (Yu et al., 2003).   This results in hypermutation (guanosine to 
adenosine transitions) of the viral genome and inhibition of virus replication.  We 
examined the number of G-to-A mutations in the nef and vpu genes amplified from DNA 
isolated from one primary lymphoid organ (thymus) and two secondary lymphoid organs 
(ileum of the small intestine and spleen) from the three macaques inoculated with 
SHIVVifHCCH(-) and one macaque inoculated with SHIVKU-2MC4.  We first PCR amplified nef 
and vpu sequences from tissue DNA and directly sequenced the amplified products. The 
results showed that there were multiple G-to-A mutations in the nef and vpu regions 
amplified from three tissues.  The number of G-to-A mutations ranged from 54 to 88 or 
1.2 to 1.9 percent of the total base pairs sequenced (Figure 39; Table VI).    While the 
percentage of mutations observed in the vpu was lower (perhaps reflecting the gradient 
of mutations from nef to vpu), the overall number of G-to-A mutations in the context of 5'-
TC to 5'-CC was approximately 2:1 (75 versus 31 mutations) (Figure 39; Table VI).  
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Figure 39.  Quantitative assessment of mutations in the nef gene.  Panels A-D.  A 
300 base pair fragment of nef was amplified using DNA isolated from the small 
intestine (ileum), spleen, and thymus of macaques inoculated with SHIVVifHCCH(-) 
and one macaque inoculated with SHIVKU-2MC4.  Mutations obtained using 
sequence analysis of fifteen independent clones from each macaque is shown.  
Each vertical bar represents an individual clone, whose height represents the total 
number of substitutions.  Each bar is shaded according to the proportion of G-to-
A substitutions that occurred in the dinucleotide context: non-G-to-A (black), GA 
(red), GG (yellow), GT (cyan), or GC (gray).  Panels E-G.  A representative 
hypermutation plot from each macaque illustrating the G-to-A and non-G-to-A 
substitutions in the clones from the ileum amplified DNA.  Mutations obtained 
from bulk (top line) sequence analysis of fifteen independent clones from each 
macaque are shown.  Each mutation is denoted by a vertical line that is color 
coded with respect to the the dinucleotide context: non-G-to-A (black), GA (red), 
GG (yellow), GT (cyan), or GC (gray).   
 
 
 
 
	   210	  
 
 
	   211	  
 
  
 
 
 
 
	   212	  
 
 
 
 
 
 
 
 
 
 
 
	   213	  
 
 
 
 
 
 
 
 
 
Table VI.  Results of sequence analysis of nef amplified from the thymus, ileum, 
and spleen.   
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Figure 40.  Quantitative assessment of mutations in the vpu gene.  Panels A-D.  A 
184 base pair fragment of vpu was amplified using DNA isolated from the small 
intestine (ileum), spleen, and thymus of macaques inoculated with SHIVVifHCCH(-) 
and one macaque inoculated with SHIVKU-2MC4.  Substitutions were determined 
using sequence analysis of fifteen independent clones from each macaque are 
shown.  Each vertical bar represents an individual clone, whose height represents 
the total number of substitutions.  Each bar is shaded according to the proportion 
of G-to-A substitutions that occurred in the dinucleotide context: non-G-to-A 
(black), GA (red), GG (yellow), GT (cyan), or GC (gray).  Panels E-G.  A 
representative hypermutation plot from each macaque illustrating the G-to-A and 
non-G-to-A substitutions in the clones from the ileum amplified DNA.  Mutations 
obtained from bulk (top line) sequence analysis of fifteen independent clones from 
each macaque are shown.  Each mutation is denoted by a vertical line that is color 
coded with respect to the the dinucleotide context: non-G-to-A (black), GA (red), 
GG (yellow), GT (cyan), or GC (gray).   
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Table VII.  Results of sequence analysis of vpu amplified from the thymus, ileum, 
and spleen.   
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We confirmed the presence of these G-to-A mutations by sequencing 15 individual 
clones of the nef and vpu genes.  We plotted the G-to-A mutations obtained from 15 
single colony sequences of nef and vpu amplified from DNA isolated from the ileum of 
macaques inoculated SHIVVifHCCH(-)  (Figures 39 and 40).     These results showed that 
many of the G-to-A mutations found in the direct bulk sequencing products were also 
found in the individually cloned both genes (Figures 39 and 40).   Similar to what we 
reported previously, the majority of the changes were in the context of 5’-TC (minus 
strand) (Table VI and VII).  Macaque 44O,  (inoculated with SHIVKU2-MC4) had very few G-
to-A substitutions in vpu and nef amplified from the same three lymphoid organs, which 
is similar to other macaques inoculated with this parental virus (unpublished 
observations).  Macaque AV18 yielded the highest number of G-to-A substitutions (88) in 
the ileum of the small intestine.  Taken together these findings suggest that one or more 
rhA3 proteins that have target sequence preference for 5’-TC is the major cytidine 
deaminase at work in vivo.   
 
 
Discussion 
There are only a limited number of studies that have analyzed the role of the Vif 
protein in the SIV or SHIV/macaque models of HIV-1 disease.   In the first study, the role 
of various accessory proteins expressed from SIVmac239 were evaluated in terms of 
potential to cause disease (Desrosiers et al., 1998).  These investigators found that an 
SIV with deletion of vif had only transient viral loads, could only be detected in PBMC for 
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a short period of time and the macaques did not produce antibodies against SIV 
proteins.  In a second study, investigators showed that a vif-deleted virus would generate 
antibody and cellular immune responses if the virus was administered 2-3 times but was 
not protective against challenge (Sparger et al., 2008).  In both studies, the lymphoid and 
non-lymphoid tissues were not examined for the presence of viral RNA from these vif-
deleted viruses. Finally, we previously showed that the introduction of amino acid 
substitutions into the SLQYLA domain of Vif (to AAQYLA) resulted in a virus 
(SHIVVifAAQYLA) that did not replicate well in hA3G/F positive cells.  However, following 
inoculation into macaques, the plasma viral loads were lowered from approximately 107 
copies per ml for wild type virus to approximately 105 copies per ml for the SHIVVifAAQYLA 
during the acute phase of infection (Schmitt et al., 2009).  In these macaques, the levels 
of circulating CD4+ T cells were maintained near pre-inoculation levels and they did not 
develop histological lesions consistent with a pathogenic X4 SHIV.  Sequence analysis 
of the vif gene amplified from the PBMC revealed that the engineered AAQYLA motif had 
mutated to TAQYLA in two of three macaques.  Since serine and threonine are 
hydroxylated amino acids that differ by a methyl group, it was possible that these Vif 
proteins may have been “partially” functional in vivo to permit limited spread within 
macaques.  Examination of the tissues from these macaques revealed that viral RNA 
was present in select tissues, and the viral sequences contained low levels of G-to-A 
substitutions.  We also showed that the inoculation of plasma from two of these 
macaques into a naive macaque did not result in detectable viral loads up to five months 
post-inoculation (Schmitt et al., 2009).  Thus, despite the low level of viral replication in 
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cell culture systems, SHIVVifAAQYLA was still capable of significant in vivo replication, thus 
validating the need to examine targeted Vif mutants in macaques.  
In the present study, we have extended our in vivo studies using SHIV mutants 
that express either a Vif protein with the first five amino acids of the SLQYLA domain 
substituted with alanines (SHIVVif5A) or a Vif with the HCCH domain substituted with 
alanines (SHIVVifHCCH(-)).   Interestingly, our restriction assays showed that incorporation 
of rhA3G but not rhA3F resulted in the greatest reduction of replication, which is 
somewhat different from the results previously reported (Zennou and Bieniasz, 2006).  
Our results indicate that unlike the parental virus, both viruses incorporated rhA3G while 
both the parental and mutant viruses incorporated rhA3F into virions.  Our analysis of 
rhA3F and rhA3G stability in the presence of viral genome indicated that rhA3F is stable 
while rhA3G is degraded.    The incorporation of rhA3F into wild type virions is in 
agreement with a previous study (Zennou and Bieniasz, 2006; Virgen and Hatzioannou, 
2007).  These paradoxical findings suggest that rhA3F can be incorporated in the 
presence of SIVmac Vif and that the virus can seemly replicate without the accumulation 
of lethal mutations.  In the former study, these investigators found that rhA3F was 
resistant to the SIVmac Vif protein.  They suggested that rhA3F may not exert a strong 
negative presence on SIVmac in vivo and that the SIVmac Vif may actually permit some 
degree of mutagenesis by rhA3F.   This was supported by analysis of HIV-1 gag, pol, 
and env for potential editing sites (GG or GA) that would yield a termination codon if 
mutated.  Their analysis revealed that the percentage of GA editing sites leading to 
termination codons was lower than GG sites in the gag, pol, and env.  Analysis of the 
SIV gag, pol, vif, vpr, vpx, and nef (the SIV genes of our SHIV) also revealed this trend 
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(unpublished observations) yet the mutations observed in the SIVmac nef   were 
predominantly in the context of GA and not GG.  Whether this was due to lethal GG-to-
AG mutations that were subsequently cleared (or not detectable) or whether this was 
due to rhA3F or another rhA3 protein is unknown at this time.   However, it should be 
noted that there were differences in our study and the previous study.  First, in the 
previous study the investigators used a HIV-1Δvif genome and we used an SIV-based 
viral genome with targeted mutations in the vif.   We showed that replication of 
SHIVVifSTOP was much lower compared to SHIVVif5A and SHIVVifHCCH(-) in the presence of 
rhA3F.  Thus, the results of SHIVVifSTOP in our study and HIV-1Δvif in their study is 
comparable.  Our study also shows that our viruses with targeted mutations (SHIVVif5A 
and SHIVVifHCCH(-) ) were restricted less efficiently in the presence of rhA3F compared to 
SHIVVifSTOP, suggesting that the presence of an intact, “crippled” Vif protein can impose 
some restriction compared to having a ΔVif virus.   This may relate to the ability of the 
VifHCCH(-) and the Vif5A proteins to still bind to rhA3F.  Previous studies have defined 
regions of the HIV-1 Vif that are required for binding various hA3 proteins.  Many of 
these regions are in the amino terminal region of the protein.  Previous studies 
demonstrated that HIV-1 Vif residues 40YRHHY44 and 12QVDRMR17 are important for the 
interaction with hA3G and hA3F/C, respectively (Russell and Pathak, 2007; Mehle et al., 
2007).  In a more recent study, a conserved YXXL domain at residues 69-72 of the HIV-1 
Vif was found to be important for the interaction of Vif with hA3G, hA3F and hA3C (Pery 
et al., 2009).  While the 12QVDRMR17 and   40YRHHY44 are not conserved in the 
SIVmac239 Vif, there is a lysine at position 27 of the SIVmac Vif that is required for 
interaction with rhA3G (Chen et al., 2009; Dang et al., 2009).  The YWGL domain of the 
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HIV-1 Vif is also conserved in the SIV Vif (as YWHL).  Thus, it is possible that the Vif 
proteins with targeted amino acid substitutions may still bind and incorporate rhA3Finto 
virus particles but may be inefficient in deamination because of its association with Vif.  A 
second difference in the two studies is the hypermutation assay used to analyze the 
percentage of G-to-A changes in the genome.  While the previous study showed that 
rhA3F caused G-to-A hypermutation at levels higher than rhA3G, we found that rhA3F 
produced little hypermutation in the viral genome.  In the previous study, these 
investigators used a VSV pseudotyped HIV-1 vector with the vif deleted as well as other 
genes and analyzed hrGFP sequences.  In our system, we used complete SIV viral 
genomes expressing the Vif mutant.  
 One goal of these studies was to determine if SHIVVif5A was effectively controlled 
by macaques during the primary phase of infection or if viral variants would emerge that 
would permit limited replication in macaque tissues. Our results indicate that following 
inoculation of SHIVVif5A into macaques, there was a further reduction of plasma viral 
loads compared to SHIVVifAAQYLA (Schmitt et al., 2009).   The mean peak plasma virus 
load (week 1) was 1.3 x 103 viral copies per ml or approximately 4,000-fold lower than 
parental SHIVKU-2MC4.   However, following this initial burst of replication, viral RNA from 
macaques inoculated with SHIVVif5A was near or below the limits in this assay (~180 
copies).  It should be noted that the virus was not completely eliminated because viral 
RNA was occasionally detected in the plasma throughout the 6-month infection using 
nested RT-PCR (data not shown).  At necropsy, the number of copies of viral RNA could 
not be quantified from various organs of these macaques (detection limit 180 copies) but 
could be detected by nested RT-PCR.  We were unable to detect the virus in PBMC by 3 
	   226	  
weeks post-inoculation and were unable to amplify the nef gene at necropsy for 
sequence analysis.  While the results presented here may be predicted based on studies 
in cell culture systems, these results demonstrate for the first time that a primate 
lentivirus expressing a Vif protein with only targeted mutations in a critical domain can be 
completely controlled by the host.  Taken together, these results indicate that the 
SHIVVif5A replicated similarly to a virus that does not express a functional Vif protein 
(Desrosiers et al., 1998).   
No studies have analyzed the role of the Zn++ binding domain of Vif in vivo.  
Previous studies have shown that this domain is critical to Vif function, interacting with 
Cul 5 of the Cul 5/ ElonginB/C/ Rbx E3 ligase (Luo et al., 2005; Xiao et al., 2007).  Our 
results showed that these macaques had slightly higher initial viral loads at one week 
post-inoculation than macaques inoculated with SHIVVif5A, however the virus was 
effectively controlled by the macaques by 3 weeks post-inoculation.   Similar to our 
previous study, the majority of the G-to-A mutations were in the context of 5'-TC (minus 
strand) and not 5'-CC.  In addition, we observed that the majority of the G-to-A changes 
found in the vif gene amplified from PBMC DNA occurred during the first weeks of 
infection.  This correlated well with the plasma viral loads, which indicated the viral 
replication primarily occurred during this time period.   
Taken together, our results show that abolishing the SLQYLA domain of Vif may 
be more detrimental to the virus in vivo than the HCCH domain.  These data bring up the 
question, “Why were we able to quantify viral RNA from tissues of macaques inoculated 
with SHIVVifHCCH(-) but not SHIVVif5A?”  While the answer is unknown, several possibilities 
exist.    First, the virus may have initially replicated in cells expressing active rhA3 
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proteins and incorporated one or more rhA3 proteins into the viral progeny.  In the next 
round of replication the genome was mutated but not to the extent that RNA polymerase 
II could not transcribe viral RNA.  Second, there may be a tissue/cellular reservoir for 
virus replication that do not express the rhA3 proteins that would restrict the crippled 
SIVmac239 Vif protein.  We previously showed using immunohistochemistry that rhA3G 
was not expressed in all cell types in the brain and kidneys (Hill et al., 2006; 2007).  
Finally, during the initial rounds of replication and potential deamination, G-to-A 
mutations may have led to compensating mutations that made the viral Vif partially 
functional.  The later scenario is not likely as our sequence analysis did not identify 
consensus mutations in either the SHIVVif5A or SHIVVifHCCH(-)-inoculated macaques. 
As previous studies showed that antibody responses were not generated with a 
single inoculation of vif-deleted viruses (Desrosiers et al., 1998; Sparger et al., 2008), we 
determined if a single inoculation of either virus would result in an antibody response 
against viral proteins.  Comparison of the antibody responses from macaques inoculated 
with either SHIVVifHCCH(-) or SHIVVif5A shows that at 12 weeks post-inoculation macaques 
had developed antibody responses against the virus but these were undetectable at 
necropsy.  This would argue that the viral RNA detected in tissues at necropsy may not 
have been translated into viral proteins.  This would also suggest that infectious virus 
was cleared by the macaque and that antigenic stimulation through viral proteins did not 
occur.  However, this study provides evidence that such viruses containing site-directed 
mutations in vif could be used to “prime” the immune system and suggests that such a 
virus could be useful in a prime-boost strategy.   It will be of interest to determine if 
multiple inoculations will result in stronger immune responses (both humoral and cellular) 
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and a further reduction of viral loads with increasing inoculations.  If successful, it will be 
of interest to determine if the immune responses are protective against challenge.  While 
the use of live attenuated lentiviruses has led to useful information concerning the role of 
accessory genes in replication of the virus in vivo, the use of such vaccines has several 
underlying risks (Koff et al., 2006).  First, these vaccines have relied on the 
deletion/disruption of accessory genes (nef, vpu, vpx/vpr) that enhance replication but 
are not absolutely required for replication in vivo.  For this reason these viruses can 
select for compensating mutations that ultimately result in the virus becoming pathogenic 
(Baba et al., 1995; 1999).  The second problem is the risk of recombination of the viral 
genome to yield a pathogenic virus (Kim et al., 2005).  A vaccine based on a “crippled 
Vif” that allows for limited replication resulting in G-to-A substitutions and inactivation of 
the virus should prevent the scenarios discussed above.  It would be of interest to 
determine if inoculation of macaques with two viruses, one harboring a mutation in vif 
and another having a mutation in another accessory gene such as nef can recombine in 
vivo to generate a wild type virus causing CD4+ T cell loss and disease prior to the virus 
accumulating G-to-A mutations.       
 
 
Experimental Methods 
 
Cells, plasmids, and viruses 
The C8166 and SupT1 lymphocyte cell lines were used for transfections of full-
length SHIVs and as indicator cells to measure infectivity and cytopathicity of the viruses 
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used in this study.   Both cell lines were maintained in RPMI-1640, supplemented with 10 
mM Hepes buffer pH 7.3, 2 mM glutamine, 5 µg per ml gentamicin, 100 units/µg 
penicillin-streptomycin and 10% fetal bovine serum (R10FBS).   Rhesus macaque 
PBMCs were obtained from uninfected animals and isolated on  Ficoll/Hypaque 
gradients for p27 growth curves.  The 293 cell line was maintained in Dulbecco’s minimal 
essential medium (DMEM) with 10% fetal bovine serum and the antibiotics described 
above.  The derivation of SHIVKU-2MC4 has been previously described (Joag et al., 1998).  
The pcDNA3.1(+)-HA-rhesus APOBEC3G and pcDNA3.1(+)-rhesus APOBEC3F-V5 
were kindly provided by Nathaniel Landau (New York University School of Medicine, 
New York, New York).   
 
Construction of SHIVVif5A, SHIVVifHCCH(-) and SHIVVifSTOP 
For the construction of SHIVVifHCCH(-), the PacI/SphI fragment (nucleotides 5132 to 
6452) from the p5’-SHIV4 was subcloned into the pGEM3Zf (+) vector.   The histidine to 
alanine substitution at position 110 of Vif was introduced using oligonucleotides (only 
sense strand shown) 5’-GCAGACATTTTACTGGCTAGCACTTATTTCC- 3’.  The cytidine 
to alanine substitution at position 116 of Vif was introduced using oligonucleotides (only 
sense strand shown) 5’- GCACTTATTTCCCTGCCTTTACAGCGGGAG- 3’.  The 
cysteines at positions 134 and 135 of Vif were substituted for alanines using the 
oligonucleotides (only sense strand shown) 5’-
CAACTGCTGTCTGCCGCCAGGTTCCCG-3’.  The histidine to alanine substitution at 
position 144 of Vif was introduced using oligonucleotides (only sense strand shown) 5’- 
GGTTCCCGAGAGCTGCTAAGTACCAGGTACC –3’.  All substitutions were made using 
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the Quick-Change Mutagenesis Kit (Stratagene) following the manufacturer’s 
instructions.  The resulting PacI/SphI fragment was digested, isolated, and subcloned 
into full length SHIVKU-2MC4.  The resulting plasmid was sequenced to ensure that the 
desired mutations were introduced as expected.  
For the construction of SHIVVif5A, the PacI/SphI fragment (nucleotides 5132 to 
6452) from full-length SHIVKU-2MC4 was subcloned into the pGEM3zf (+) vector.  The 
serine and leucine at positions 147 and 148 were substituted for alanines using the 
oligonucleotides (sense strand shown) 5’- 
CCAGGTACCAGCCGCACAGTACTTAGCAC-3'.  The glutamine and tyrosine at 
positions 149 and 150 were substituted for alanines using the oligonucleotides (sense 
strand shown) 5’-CCAGGTACCAGCCGCAGCGGCCTTAGCACTGAAAGTAGTAAGC-
3’.  The leucine at position 151 was substituted for an alanine using the oligonucleotide 
(sense strand shown) 5’-
GGTACCAGCCGCAGCGGCCGCAGCACTGAAGTAGTAAGCG-3'.  All substitutions 
were made using the Quick-Change Mutagenesis Kit (Stratagene) following the 
manufacturer’s instructions and virus constructed and prepared as described above. 
For the construction of SHIVVifSTOP, the tyrosine and leucine at amino acid 
positions 28 and 29 were engineered to have stop codons using site-directed 
mutagenesis in order to produce a full-length SHIV that does not express a functional Vif 
protein.  The oligonucleotide used to introduce these mutations was 5’-
GCCTCATTAAAATAGTAGAAATATAAAACTAAAG-3’ (only sense strand shown).  The 
substitutions were made using the Quick-Change Mutagenesis Kit (Stratagene) following 
the manufacturer’s instructions.  The resulting PacI/SphI fragment was digested, 
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isolated, and subcloned into full length SHIVKU-2MC4.  The resulting plasmid was 
sequenced to ensure that the desired mutations were introduced as expected.   For all 
three viruses, the plasmids containing the full-length genomes were transfected into 
SupT1 cells as previously described (Stephens et al., 2002; Hout et al., 2005).  Stocks of 
SHIVVifHCCH(-), SHIVVif5A, and SHIVVifSTOP were prepared, tittered on SupT1 cells, and 
stored at -86°C.   
 
Analysis of the replication of SHIVVif5A and SHIVVifHCCH(-) in APOBEC3G/F positive 
and negative cells 
C8166 (A3G/F positive) and SupT1 (A3G/F negative) cells were inoculated with 
equivalent levels (25 ng) of parental SHIVKU-2MC4, SHIVVif5A, SHIVVifHCCH(-), SHIVVifAAQYLA, 
or SHIVVifSTOP for 4 hours at 37C.  For rhesus PBMC, cells were isolated on Ficoll-
Hypaque gradients, stimulated for 48 hours in R10FBS supplemented with concanvalin A 
(10 µg/ml) and interleukin-2 (IL-2; 50 ng/ml).  The cells were washed, and inoculated with 
virus (25 ng) incubated in R10FBS containing interleukin-2 (50 ng/ml) for 4 hours.   At 4 
hours, cells were centrifuged, washed 3 times to remove the inoculum and incubated in 
fresh medium (medium for the rhesus PBMC also contained 50 ng/ml IL-2) at 37C for up 
to 15 days.  Aliquots of culture supernatants were obtained at 0, 1, 3, 5, 7, 9, 11, 13, and 
15 days post-inoculation and the levels of p27 assessed using commercial p27 antigen 
capture kits (Zeptometrix).   
 
APOBEC3G/F incorporation assays   
Plasmids containing the genomes viruses (derived from SHIVKU-2MC4) expressing 
each of the mutant Vif proteins described above were co-transfected into 293 cells using 
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PEI Transfection reagent (Ex-Gen 500) along with plasmids expressing either HA-rhA3G 
or V5-rhA3F.  At 48 hours, the virus containing supernatants were harvested and 
clarified by low speed centrifugation.  The clarified supernatant was then subjected to 
ultracentrifugation to pellet the virus (SW41 rotor, 247,000xg, 1 hour).  The pellet was 
resuspended in PBS (pH 7.4) and layered on a 20/60% sucrose step gradient and again 
subject to ultracentrifugation (SW55Ti, 247,000xg, 1 hour).  The virus (at the interface) 
was harvested, pelleted again by ultracentrifugation described above, and resuspended 
in 200µl of 1x PBS (pH 7.4).  An aliquot was saved to determine the p27 content by 
antigen capture assay (Zeptometrix).  The remaining sample was boiled in sample 
reducing buffer.  Equivalent amounts of p27 were loaded on a 12% SDS-PAGE gel and 
transferred to PVDF membranes.  APOBEC3 proteins were detected by Western blotting 
using an antibody directed against either the HA tag (HA-probe; Santa Cruz) or V5 tag 
(Clone V5-10; Sigma).   Blots were stripped in 1X stripping buffer (62.5 mM Tris-HCl, 
pH 6.8 and 2% SDS) and reprobed using a rabbit polyclonal antibody specific for p27.  
As a control, plasmids expressing either rhA3G or rhA3F were transfected into 293 cells 
using PEI transfection reagent (ExGen500, Fermentas).  At 48 hours post-transfection, 
cells were lysed in 1x RIPA and the nuclei were removed.  Whole protein was 
precipitated with methanol and resuspended in 2x sample buffer.  Normalized to β-actin, 
the samples were run on a 12%-SDS-PAGE gel, and probed with the antibodies stated 
above.  
 
Stability of rhA3G and rhA3F in the presence of SHIV genomes 
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 We determined if rhA3G or rhA3F were stable in the presence of SHIVKU-2MC4, 
SHIVVifHCCH(-), SHIVVif5A, or SHIVVifSTOP.  Full-length mutated SHIVs were co-transfected 
in a 2:1 ratio with either APOBEC3G-HA or APOBEC3F-V5 using polyethylenimine 
transfection reagent (PEI, Fermentas).  Twenty-four hours post-transfection, the 
supernatant was removed and the cells were harvested and lysed using 1 x RIPA (50 
mM Tris-HCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA).  
Following lysis, the nuclei were removed by microcentrifugation at 1400 rpm for 15 
minutes.  The protein was prepared using methanol, resuspended in 2X sample reducing 
buffer, and boiled for 5 minutes.  Proteins were separated on a 10% SDS-PAGE gel and 
probed using commercially available rabbit polyclonal HA antibody (HA-probe, Santa 
Cruz) for rhA3G-HA or mouse monoclonal V5 antibody (Clone V5-10, Sigma) for rhA3F.  
All samples were normalized to the amount of β-actin protein using a mouse monoclonal 
antibody (Novous Biologicals) specific for β-actin.    
 
Hypermutation assays in the presence of rhA3G or rhA3F 
 Hypermutation of various SHIVs in the presence of rhesus APOBEC3G/F 293 
cells were transfected with SHIVKU-2MC4, SHIVVifHCCH(-), SHIVVif5A, or SHIVVifSTOP in the 
presence of either rhA3G or rhA3F using polyethylenimine transfected reagent (PEI, 
Fermentas).  Twenty-four hours post-transfection, cells were washed and fresh DMEM 
was added.  After forty-eight hours, the supernatant containing virus was subjected to 
low speed centrifugation.  The resulting supernatant was DNase-I—treated (Fermentas) 
at 37°C for 30 minutes to eliminate any trace of plasmid carry-over from the initial 
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transfection.  The DNase-I-treated supernatant was titrated on TZM-bl cells to both 
assess infectivity and hypermutation.  Twenty-four hours post-infection, total DNA 
cellular DNA was harvested and extracted using the DNeasy kit and the manufacturer’s 
instructions (Qiagen).  The DNA was used in a nested DNA polymerase chain reaction to 
amplify a 300 base pair fragment of nef.  The PCR reaction was carried out using rTaq, 
the manufacturer’s instructions (Takara), and the oligonucleotides listed below.  1 µl of 
the first PCR product was added to a nested reaction.  The PCR reactions were 
perfomed using an Applied Systems 2720 Thermal Cycler with the following thermal 
profile: 95°C for 2 minutes, 1 cycle; 95°C for 30 seconds, 48°C for 30 seconds, 65°C for 
2 minutes, 35 cycles; 65°C for 7 minutes.  The PCR products were separated by 
electrophoresis, isolated, purified, sequenced and sub-cloned into pGEM-TEasy 
(Promega) as described below.  Fifteen independent clones were sequenced and 
assessed for each mutant SHIV as described above.   
 
Restriction of Vif Mutants on rhA3G or rhA3F 
We determined the effect of the Vif mutants on the suppression of rhA3G and 
rhA3F.  Full-length mutated SHIVs were co-transfected with either rhA3G or rhA3F using 
PEI transfection reagent (ExGen500, Fermentas).  Forty-eight hours post-transfection, 
the supernatant was harvested and purified by low speed centrifugation.  Equivalent 
amounts of p27 were serially diluted using 10-fold dilutions from 101 to 106 and used to 
inoculate TZM-bl cells.  Forty-eight hours later, the media was removed, cells washed 
with 1X PBS and the monolayer fixed using 1% formaldehyde-0.2% glutaraldehyde in 
	  
	  
	  
	  
235	  
phosphate-buffered saline (1 x PBS).  The cells were washed and incubated in a solution 
for 2 hours at 37C in 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 4 mM 
magnesium chloride, and 0.4 mg X-gal per ml.  The reaction was stopped and the 
number of TCID50 were calculated  (Derdeyn et al., 2000; Wei et al., 2002).   
 
Macaques analyzed in this study   
Three rhesus macaques (Macaca mulatta: CX54, ER65, and I92) were 
intravenously inoculated with 1 ml of undiluted culture supernatant from SupT1 grown 
virus stocks (containing 104 TCID50 per ml).  Three additional rhesus macaques (AS34, 
AS51, and AV18) were inoculated with 104 TCID50 SHIVVifHCCH(-) (titered in SupT1 cells).   
The animals were housed in the AAALAC-approved animal facility at the University of 
Kansas Medical Center.   All aspects of the animal studies were performed according to 
the institutional guidelines for animal care and use at the University of Kansas Medical 
Center.   Heparinized blood was collected weekly for the first 4 weeks, then at 2-week 
intervals for the next month and at monthly intervals thereafter.  
 
Assays for circulating CD4+ T cells 
Changes in the levels of CD4+ T cells after viral inoculations were 
monitoredsequentially by flow cytometric analysis (BD Biosciences).   T cell subsets 
were labeled with a commercially available anti-CD3/CD4/CD8 mixture.  T cell subsets 
from a normal uninfected macaque were always performed at the same time to serve as 
a control for the flow cytometry analysis.     
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Processing of tissue samples at necropsy 
 At the time of euthanasia (26 or 28 weeks), all macaques in this study were 
anesthetized by administration of 10 mg/kg ketamine (IM) followed by intravenous 
administration of sodium phenobarbital at 20-30 mg/kg.  At the time of necropsy, all 
macaques were in a healthy condition.  A laparotomy was performed. The animal was 
exsanguinated by aortic canulation and perfused with one liter of cold Ringer’s saline.   
Lymphoid and non-lymphoid tissues (heart, kidneys, liver, lungs, mesenteric, inguinal 
and axillary lymph nodes, pancreas, salivary gland, small intestine, spleen, thymus, and 
tonsils) were obtained and aliquots of tissue snap frozen for DNA and RNA assays.  
Aliquots of lymphoid tissues were immersed in HBSS to quantify levels of infectious virus 
in tissues using infectious centers assays with SupT1 cells.    
 
Sequence analysis of the vif, nef, and vpu genes 
 To determine the stability of the mutations that were introduced into vif and 
assess whether these macaques acquired G-to-A mutations, the vif, nef, and vpu genes 
were amplified from either PBMCs at different time points during infection (vif) or from 
several tissue DNA samples taken at necropsy (nef and vpu) that were positive for viral 
RNA. One hundred nanograms of extracted genomic DNA was used in a nested DNA 
polymerase chain reaction (Takara, Madison, WI) following the manufacturer’s 
instructions.  The oligonucleotides employed during the first round to amplify vif were 5’-
GGCTAAAATTATCAAAGATTATGGAGG-3’ (sense) and 5’-
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GGTGACATCCCTTGTTCATCATGCC-3’ (antisense), which corresponds to bases 5326-
5352 and 5984-6008, respectively.  The nested oligonucleotides were 5’-
GGAGGAGGAAAAGAGGTGGATAGCAGTTCCC-3’ (sense) and 5’-
CCAGTATTCCCAAGACCTTTGCC-3’ (antisense), which corresponds to bases 5348-
5378 and 5963-5985, respectively.    The oligonucleotides used during the first round to 
amplify the nef gene were 5’-GGTGGAGCTATTTCCATGAGG-3’ (sense) and 5’-
GTCTTCTTGGACTGTAATAAATCCC-3’ (antisense), which corresponds to bases 9445-
9465 and 9832-9856, respectively.  The nested oligonucleotides were 5’-
CCATGAGGCGGTCCAGGCAGTCTAGAG-3’ (sense) and 5’-
CCTCCCAGTCCCCCCTTTTC-3’ (antisense), which corresponds to bases 9458-9484 
and 9814-9833, respectively.  The oligonucleotides used during the first round to amplify 
the vpu gene were 5’-CCTAGACTAGAGCCCTGGAAGCATCC-3’ (sense) and 5’-
GTACCTCTGTATCATATGCTTTAGCAT-3’ (antisense), which corresponds to bases 
6486-6511 and 7034-7061, respectively.  The nested oligonucleotides used were 5’-
TTAGGCATCTCCTATGGCAGGAAGAAG-3’ (sense) and 5’-
CACAAAATAGAGTCCTGGTTGCTTCCT-3’ (antisense), which corresponds to bases 
6597-6623 and 7001-7027, respectively.   
For sequence analysis, the PCR products from three separate PCR reactions 
were pooled and separated by electrophoresis in a 1.5% agarose gel, isolated, and each 
PCR reaction directly sequenced.  Cycle sequencing reactions using the BigDye 
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA polymerase, FS 
(PE Applied Biosystems, Foster City, CA) sequence detection was conducted with an 
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Applied Biosystems 377 Prism XL automated DNA sequencer and visualized using the 
ABI Editview program.  Sequences were compared to the sequence of SHIVKU-2MC4.   A 
total of 615 nucleotides were analyzed from vif, 300 nucleotides analyzed from nef, and 
184 nucleotides from vpu using the SE Central Software package. In order to isolate and 
analyze single sequences, bulk PCR reactions were subcloned into the pGEM-TEasy 
(Promega) cloning vector.  Fifteen clones were selected, sequenced as described above, 
and analyzed to assess the number of G-to-A substitutions that occurred.   
 
Plasma virus loads   
Plasma viral RNA loads were determined on RNA extracted from 1 ml of EDTA-
treated plasma.  Virus was pelleted using ultracentrifugcation (Beckman SW55Ti, 
250,000xg, 2 hours) and RNA extracted using the Qiagen viral RNA kit (Qiagen).  RNA 
samples were analyzed by real-time RT-PCR using gag primers and a 5'FAM and 
3'TAMRA labeled Taqman probe that is homologous to the SIV gag gene as previously 
described (Hofmann-Lehmann et al., 2000).   Standard curves were prepared using a 
series of six ten-fold dilutions of viral SIV gag RNA of known concentration.  The 
sensitivity of the assay was 100 RNA equivalents per ml.  Samples were analyzed in 
triplicate and the number of RNA equivalents per ml of plasma were calculated.  Viral 
RNA was also quantified from in visceral tissues using this primer/probe reaction.  In 
order to quantify the amount of viral RNA, GAPDH was used as a control and data is 
presented as copies per 106 GAPDH molecules (Marcario et al., 2008).   
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Immunoprecipitation assays 
To determine if the macaques developed antibodies to SHIV proteins following 
inoculation, the plasma at 12 weeks and at necropsy was used in immunoprecipitation 
assays.  C8166 cells were inoculated with approximately 104 TCID50 of SHIVKU-2MC4 for 
5 days.  The cells were then incubated in methionine/cysteine-free media for 2 hours 
and radiolabeled labeled with 500 µCi of 35Smethionine/cysteine for 15 hours.  The cells 
were lysed in 1ml of 1X RIPA buffer and nuclei were removed by centrifugation.   The 
cell lysates were incubated overnight at 4oC with 10 µl of plasma from each macaque 
and protein A Sepharose beads.  The immunoprecipitates bound to the beads were 
washed three times in 1X RIPA, resuspended in 75 µl of 2X sample reducing buffer, and 
boiled for 5 minutes.  Proteins were separated on a 10% SDS-PAGE gel and visualized 
by autoradiography.  Controls included pooled prebleed plasma from macaques 
(negative control) and plasma from macaques that had been previously inoculated with 
a non-pathogenic SHIV (SHIVTM, positive control).  	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VIII.  Chapter 4:  Differential virus restriction patterns of rhesus macaque and 
human APOBEC3A:  Implications for lentivirus evolution 
 
 
Abstract 
 
The human apolipoprotein B mRNA editing enzyme catalytic peptide-like 3 
(APOBEC3; A3) family of proteins (A3A-H) are known to restrict various retroviruses 
and retroelements, but the full complement of rhesus macaque A3 proteins remains 
unclear. We report the isolation and characterization of the hA3A homologue from 
rhesus macaques (rhA3A) and show that the rhesus macaque and human A3 genes are 
orthologous. RhA3A is expressed at high levels in activated CD4+ T cells, is widely 
expressed in macaque tissues, and is degraded in the presence of the human 
immunodeficiency virus (HIV-1) and simian-human immunodeficiency virus (SHIV) 
genomes. Our results indicate that rhA3A is a potent inhibitor of SHIVΔvif and to a 
lesser extent HIV-1Δvif. Unlike hA3A, rhA3A did not inhibit adeno-associated virus 2 
(AAV-2) replication and L1 retrotransposition.  These data suggest an evolutionary 
switch in primate A3A virus specificity and provide the first evidence that a primate A3A 
virus specificity and provide the first evidence that a primate A3A can inhibit lentivirus 
replication.   
 
 
Introduction  
In the last decade several host restriction factors have been discovered that can 
restrict the replication of HIV-1. One of these restriction factors, Apolipoprotein B 
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mRNA-editing catalytic polypeptide-like 3 (APOBEC3; A3), has been shown to inhibit a 
wide range of retroviruses and other viruses such as the parvoviruses, 
papillomaviruses, and hepadnaviruses (Abe et al., 2009; Baumert et al., 2007; Bonvin et 
al., 2006, 2007; Chen et al., 2006; Henry et al., 2009; Jarmuz et al., 2002; Köck et al., 
2008; Mahieux et al., 2005; Narvaiza et al., 2009; Noguchi et al., 2007; Paprotka et al., 
2010; Sheehy et al., 2002; Strebel et al., 2005; Turelli et al., 2004; Vartanian et al., 
2008; Zhang et al., 2008).  A3 proteins comprise a family of seven cytidine deaminases 
(A3A, A3B, A3C, A3D, A3F, A3G, and A3H) that catalyze the deamination of cytidine to 
uracil on single-stranded DNA or RNA through a highly conserved Zn+2-binding motif 
(C/H-X-E-X23-28-P-C-X2-4-C) (Chiu et al., 2009; Goila-Gaur and Strebel., 2008; Huthoff et 
al., 2005; Yu et al., 2004). These proteins also contain a key glutamate required for 
proton shuttling during catalysis and two aromatic amino acids residues required for 
RNA substrate binding (Jarmuz et al., 2002).   
The A3 proteins can be divided into those with a single (A3A, A3C, A3H) or 
double  (A3B, A3D, A3F, and A3G) cytidine deaminase domains (CDA). The double 
CDA proteins A3D, A3F, and A3G have been shown to restrict the replication of HIV-1 
isolates that do not express a functional Vif protein while A3B could inhibit HIV-1 
independent of Vif (Dang et al., 2006; Doehle et al., 2005; Kao et al., 2003; Liddament 
et al., 2004; Sheehy et al., 2002; Smith et al., 2010; Wiegand et al., 2004; Yu et al., 
2004; Zheng et al., 2004).  The Vif protein is known to bind to select A3 proteins and 
shunt the A3 proteins to the proteasome for degradation (Liu et al., 2004; Marin et al., 
2003; Mehle et al., 2004; Sheehy et al., 2003; Yu et al., 2003). Mutagenesis studies 
have shown that the N-terminal CDA lacks catalytic activity and is responsible for 
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binding the RNA while the C-terminal CDA mediates sequence-specific deamination of 
single-stranded DNA (Yu et al., 2004). In addition to deaminase dependent functions, 
hA3G and hA3F inhibit virus replication by deaminase-independent mechanisms 
(Holmes et al., 2007a,b). Human A3G (hA3G) and hA3F can also inhibit DNA synthesis, 
which may involve interference of t-RNA Lys3 primer annealing, initiation and elongation 
of DNA synthesis and minus or plus strand DNA transfers (Bishop et al., 2008; Guo et 
al., 2006, 2007; Holmes et al., 2007a; Iwatani et al., 2007; Li et al., 2007; Luo et al., 
2007; Newman et al., 2005; Ooms et al., 2010). Of the single CDA A3 proteins, hA3A 
has no activity against HIV-1 while hA3C can be incorporated into virions but only has 
weak activity against HIV-1 and foamy virus (Langlois et al., 2005; Perkovic et al., 
2009). Human A3H is now known to have seven haplotypes, several of which can be 
stably expressed (Harai et al., 2009; Ooms et al., 2010; Wang et al., 2011). However, 
attempts to detect hA3H in isolated peripheral blood mononuclear cells (PBMC) has 
been unsuccessful (Li et al., 2010).   
Human A3A is a nucleocytoplasmic protein that is expressed mainly in primary 
monocytes and keratinocytes (Koning et al., 2009; Madsen et al., 1999; Peng et al., 
2007). Sequences consistent with hA3A-mediated editing have been observed in the 
genome of papilloma virus, which is known to infect both cutaneous and mucosal 
keratinocytes (Vartanian et al., 2008).  Previous studies shown that hA3A lacks antiviral 
activity against HIV-1, but inhibits the replication of adeno-associated virus 2 (AAV-2), 
intracisternal A particles (IAP), and long interspersed nuclear element 1 (L1) (Bogerd et 
al., 2006a,b; Chen et al., 2006; Muckenfuss et al., 2006). The expression of HA3A is 
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induced by foreign DNA detection and interferon (IFN) in phagocytes, which leads to the 
degradation and clearance of foreign DNA (Stenglein et al., 2010).  
Although hA3A contains one CDA, the deaminase activity of hA3A is not required 
for its inhibitory role against AAV or retrotransposons, suggesting that a deaminase-
independent mechanism of inhibition is occurring (Narvaiza et al., 2009). Human A3A 
also contains significant homology to the N-terminal half of hA3G, does not associate 
with the viral nucleocapsid complex (NPC) of HIV-1 but is readily incorporated into 
virions (Goila-Gaur et al., 2007).  
Simian immunodeficiency (SIV) and simian-human immunodeficiency (SHIV) 
viruses have been invaluable models for studying various aspects of HIV-1 
pathogenesis. Sequencing of the rhesus macaque genome has led to the identification 
of rhesus homologues of A3B, A3C, A3D, A3F, A3G and A3H. Here we describe the 
identification of an A3A homologue in rhesus macaques (rhA3A) and present evidence 
that the human and macaque Apobec3 genes are orthologous. We show that the rhA3A 
protein is expressed well in activated macaque CD4+ T cells and other rhesus macaque 
tissues, is incorporated into virions, is degraded by both HIV-1 and SHIV in a Vif 
dependent manner, and restricts the replication of SHIV (expressing the SIVmac239 Vif) 
and HIV-1.       
 
 
Results 
 
Molecular cloning of rhesus macaque A3A 
	  
	  
	  
	  
244	  
Humans encode seven APOBEC3 (hA3) genes that are tandemly arrayed on 
chromosome 22, but there is uncertainty on whether a similar array of rhA3 genes is 
expressed in the syntenic region on rhesus macaque chromosome 10. In particular, no 
rhA3A gene has been cloned from rhesus macaques suggesting that this gene may 
have been deleted in the genome of this primate species (OhAinle et al., 2008; Virgen 
et al., 2007). However, a recent study showed that A3A is encoded in the genome of 
several monkey species, including African green and owl monkeys (Bulliard et al., 
2011).  The evolutionary conservation of A3A therefore suggested that the rhA3A gene 
was missed in previous cloning attempts. To determine whether rhA3A is expressed, we 
took advantage of the sequencing of the rhesus macaque genome (Rhesus Macaque 
Genome Sequencing and Analysis Consortium, 2007). BLAST analysis of the hA3A 
sequence revealed that the first exon has a counterpart on the rhesus macaque 
chromosome 10, thus providing a potential forward primer for PCR amplification. 
However, counterparts of other hA3A exons were not detected in the rhesus macaque 
genome immediately downstream of this putative exon 1 sequence. Thus, the last exon 
of hA3A was used as a reverse primer.  
Human A3A is not expressed in resting peripheral blood mononuclear cells 
(PBMC), but is substantially induced by cellular activation and cytokines (Koning et al., 
2009; Refsland et al., 2010). We therefore utilized cDNA from Concanavilin A-activated 
rhesus macaque PBMCs in an attempt to detect rhA3A. A dominant band of the correct 
size was amplified in the first attempt by PCR.  BLAST analysis of the cloned amplicon 
revealed 89% nucleotide identity with hA3A. Alignment of the amino acid sequence with 
recently identified A3A sequences showed the highest identity (90%) with A3A from  
	  
	  
	  
	  
245	  
 
 
Figure 41.  Sequence analysis of the rhA3A proteins.  Panel A.  Protein sequence 
alignment of primate A3A proteins.  Dashes correspond to indels, while residues 
highlighted in pink or orange are conserved or mathed the consensus, 
respectively.  Some indels were associated with specific primate taxons.  This 
includes homiind-specific deletion at amino acid positions 27 to 29, and a 
deletion in residues 108-109 in New World monkeys.  Panel B.  A3A phylogeny.  
The amino acid sequence alignment was subjected to phylogenic analysis using 
the neighbor joining method, excluding sequence gaps, and rooted using the C-
terminal half of rhesus macaque A3G as an outgroup.  Numbers correspond to 
the percentage of clustering following 1000 subreplicates.  RhA3A clustered most 
significantly with A3A from another Old World monkey species, African Green 
monkey (AGM).     
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African green monkeys, which, together with Asian macaques, are considered as “Old 
World” monkeys (Figure 41). This alignment also revealed primate lineage-specific 
insertions/deletions (indels).  In particular, we observed deletions at positions 27 to 29 in 
the hominid A3A genes. To further explore the clustering of A3A sequences with 
specific primate lineages, we constructed a phylogenetic tree that excluded the 
contribution of indels. As shown in Figure 41, A3A sequences clustered accordingly with 
their corresponding primate taxons. These analyses demonstrate that the cloned rhA3A 
gene is a bona fide member of the A3A gene family. 
 
Evidence that seven A3 genes are tandemly arrayed on chromosome 10 of rhesus 
macaques 
While the sequence of the rhesus macaque genome has been “completed,” it still 
remains unclear why this did not reveal the rhA3A gene. We attempted to determine the 
position of the cloned rhA3A sequence in relation with other rhA3 genes. At the time 
that the analyses were performed, only the nucleotide sequences for rhesus macaque 
rhA3C, rhA3F, rhA3G and rhA3H had been deposited into GenBank. BLAST analysis of 
these cDNA sequences against the rhesus macaque genome revealed their distinct 
positions as shown in Figure 42. The position of rhesus macaque rhA3B and rhA3DE 
remains unknown, although their amino acid sequences were published (Virgen et al., 
2007). We first attempted to determine the relative positions of rhA3B and rhA3D in 
chromosome 10 based solely on the genome sequence. Using the geneid program 
(http://genome.crg.es/geneid.html), genome sequences between rhA3C and rhA3F 
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predicted rhA3D (Figure 43), while genomic and previously unlocalized sequences 
upstream of rhA3C predicted rhA3B (Figure 44).   
The relative placement of rhA3B and rhA3D in the rhesus macaque genome 
suggested a similar A3 gene organization as found in humans, with the notable 
uncertainty of rhA3A. We therefore focused on genomic sequences immediately 
upstream of rhA3B. BLAST analysis of the cloned rhA3A sequence revealed an 
identical sequence corresponding to rhA3A exon 1 in the genome. This putative rhA3A 
exon 1 was immediately followed by 560 bp of CT-rich repeat sequences and 16.8 kb of 
unresolved sequence. It is possible that these repeat sequences interfered with 
accurate sequencing of this region. On the other hand, exons 2 to 4 of rhA3A mapped 
to an unlocalized chromosome 10 genomic scaffold sequence with GenBank Accession 
NW_001096321.1. The 3,764 bp NW_001096321.1 sequence could easily be 
accommodated in the 16.8 kb genomic gap.  Notably, the NW_001096321.1 sequence 
contained 838 bp of intron sequence upstream of exon 2. We therefore investigated 
whether the NW_001096321.1 links directly with the genome by amplifying rhesus 
macaque genomic DNA with primers designed in exon 1 and 2 of rhA3A (Figure 42). 
Direct sequencing of the 1.8-kb amplicon revealed identity with the flanking sequences 
following the putative exon 1 in the genome and prior to exon 2 in NW_001096321.1 
(Figure 42). These results provide strong evidence that rhA3A is likely encoded in the 
rhesus macaque genome immediately upstream of rhA3B. Overall, these analyses 
suggest that the seven rhA3 members are tandemly arrayed in the rhesus macaque 
genome, similar to humans.   
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Figure 42. Sequence characterization of the rhesus macaque A3 locus. Panel A.  
Genome organization of rhesus macaque A3 genes.  (Top)  Published cDNA 
sequences for rhA3C, rhA3F, rhA3G, and rhA3H were subjected to BLAST 
analysis against the rhesus macaque genome.  Matching exons were plotted 
against assigned genome coordinates, shown here in 20 kb intervals.  *RhA3B 
and rhA3D were predicted by subjecting the genome sequences upstream from 
rhA3C or flanked by rhA3C and rhA3F to the geneid prediction program 
(http://genome.crg.es/geneid.html), respectively.  RhA3A amplified from activated 
PBMC was subjected to BLAST analysis.  RhA3A exon 1 mapped in the genome 
directly upstream of A3B, but this was followed by a 16.8 kb of unresolved 
sequence (dotted lines).  (Bottom)  A3A exons 2 to 4 matched sequences from an 
unlocalized chromosome 10 genomic scaffold sequence.  Primers based on A3A 
exons 1 and 2 amplified a 1.8 kb product that matched flanking sequences after 
exon 1 in the genome and before exon 2 in the unlocalized genomic scaffold (gray 
lines).  This provides strong evidence for the current placement of rhA3A in the 
rhesus macaque genome.  Panel B.  Phylogeny of rhesus macaque and human A3 
proteins.  Amino acid sequences from rhesus macaque and human A3 genes 
were aligned, with the double-CDA members split into an N- and C-terminal half.  
For example, A3B-C corresponds to the C-terminal half of A3B.  RhA3A clustered 
with the C-terminal half of A3B and A3G, forming the Z1 clade.  Each rhesus 
macaque A3 gene clustered significantly with the corresponding human A3 gene, 
suggesting that rhesus macaque and human A3 proteins are orthologous.   
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Figure 43.  Nucleotide sequence alignment of huA3D and genome-predicted 
rhA3D.  The rhesus macaque genome sequence flanking rhA3C and rhA3F could 
potentially encode rhA3D.  To investigate this possibility, we subjected this 
genomic sequence to a gene prediction program, 
(http://genome.crg.es/geneid.html).  This analysis revealed a putative rhA3D gene 
that exhibited 86% nucleotide identity with hA3D.  However, multiple attempts to 
clone the full-length gene in activated rhesus macaque PBMCs failed, likely due 
to the fact that the reverse primer cross-reacted significantly with the more highly 
expressed rhA3C gene and that rhA3D is very poorly expressed in these cells.  In 
contrast, the 5’ half of this gene was cloned (unpublished data).     
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Figure 44.  Nucleotide sequence alignment of hA3B and genome-predicted rhA3B.  
Upstream of rhA3C are genome sequences that matched some exons of hA3B.  
Closer inspection revealed unresolved sequences in regions that could putatively 
encode exons 2, 7, and 8.  A substantial portion of these gaps was resolved with 
the inclusion of “unlocalized genomic scaffold sequences” from chromosome 10.  
In particular, chromosome 10 sequences designated with GenBank Accession 
numbers AANU01162607.1 and AANU01065938.1 encoded putative exons 2 and 7 
of A3B and formed contiguous bases to bridge a portion of the unresolved 
regions.  A 2.7-kb gap that likely encodes the last 4 amino acids of A3B still 
remains unresolved in the macaque genome.  Using the geneid program, the 
rhA3B nucleotide sequence was predicted, and this sequence exhibited 85% 
identity with hA3B.  These analyses provided strong evidence for the current 
position of rhA3B upstream of rhA3C.  However, our multiple attempts to clone 
rhA3B from activated rhesus macaque PBMC mRNA were unsuccessful.   
The rhesus macaque and human A3 genes are orthologous 
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Rodents encode a single A3 gene, while humans encode seven. Other 
mammals, such as dogs, pigs, horses and sheep encode a variety of A3 genes that 
reveal substantial duplication, unequal cross-over and divergent evolution of individual 
members and are therefore considered paralogues (Conticello et al., 2005; LaRue et al., 
2006). This pattern of “evolutionary shuffling” could be roughly inferred in phylogenetic 
trees, where A3 segments containing the canonical deoxycytidine deaminase motif can 
be classified into Z1, Z2 and Z3 clades (LaRue et al., 2006). To extend this 
classification to rhA3 genes, a phylogenetic tree comparing the human, rodent and 
rhesus macaque A3 amino acid sequences was constructed (Figure 42B). The rhA3 
genes consistently clustered with the hA3 counterparts (Figure 42B). Thus, each of the 
seven rhesus macaque and human A3 genes appear to originate from a common 
ancestor, indicating that the genes are orthologous. In other words, we found no 
evidence for significant “shuffling events” in the A3 locus after the evolutionary split 
between monkeys and humans.  
 
Expression of rhA3 genes in rhesus macaque tissues and activated CD4+ T cells  
We next determined rhA3A mRNA expression in various perfused rhesus 
macaque organs and tissues. Specific rhA3A primers were used to determine 
expression in 14 visceral organs and 12 regions of the central nervous system (CNS) by 
RT-PCR. GAPDH was used to assess the integrity of RNA in the samples (data not 
shown). Our results indicate that rhA3A was not only widely expressed in the visceral 
organs but also in different regions of the CNS (Figure 45A). We verified the specificity 
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of the rhA3A amplification by directly sequencing the PCR amplicons (data not shown). 
Extensive detection of rhA3A in various lymphoid organs raised the possibility that 
rhA3A may also be expressed in CD4+ T cells, a primary cellular target of SHIV and SIV 
infection in vivo.  
To determine the relative expression of rhA3A against other rhA3 members, we 
developed Taqman-based real-time PCR assays to specifically quantify each of the 
seven rhA3 genes (Table VIII). To evaluate specificity, we first performed an end-point 
PCR and determined by agarose gel electrophoresis whether the primers could amplify 
other rhA3 cDNAs. If some cross-reactivity with the primers was observed, we 
subjected 108 rhA3 cDNA copies in a real-time PCR reaction that also includes the 
probe. The results of these analyses are presented in Table VIIII. Most of the assays 
developed did not cross-react with other A3 family members. In those instances where 
some cross-reactivity was observed, detection of similar A3 members were least 104  
 
 
 
 
 
 
 
 
 
	  
	  
	  
	  
259	  
Figure 45.  Expression of rhA3A in rhesus macaque tissues and CD4+ T cells.  
Panel A.  RhA3A expression profile in visceral organs and the CNS. Multiple 
tissues were obtained from an SIV negative rhesus macaque.  RNA from these 
tissues was analyzed for the presence of rhA3A mRNA by RT-PCR. Amplicons 
were run on 1.5% agarose gels and visualized by staining with ethidium bromide.  
Amplicons were directly sequenced and found to correspond to rhA3A.  All 
samples were positive for GAPDH RNA to control for integrity of RNA in the 
samples (data not shown).  Upper gel, rhA3A mRNA from 14 visceral organs.  
Lower gel, rhA3A mRNA from 12 regions of the central nervous system (CNS).  
The size markers (in base pairs) are shown to the left.  Panel B.  Expression of A3 
genes in rhesus macaque CD4+ T cells.  Upper,  Activation of rhesus CD4+ T cells.  
Rhesus macaque PBMCs were activated with 2.5 µg/ml SEB overnight, and 
subjected to FACS analysis.  FACS histograms of CD25 expression in CD3+CD4+ 
cells before (resting, blue) and after SEB activation (activated; red) are shown.  
CD4+ T cells were magnetically purified by negative selection, and RNA was 
extracted for quantitative RT-PCR analyses.  Lower, rhA3 mRNA levels in activate 
rhesus macaque CD4+ T cells, A3 cDNA was subjected to real-time quantitative 
RT-PCR using primers specific for individual rhA3 genes (Table VIIII) Dashed 
lines correspond to the assay limit of detection (5 input copies/reaction), while 
error bars correspond to standard deviation from triplicate determinations.   
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Table VIII.  Rhesus macaque A3 real-time PCR primers and probes.   
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Table VIIII.  Specificity evaluation of rhA3 primers and probes 
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fold lower in magnitude than what would be expected for the gene of interest. Thus, the 
real-time PCR methods could be used to distinguish the relative levels of the individual 
A3 members.  
Rhesus macaque PBMCs from three uninfected donors were stimulated with 
Staphylococcal Enterotoxin B (SEB), previously determined to be a potent activator of 
rhesus macaque T cells (Kakimoto et al., 1999). However, SEB-stimulation still did not 
result in consistent activation, since the levels of CD25 expression in CD4+ T cells 
varied between the 3 donors (Figure 45B). Total RNA was extracted from magnetically 
purified CD4+ T cells from these activated PBMCs, and subjected to real-time RT-PCR. 
Consistent with our failure to clone rhA3B from activated PBMCs, rhA3B mRNA was not 
detected in any donor (Figure 45A). With one exception (rhA3A donor 3), the expression 
of individual rhA3 genes between the donors did not vary more than 10-fold, and did not 
appear to correlate with CD25+ expression levels. Since rhA3G is well accepted as a 
biologically relevant restriction factor against SIV (Schmitt et al., 2009; 2010; 
Schrofelbauer 2006; Sui et al., 2010), we compared the expression of other rhA3 genes 
relative to rhA3G. Setting the average rhA3G level from the 3 donors as 1, only rhA3A 
(excluding donor 3), rhA3C and rhA3H exhibited mRNA expression levels that are 
similar in magnitude (1.0-1.5 fold) to that of rhA3G. In contrast, rhA3F and rhA3D were 
on average expressed at 2.4- and 13.6-fold lower than rhA3G, respectively. Thus, 
rhA3A, rhA3C and rhA3H mRNAs are expressed to similar levels as rhA3G in SEB-
activated rhesus macaque CD4+ T cells.   
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Nucleocytoplasmic localization of HA-tagged rhA3A 
Previous studies have shown that the cytoplasmic localization of hA3G and the 
nucelocytoplasmic localization of hA3A could partially explain the differences in the 
range of retroviruses or retrotransposons that were inhibited by these proteins (Bogerd 
et al., 2006a,b; Chen et al., 2006; Giola-Gaur et al., 2007; Muckenfuss et al., 2006).   To 
determine whether rhA3A exhibited a similar subcellular localization, we generated a 
molecular clone of rhA3A with an HA-tag at the amino terminal end for detection 
purposes.  A plasmid expressing either rhA3G or rhA3A (Figure 46A) was transfected 
into 293 cells and the expression examined by Western blot analysis using an antibody 
directed against the HA tag.  As shown in Figure 46A, 293 cells transfected with the 
vector expressing rhA3G expressed a protein with an Mr of 45kD while cells transfected 
with the vector expressing rhA3A expressed a protein with an Mr of 24kD, which reflects 
the size of the two different proteins (363 amino acids for rhA3G versus 202 amino 
acids for rhA3A). Using confocal microscopy, we found that rhA3G was observed 
exclusively in the cytoplasm (Figures 46B, C, D) and that rhA3A was detected in both 
the cytoplasm and nucleus as it co-localized with a nuclear marker (Figures 46B, E, F, 
G). Similar to other studies, hA3A was observed rhA3A in both the nucleus and 
cytoplasm (Figures 46G, H, I). Thus any differences in the retroviral restriction 
properties of hA3A and rhA3A could not be explained by the subcellular localization.  
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Figure 46.  Expression of an HA-tagged rhA3A.  Panel A.  293 cells were 
transfected with 1.5 µg of HA-tagged rhA3A, rhA3G, or the empty expression 
vectors.  At 48 h, cells were lysed and proteins separated by SDS-PAGE and 
analyzed by Western blot using an antibody directed against the HA-tag.  Sizes of 
the molecular standards are to the right.  RhA3A migrates at about half the 
molecular weight than rhA3G, consistent with their amino acid sequences.  Panel 
B-J.  Subcellular localization of rhA3G, rhA3A, and hA3A.  293 cells were 
transfected with HA-tagged vectors expressing rhA3A, rhA3G, or hA3A and a 
vector expressing an eGFP tagged nuclear marker (Clontech).  At 48 h, cells were 
fixed and stained with anti-HA for 1 h, washed, and detected using a horse anti-
rabbit-Ig Cy5 antibody.  Cells were examined under a Nikon A1 fluorescent 
microscope and micrographs taken using a 100x objective with a 2x digital zoom 
using the E2-C1 software package as described in the Materials and Methods.   
Minimal inhibition of foreign DNA reporter gene expression by rhA3A and hA3A 
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In a recent study, hA3A was shown to inhibit the expression of transfected 
plasmid DNA by deamination of the incoming plasmid DNA (Stenglein et al., 2010). Co-
transfection of an eGFP reporter plasmid with hA3A in 293 cells resulted in 
approximately 20% reduction in the number of cells expressing eGFP signal 2 days. In 
these investigators’ model, the incoming DNA induces an interferon-induced up-
regulation of hA3A expression, the cytidine residues are deaminated resulting in uracils, 
which are excised by UNG2. This will eventually result in cleavage and degradation of 
the DNA backbone (Stenglein et al., 2010). This phenomenon could significantly 
confound experiments that involve co-transfection of A3A with viral plasmid constructs. 
Since our virus experiments involving rhA3A or hA3A lasted no longer than 48 h, 
we determined whether rhA3A, hA3A or rhA3G interfered with the expression of 
enhanced green fluorescent protein (eGFP) from a foreign plasmid. Plasmids 
expressing either rhA3A, hA3A or rhA3G were co-transfected into 293 cells 24 h prior to 
transfection with the plasmid expressing eGFP under the control of the CMV promoter.  
At 2 days post-transfection of eGFP, the cells were analyzed for fluorescence by flow 
cytometry. We detected 14.1, 14.5, 11.2, and 14.6% eGFP positive cells in the 
presence of empty vector, rhA3A, hA3A, or rhA3G, respectively (Figure 47A). These 
results indicate that hA3A had minimal impact (<20%) while rhA3A had no impact on 
reporter gene expression from foreign plasmids at 48 h.   
 
Human and rhesus macaque A3A does not inhibit SHIV or HIV-1 production in 293 
cells 
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Figure 47.  Minimal restriction of foreign DNA by rhA3A and hA3A.  Panel A.  
Expression constructs (3 µg) of HA-tagged rhA3A, hA3A, and rhA3G were first 
transfected into 293 cells for 24 h.  At 24 h post-transfection, the 293 cells were 
re-transfected with a plasmid encoding a CMV-driven eGFP reporter and assayed 
for reporter expression.  The cells were removed from the plate and fixed.  All 
samples were analyzed by a flow cytometer and the mean fluorescence intensity 
(MFI) for eGFP positive cells was calculated.  The MFI ratio and percentage of 
eGFP cells were calculated for each sample and the experiment was run in 
triplicate.  All groups were compared to the pcDNA3.1(+) plus EGFP control using 
a Student’s t-test with p<0.05 considered significant.  Panel B.  SHIVΔVif 
production in the presence of rhA3A, hA3A and rhA3G.  Cells were first 
transfected with 0.5 µg of plasmids expressing HA-tagged rhA3A, hA3A, rhA3G or 
empty vector.  At 24 h post-transfection, the 293 cells were re-transfected with a 
plasmid containing the SHIVΔvif.  Virus supernatants were harvested at 2 days 
post-transfection with the viral genome.  Mean Gag p27 levels as measured using 
a commercially available ELISA kit (Zeptometrix) are shown.  In all panels, error 
bars correspond to standard deviations from triplicate determinations.  Panel C.  
HIV-1Δvif production in the presence of hA3A and rhA3A.  Cells were first 
transfected with 0.5 µg of plasmids expressing HA-tagged rhA3A, hA3A, rhA3G, 
or empty vector.  At 24 h post-transfection, the 293 cells were re-transfected with 
a 1 µg plasmid containing the HIV-1Δvif.  Virus supernatants were harvested at 2 
days post-transfection with the viral genome.  Mean Gag p24 levels as measured 
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using a commercially available ELISA kit (Zeptometrix) are shown.  In all panels, 
error bars correspond to standard deviations from triplicate determinations.      
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It can be argued that the slight inhibition of plasmid reporter gene expression by 
hA3A may be amplified with typically longer plasmids containing a full-length viral 
genome. Similarly, the absence of an effect by rhA3A in plasmid reporter expression 
may be enhanced in the context of a full-length viral molecular clone. We conjectured 
that if A3A can degrade viral infectious molecular clones, then virus production would be 
significantly inhibited. We therefore investigated whether virus production was inhibited 
in cells transfected with rhA3A or hA3A. 293 cells were transfected with the plasmids 
expressing hA3A, rhA3A, rhA3G or the empty plasmid 24 hours prior to transfection with 
plasmids with the SHIVΔvif or HIV-1Δvif constructs. At 2 days post-transfection with the 
viral genomes, the culture medium was assayed for either p27 (SHIV) or p24 (HIV-1). 
We did not observe a significant decrease in the level of SHIVΔvif p27 released into the 
culture medium in cells co-transfected with empty vector, rhA3A, hA3A, or rhA3G at 5 
days post-transfection (Figure 47B). Similar findings were observed for HIV-1Δvif 
(Figure 47C). These data suggests that rhA3A and hA3A likely have no post-entry 
restriction activity against SHIV or HIV-1 and reinforce the conclusion that rhA3A and 
hA3A have minimal impact on plasmid DNA stability at 2 days post-transfection. Thus, 
our subsequent experiments, which involve analyzing cells within 48 h, should not be 
influenced by potential plasmid-specific restriction. 
 
Rhesus macaque A3A inhibits the infectivity of SHIVΔvif and HIV-1Δvif  
We next determined if rhA3A could inhibit the infectivity of SHIV and SHIVΔvif.  
For comparison, we also co-transfected these viral constructs with plasmids expressing 
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rhA3G, rhA3C, or hA3A. Virion infectivity was measured by taking the ratio of infectious 
titer in TZM-bl cells and comparing to the wild-type SHIV construct co-transfected with 
empty vector control. Our results indicate that rhA3A and rhA3G reduced the level of 
infectious SHIVΔvif nearly 20-fold compared to the parental SHIV, while hA3A reduced 
the infectivity of SHIVΔvif approximately 10-fold (Figure 48A). In contrast, rhA3C did not 
inhibit the level of infectious virus released from cells. SHIV virions produced in the 
presence of rhA3A, hA3A or rhA3G were purified and concentrated by 
ultracentrifugation and analyzed by Western blot. Consistent with the virion infectivity 
data, rhA3A was incorporated into SHIVΔvif and to a lesser extent in SHIV (Figure 48B). 
However, we were unable to detect hA3A in either SHIV or SHIVΔvif virions.  
We also tested whether rhA3A had activity against HIV-1. HIV-1(NL4-3) and HIV-
1Δvif constructs were co-transfected with plasmids expressing rhA3A, hA3A, or hA3G. 
Consistent with previous reports, hA3A did not inhibit infectivity of HIV-1Δvif virions, 
while hA3G reduced HIV-1Δvif virion infectivity by 10-fold. Surprisingly, rhA3A reduced 
HIV-1Δvif virion infectivity approximately 3-fold (Figure 48C).  HIV-1 virions released 
from 293 cells expressing either hA3G, hA3A or rhA3A were partially purified by 
ultracentrifugation. The resulting virions were analyzed by Western blot using an anti-
HA antibody.  Consistent with previously published data, hA3A was detected in both 
HIV-1 and HIVΔvif virions.  However, rhA3A was not detected in HIV-1 and HIVΔvif 
virions (Figure 48D). Together, these findings indicate that unlike hA3A, rhA3A reduces 
the infectivity of both SHIVΔvif and HIV-1Δvif. 
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Figure 48.  Inhibition of SHIVΔVif and HIV-1ΔVif virion infectivity by rhA3A.  Panel 
A.  RhA3A restricts SHIVΔvif.  293 cells were co-transfected with 1 µg wild-type 
SHIV or SHIVΔvif molecular clones and 0.5 µg plasmids expressing either empty 
vector (pcDNA3.1), rhA3A, hA3A, or rhA3G.  At 48 h, the culture medium was 
harvested and virion infectivity measured by taking the ratio of infectious viral 
titers on TZM-bl cells.  Shown is the percentage virion infectivity with the empty 
plasmid control normalized to 100%.  Panel B.  293 cells were transfected with 
wild-type SHIV or SHIVΔvif molecular clones and HA-tagged rhA3A, hA3A, or 
rhA3G.  At 48 h, the culture medium was collected, clarified by low speed 
centrifugation, and concentrated by ultracentrifugation through a 20%/60% (w/v) 
step-gradient.  Each sample was resuspended in 2x sample reducing buffer, 
boiled, and the proteins were separated by SDS-PAGE.  The presence of rhA3G, 
hA3A, or rhA3A was detected by Western blot using an antibody directed against 
the HA-tag (Upper panel) and the presence of p27 using an antibody directed 
against p27 (Middle panel).  The lower panel are 293 cells transfected with vectors 
expressing rhA3G, hA3A, rhA3A, or pcDNA3.1(+) vector in the absence of the viral 
genome.  Panel C.  RhA3A restricts HIV-1Δvif genomes were co-transfected with 
HA-tagged hA3A, hA3G, or rhA3A as described for the SHIV experiments in Panel 
A.  Shown is the percentage virion infectivity with the empty plasmid control 
normalized to 100%.  Panel D.  Undetectable rhA3A in HIV-1Δvif virions.  Virions 
were purified as described for the SHIV experiments in Panel B, and hA3G, hA3A, 
and rhA3A incorporation were detected by Western blot using an anti-HA 
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antibody, normalizing for Gag p24 levels.  The lower panel are 293 cells 
transfected with vectors expressing rhA3G, hA3A, rhA3A, or pcDNA3.1(+) vector 
in the absence of the viral genome.  Mean values in triplicate experiments are 
shown, and the statistical differences with the wild-type control were evaluated 
using a two-tailed Student’s t-test, with p<0.05,  (  ) considered significant.     
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Deletion of amino acids 27-29 of rhA3A abolishes its anti-viral activity 
Hominid and monkey A3As can be distinguished by a 3 amino-acid indel 
between residues 27 to 29. We hypothesize that this region may contribute to the 
differential activity of rhA3A and hA3A against SHIVΔvif and HIV-1Δvif. To test this 
hypothesis, we constructed a rhA3A mutant in which amino acids 27-29 (SVR) were 
deleted. The resulting mutant, rhA3AΔSVR, was found to be stable in cells (data not 
shown). Interestingly, rhA3AΔSVR was inactive against SHIVΔvif (Figure 49A) and	  HIV-­‐
1Δvif (Figure 49B). However, when the amino acids 27-29 (SVR) were introduced into 
hA3A, we restored the ability of hA3A to partially inhibit HIV-1Δvif (Figure 49B).  These 
findings suggested that these monkey-specific A3A residues were critical for lentivirus 
inhibition, but was functionally lost in the hominid lineage.  
 
RhA3A, but not hA3A, is sensitive to SIV and HIV-1 Vif-mediated degradation 
 We next determined the stability of rhA3A and hA3A in the presence of the 
SHIV, SHIVΔvif, HIV-1, or HIVΔvif genomes. Each full-length molecular clone was co-
transfected into 293 cells along with plasmids expressing HA-tagged rhA3A, rhA3G, 
hA3A, or rhA3AΔSVR. At 24 h, the cells were lysed, proteins precipitated, and analyzed 
by Western blot using an antibody specific to the HA-tag.  Our results show that rhA3G 
was degraded in the presence of the parental SHIV but not in cells co-transfected with 
the SHIVΔvif genome. In contrast, hA3A was stable in the presence of parental SHIV or 
SHIVΔvif (the apparent difference of the hA3A in lanes 4 and 5 is due to less protein  
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Figure 49.  Deletion of three amino acids from the N-terminus region of rhA3A 
abolishes restriction.  Panel A.  RhA3AΔSVR is inactive against SHIVΔvif.  293 
cells were co-transfected with (1.0 µg) SHIV and SHIVΔvif molecular clones with 
vectors expressing (0.5 µg) rhA3A, rhA3AΔSVR, rhA3G, or empty vector 
(pcDNA3.1) in a 12-well plate.  At 48 h, the culture medium was harvested, 
assessed for p27 and the amount of infectious virus titrated onto TZM-bl cells.  
Panel B.  RhA3AΔSVR is inactive against HIV-1Δvif.  293 cells were co-transfected 
with (1.0 µg) HIV-1 and HIV-1Δvif molecular clones with vectors expressing (0.5 
µg) rhA3A, rhA3AΔSVR, hA3AΔSVR, hA3A, or empty vector (pcDNA3.1) in a 12-
well plate.  Virion infectivity was calculated normalizing to the wild-type HIV-1 
empty vector control.  In both panels, A and B, the assays were run at least in 
triplicate.  Significance in the restriction was determined with respect to the wild-
type empty vector control using a two-tailed Student’s t-test (p<0.05;  ) 
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Figure 50.  Sensitivity of rhA3A to lentivirus Vif-mediated degradation.  Panel A.  
SHIV Vif mediates rhA3A degradation.  SHIV and SHIVΔvif molecular clones were 
co-transfected with rhA3G, hA3A, rhA3A, or rhA3AΔSVR.  At 24 h post-
transfection, cells were lysed and proteins were precipitated using methanol.  
Proteins were separated on a 12% SDS-PAGE gel and probed using an antibody 
directed against the HA-tag.  All samples were normalized to the amount of β-
actin.  Panel B.  HIV-1 Vif mediates rhA3A degradation.  HIV-1 and HIV-1Δvif 
molecular clones were co-transfected with rhA3G, hA3A, rhA3A, and rhA3AΔSVR.  
In both panels, blots were stripped and re-probed with an antibody against β-
actin.  All assays were performed twice.   
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loaded in lane 4). Unlike hA3A, rhA3A was degraded in the presence of the SHIV 
genome but stable in the presence of the SHIVΔvif genome (Figure 50A). From these 
results we conclude that rhA3A interacts with the SIV Vif protein. Finally, rhA3A 
appeared to be less stable in the presence of the HIV-1 genome and more stable in the 
presence of NL4-3Δvif (Figure 50B). Similar results were observed at 48 h post-
transfection (data not shown). From these results we conclude that the SIV and HIV-1 
Vif proteins may interact with rhA3A promote its rapid turnover. 
 
RhA3A causes low levels of G-to-A mutations in nascent SHIVΔVif reverse 
transcripts 
RhA3A incorporation into SHIVΔvif virions led to a significant decrease in 
infectivity (Figures 48B). Our previous study revealed that rhA3G inhibition of SHIVΔvif 
virions in target cells was accompanied by substantial G-to-A mutations (Schmitt et al., 
2010). To determine whether rhA3A has a similar effect, we amplified a 300 bp region in 
nef from target TZM-bl cells and sequenced 15 independent clones.  
The results indicate that while rhA3G caused 33 G-to-A mutations in 15 clones 
(300 bases sequenced in each clone or total of 4,500 bp) in the nef gene of SHIVΔvif, 
most of which (29) were in the context of 5'-TCT-3' (Schmitt et al., 2010), while only 7 
such mutations were detected with rhA3A (Figures 51B). As expected, the 
corresponding wild-type SHIV had significantly lower G-to-A mutation frequencies  
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Figure 51.  RhA3A induces low frequencies of G-to-A mutations in SHIVΔvif 
nascent reverse transcripts.  TZM-bl cells were infected with DNase-I treated SHIV 
or SHIVΔvif virions and DNA was extracted after 24 h.  A 300-bp segment of nef 
was amplified, cloned, and 15 independent clones were sequenced.  Panel A.  
Moderate G-to-A mutations induced by rhA3A on SHIVΔvif.  Panel B.  Graph 
depicting the cumulative number of mutations from the 15 clones.  RhA3A 
induced 5-fold lower G-to-A mutations than rhA3G against SHIVΔVif.  Panel C.  
Lack of G-to-A mutations in wild-type SHIV in the presence of either rhA3A or 
rhA3G.  Panel D.  Graph of cumulative substitutions in wild type SHIV.  In panels 
A and C, each mutation is denoted by a vertical line that is color coded with 
respect to the dinucleotide context: GA (red), GG (yellow), or non-G-to-A (black).  
In panels B and D, each bar is shaded according to the proportion of G-to-A 
substitutions that occurred in the context of GA (red), GG (yellow), or non-G-to-A 
(black).   
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Figure 52.  RhA3A does not inhibit AAV-2 replication.  Panel A.  Low molecular 
weight DNA extracted from 293 cells transfected with recombinant AAV-2 
plasmids and either empty vector (pcDNA3.1), hA3A, rhA3A, or rhA3G.  A 1% 
Southern blot was run and hybridized with a 32P-labeled probe from SSV9 as 
previously described (Qiu and Pintel, 2002).  The following AAV replication 
products are shown as RF (double recombinant form), RF (recombinant form), 
and ssDNA.  These experiments were performed two times with identical results.  
Panel B.  A Western blot was performed on an aliquot of the lysate to show that 
each A3 protein was expressed.   
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(Figures 53D). These results suggest that while rhA3A and rhA3G appear to have 
similar antiviral potency against SHIVΔvif (Figure 51D), rhA3A produced an 
approximately 5-fold decrease in the number of G-to-A mutations in SHIVΔvif compared 
to rhA3G. 
 
Rhesus A3A does not inhibit adeno-associated virus 2 (AAV-2) 
Previous studies have shown that hA3A can inhibit the replication of AAV-2 and 
autonomously replicating parvoviruses (Chen et al., 2006). We determined if rhA3A 
could inhibit the replication of AAV-2. 293 cells were transfected with vectors expressing 
hA3A, rhA3G, rhA3A or the empty vector and plasmids expressing AAV-2 and a helper 
plasmid. At 48 h, the cells were harvested, the extrachromosomal DNA isolated by Hirt 
extraction and analyzed using Southern blots for the presence of replicating AAV-2 
DNA. The results, shown in Figure 52A, indicate that hA3A, but not rhA3G, inhibited 
AAV-2 replication, as previously reported (Narvaiza et al., 2009; Chen et al., 2006). In 
contrast, rhA3A did not significantly inhibit AAV-2 replication. A Western blot from an 
aliquot of the 293 lysates showed that the A3 proteins were similarly expressed (Figure 
52B). 
 
RhA3A does not inhibit LINE-1 retrotransposition  
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L1 elements are autonomous non-LTR retrotransposons that constitute about 
17% of the human genome (Babushok and Kazazian, 2007). L1 elements, through the 
ORF2 gene product, also facilitate the retrotransposition of Alu elements, which are 
present in an additional 11% of the genome. These in vitro retrotransposition assays 
require the co-transfection of hA3A with L1 plasmids (Rangwala and Kazazian, 2009) 
and assaying after 3-4 days, a timepoint where significant hA3A inhibition of plasmid 
DNA may be observed (Stenglein et al., 2010).  
To determine whether rhA3A could inhibit L1 retrotransposition, we used an L1-
eGFP plasmid construct that contains a self-splicing intron in the opposite orientation 
within eGFP (pLRE3-EF1-mEGFPI) (Wissing et al., 2007). As a positive control, an 
intronless isogenic construct that encoded an intact eGFP (pLRE3-EF1-mEGFP) was 
used. L1 (1 µg) and A3A (200 ng) plasmids were co-transfected into 293T cells and the 
cells were harvested at 2 and 4 days. Similar to our earlier results (Figure 53B), at 2 
days post-transfection, we observed minimal (22%) inhibition of the eGFP control 
plasmid, while rhA3A had no effect (data not shown). However, the L1 signals we 
obtained at 2 days were still very low, which is line with previous reported data (Kroutter 
et al., 2009). By 4 days post-transfection, we observed detectable L1 retrotransposition 
(Figure 53A). As expected, hA3A potently inhibited L1 retrotransposition. In contrast, 
rhA3A, as well as the rhA3A_SVR mutant, had no effect (Figure 53A). The effect of 
hA3A on L1 retrotransposition could be partially attributed to foreign DNA restriction, 
since at 4 days post-transfection, we observed a 2-fold reduction in eGFP signal from 
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the control plasmid (Figure 53A). However, it should be noted that substantial eGFP 
signals were still detected, in contrast to near-complete inhibition of L1 by hA3A (Figure 
53A). Importantly, under conditions where we detected significant foreign DNA 
restriction by hA3A, no such activity was observed for rhA3A and rhA3A_SVR. Thus, we 
conclude that unlike hA3A, rhA3A does not restrict L1 retrotransposons and/or foreign 
DNA. 
 
 
Discussion 
SIV and SHIV infections of rhesus macaques have been used extensively as 
models for studying HIV pathogenesis and in vaccine development. The fact that the 
dose, timing and route of infection can be controlled also makes it ideal for investigating 
the earliest events following pathogenic lentivirus infection, including innate immune 
responses. Recent discoveries have shown that specific lentivirus genes could 
antagonize the effects of host innate restriction factors. Thus, the macaque/SIV or SHIV 
models provides a compelling system to explore how these restriction factors are 
regulated in vivo following lentivirus infection.  
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Figure 53.  RhA3A does not inihibit retrotransposition.  One microgram of L1 
constructs containing eGFP with or without the γ-globin intron in the opposite 
orientation and 200 ng of empty vector, hA3A, rhA3A, or rhA3AΔSVR plasmid 
were co-transfected into 293 T cells using Fugene 6 (Roche).  At 4 days post-
transfection, cells were harvested and analyzed for eGFP expression using a 
FACSCalibur machine (BD Biosciences) with 150,000 events.  Panel A.  Results of 
co-transfection of LINE 1 plasmid (with intron) with either the empty vector, hA3A, 
or rhA3A plasmids.  To minimize autofluorescence background, the percentage of 
eGFP+ cells from the untransfected control was gated against an empty 
fluorescence channel (FL3).  Panel B.  Results of co-transfection of eGFP control 
plasmid (no introns) with either the empty vector, hA3A, or rhA3A plasmids.   
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Identification of rhA3A as a novel lentivral restriction factor 
The APOBEC3 family of deoxycytidine deaminases function as potent 
antiretroviral factors. Incorporation of select A3 proteins can inhibit reverse transcription 
and/or induce G-to-A hypermutation in nascent reverse transcripts in the next target cell 
(Bishop et al., 2004; Celico et al., 2006; Russell et al, 2009; Sova et al., 1993; von 
Schwedler et al., 1993; Zheng et al., 2005). Seven A3 genes are encoded in the human 
genome, but only a subset, hA3G, and to a lesser extent, hA3F and hA3C, are 
expressed in CD4+ T cells, inhibit HIV-1 and are counteracted by the HIV-1 encoded Vif 
protein (Koning et al., 2009; Refsland et al., 2010). There is uncertainty whether a 
similar complement of A3 genes are present in rhesus macaques, particularly since no 
rhA3A gene has yet to be identified. In this study, we cloned the rhA3A gene. This result 
is consistent with a recent study that revealed evolutionary conservation of A3A among 
hominids, Old World and New World monkeys (Bulliard et al., 2011).  In addition, 
analysis of the rhesus macaque genome provided evidence of seven encoded A3 
members that based on phylogenetic analyses are orthologous to the corresponding 
hA3 genes. These findings suggest that the seven rhA3 genes have been maintained 
after the evolutionary split between monkeys and humans. Thus, the vif genes of 
various SIV strains naturally infecting Old World monkey species have likely been co-
evolving with the same set of A3 genes for millions of years.    
Rhesus macaque A3G is a potent A3 deaminase against SIV, SHIV and HIV-1 
(Schmitt et al., 2010; Virgen et al., 2007; Zennou et al., 2006). We therefore determined 
	  
	  
	  
	  
298	  
the expression of the other rhesus macaque A3 genes in primary, activated CD4+ T 
cells, the main cellular targets of SIV and SHIV in vivo, in relation to rhA3G. Our results 
indicate that rhA3B mRNA is not expressed and that rhA3D mRNA is expressed at 
levels that are likely not biologically relevant in vivo. RhA3F is expressed at 2-fold lower 
levels than rhA3G, but rhA3F appears to be incorporated promiscuously into virions and 
is not as functional as rhA3G in side-by-side co-transfection studies (Schmitt et al., 
2010). Only rhA3A, rhA3C and rhA3H are expressed at similar or higher levels than 
rhA3G.  RhA3H has been previously shown to have potent antiretroviral activity against 
HIV-1 (OhAinle et al., 2008) and we found significant activity against SHIV (unpublished 
data). We also found no significant antiviral activity of rhA3C against SHIV. Surprisingly, 
rhA3A exhibited potent antiretroviral activity. Based on this data, we conclude that 
rhA3A, rhA3G, and rhA3H most likely are the dominant rhesus macaque APOBEC3 
deaminases that could restrict SHIV or SIV in vivo. 
 
Insights on rhA3A restriction of lentiviruses  
Rhesus macaque A3G inhibits SHIVΔvif and HIV-1Δvif virion infectivity through a 
mechanism that involves virion incorporation. Virion incorporated rhA3G blocks reverse 
transcription and/or induces G-to-A hypermutation in the next target cell. Consistent with 
this mechanism, we readily detected rhA3G in SHIVΔvif and HIV-1Δvif virions, and 
observed substantial G-to-A mutations in reverse transcripts newly formed in target 
cells. Given these consistent phenotypes, we used rhA3G as a positive control for 
evaluating the antiretroviral activity of rhA3A. In this study, we found that rhA3A is as 
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potent as rhA3G in restricting virus infectivity. Both proteins inhibited SHIVΔvif infectivity 
by approximately 20-fold. In addition, rhA3A modestly inhibited HIVΔvif infectivity by 
about 3-fold. We found that in contrast to rhA3G, rhA3A was incorporated at low levels 
into SHIVΔvif virions and was undetectable in HIVΔvif virions (Figure 48). The results 
may be due to the sensitivity of the Western blots and that rhA3A is incorporated into 
virions at very low levels compared to rhA3G. This would also suggest that rhA3A 
enzymatic activity may be higher than rhA3G on a per-molar basis. 
As a first step in gaining mechanistic insights on rhA3A-mediated restriction of 
SHIV and HIV-1, we evaluated whether two rhA3A domains are critical for restriction. 
Comparison of the amino acid sequences of human and rhesus macaque A3A reveals a 
monkey-specific insertion at position 27-29 (SVR) that is critical for SHIVΔvif and HIV-
1ΔVif inhibition by rhA3A that was lost in the hominid lineage (Figure 41). In a recent 
modeling study of hA3A, it was shown that amino acids 29 and 30 likely form part of a 
polynucleotide accommodating groove near the active-site pocket (Bulliard et al., 2011). 
We observed that the rhA3A ΔSVR mutant is totally inactive, while remaining sensitive 
to SHIV and HIV-1 Vif-dependent degradation. In addition, we made just the opposite 
mutation, the addition of the SVR motif to hA3A. We found that this mutant gained 
partial activity against HIV-1Δvif but was not as active as rhA3A, suggesting that other 
amino acid substitutions are likely involved in this function. We also determined if the 
canonical cytidine deaminase Zn+2 binding domain (C/H-X-E-X23-28-P-C-X2-4-C) was 
critical for rhA3A anti-lentiviral activity. Mutation of the histidine at position 70 to 
glutamic acid resulted in no restriction of SHIVΔvif (unpublished data). Thus, the 
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monkey-specific residues SVR (27-29) and the canonical Zn+2 binding domain are 
critical for rhA3A-mediated Δvif lentivirus restriction. 
Human A3A is largely inactive against HIV-1ΔVif, but when targeted to the viral 
nucleocapsid, it has potent activity against HIV-1ΔVif (Goila-Gaur et al., 2007). Since 
hA3A and the C-terminal region of hA3G are derived from a common ancestor, the N-
terminal domain of hA3G was fused to hA3A (hA3G-A3A). This hA3G-A3A fusion 
protein localized to the cytoplasm, incorporated into the viral nucleoprotein complexes, 
and inhibited HIV-1 replication (Goila-Gaur et al., 2007). Similarly, fusion of hA3A to the 
Vpr protein resulted in its incorporation into viral nucleoprotein complexes and inhibition 
of HIV-1 and SIV replication (Aguiar et al., 2008). These results suggested that the 
reason that hA3A could not restrict lentiviruses is that it could not be targeted to the 
virion core.  While hA3A had no substantial activity against HIV-1ΔVif, hA3A surprisingly 
decreased SHIVΔVif virion infectivity by approximately 10-fold. Although we did not 
detect hA3A in virions; it is possible that like rhA3A, very little is incorporated into 
nascent virions and is below the limits of detection by Western blot analysis.   
 
Evidence for recent evolutionary gain of function of DNA restriction in hominids 
Previous studies have shown that while hA3A is inactive against HIV-1, it can 
block endogenous retroviral elements such as LTR-retrotransposons or Alu elements 
(Chen et al., 2006; Bogerd et al., 2006b). Human A3A has antiviral activity against 
autonomous (minute virus of mice; MVM) and non-autonomous (AAV-2) replicating 
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parvoviruses and has editing activity against the human papillomavirus genome (Chen 
et al., 2006; Narvaiza et al., 2009; Vartanian et al., 2008). Finally, hA3A has been 
shown to counteract foreign DNA (Stenglein et al., 2010) and promote DNA damage 
(Landry et al., 2011). These studies suggest that hA3A biology is intimately linked to the 
restriction of double-stranded DNA elements. Surprisingly, we found no evidence for 
rhA3A restricting AAV-2, L1 elements and foreign DNA. While it can be argued that 
rhA3A may have activity against rhesus macaque AAV, no infectious macaque AAVs 
have been isolated to date. Thus, the DNA restriction properties of A3A may have been 
a recent evolutionary development in the hominid lineage.  
The mammalian A3 locus encodes genes that have among the highest 
detectable evolutionary pressures known (Sawyer et al., 2004). This is thought to reflect 
a long-standing host-pathogen genetic conflict that eventually helps dictate current 
trends in cross-species transmission and viral host range. Our findings now enter A3A 
into this select group of genes, given the divergent virus specificities of the human and 
monkey homologues. RhA3A inhibits the SHIVΔvif and HIV-1ΔVif, but not the DNA virus 
AAV-2 and L1 retroelements,	  while	  hA3A	  inhibits	  SHIVΔvif, AAV-2 and L1 elements but 
not HIV-1Δvif. Thus, it would appear that rhA3A could inhibit a broader range of 
lentiviruses at the cost of having no activity against DNA viruses. On the other hand, 
hA3A appears to have acquired activity against DNA viruses, at the expense of losing 
broad potency against lentiviruses. The rhA3A mutant with amino acids 27-29 deleted 
(rhA3AΔSVR)	   was	   incapable	   of	   restricting	   SHIVΔvif	   and	   HIV-­‐1Δvif. Thus, the divergent 
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viral specificities of hA3A and rhA3A may be dictated, at least in part, by an evolutionary 
switch that involved alterations in the polynucleotide-binding groove of A3A. The 81% 
identity between hA3A and rhA3A at the amino acid level should enable structure-based 
domain-swap experiments to determine which residues account for differential virus 
restriction. These types of studies should provide a biologically relevant system to 
interrogate which changes in the molecular determinants of nucleic acid specificity of 
the A3A proteins dictates the antiviral activity of A3A against lentiviruses, parvoviruses 
and L1 retroelements. 
 
 
Experimental Methods 
 
Cells, viruses, and plasmids 
HeLa and 293 cells were used for transfections of vectors expressing various 
APOBEC3 proteins, full-length SHIV or HIV-1 (NL4-3). The TZM-bl cell line was used as 
an indicator cell line to measure the infectivity of viruses (Derdeyn et al., 2000; Platt et 
al., 2009; Takeuchi et al., 2008; Wei et al., 2002). Both cell lines was maintained in 
Dulbecco’s minimal essential medium (DMEM) with 10% fetal bovine serum (R10FBS), 
10 mM Hepes buffer, pH 7.3, and 100 U/µg penicillin-streptomycin and 5 µg gentamicin.  
Rhesus macaque PBMCs were obtained from uninfected animals and isolated on 
Ficoll/Hypaque gradients. The derivation of SHIVKU-2MC4 (a pathogenic molecular clone; 
referred to in the text as SHIV) and SHIVVifSTOP (referred to in the text as SHIVΔvif) has 
	  
	  
	  
	  
303	  
been previously described (Liu et al., 1999; Schmitt et al., 2010). A plasmid with the 
genome of HIV-1 strain NL4-3 (referred to in the text as HIV-1) was used to construct a 
Δvif version (referred to in text as HIV-1Δvif) (pNL4-3; NIH AIDS Research and 
Reference Reagent Program). This plasmid was digested with PflM1, phenol: 
chloroform extracted, and ethanol precipitated. The 5’-protruding ends were filled using 
DNA Polymerase I Large Fragment (Klenow; Promega).  The resulting Klenow fragment 
reaction produced blunt ended fragments that were purified and re-ligated. The resulting 
plasmid was sequenced and found to contain a deletion in pNL4-3 vif between base 
pairs 5301 to 5308.  Therefore, only the first 79 amino acids of pNL4-3 Vif could be 
expressed. The plasmids pcDNA3.1(+)-HA-rhA3G and pcDNA3.1(+)-HA-hA3A were 
kindly provided by Nathaniel Landau (New York University School of Medicine). A 
plasmid expressing HA-rhA3C was constructed in this laboratory and cloned into the 
pCruz-HA vector (Santa Cruz Biotechnology) using restriction sites Sca I and Kpn I. A 
plasmid expressing pcDNA3.1(+)-HA-hA3G used in these studies was provided by the 
NIH AIDS Reference and Reagent Program.   
  
Molecular cloning of rhA3A 
       Total RNA from mitogen-activated rhesus macaque PBMCs was isolated using the 
RNAEasy Kit (QIAGEN; Valencia, CA). Three hundred ng of sample was subjected to 
random hexamer priming using the RT2 EZ first strand kit (SA Biosciences), and 4 µl of 
this cDNA was subjected to a 40 µl PCR reaction consisting of 1x Sweet PCR Mix (SA 
Biosciences), 12.5 pmol of rhA3A.F (5’-GACAAGCACATGGACGGCAG) and rhA3A.R 
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(5’-CATCCTTCAGTTTCCCTGAT) primers, designed based on the first and last exons 
of human A3A (hA3A). Amplification conditions included 95oC for 15 min hot-start, 
followed by 40 cycles at 94oC 30 s, 50oC 30 s and 72oC 3 min in a PE 9700 machine 
(Perkin Elmer). A dominant PCR amplicon of 600 bp was subcloned into the TOPO-TA 
vector (Invitrogen) and sequenced. The sequence for rhesus macaque A3A (rhA3A) 
was submitted to GenBank with Accession number JF831054. An expression construct 
containing rhA3A linked to an N-terminal HA-tag was synthesized (GenScript). The HA-
rhA3A gene was subcloned into pcDNA3.1(+) using restriction sites Kpn I and Eco RV 
sites of pcDNA3.1(+) and sequence-confirmed.   
 
Positioning of rhA3 genes in the rhesus macaque genome 
      Analysis of the Apobec3 loci was performed using NCBI Build 1.2 version of the 
macaque chromosome 10 sequence.  RhA3C (Accession # EU381233), rhA3G 
(XM_001094452), rhA3F (DQ514917) and rhA3H (DQ507277) cDNA sequences were 
subjected to BLAST analysis against the macaque genome, and the corresponding 
coordinates were obtained. To characterize the intronic sequence flanked by exons 1 
and 2 of rhA3A, exon 1 (5’-AGAAGAGACAAGCACATGGAC) and exon 2 (5’-
GCTCCACCTCGTAGCACAA) specific primers were used to directly amplify rhesus 
macaque genomic DNA. The resulting PCR amplicon was directly sequenced (Figure 
42; see text for details).   RhA3B and rhA3DE sequences were predicted based on the 
genome sequences upstream of rhA3C and between rhA3C and rhA3F, respectively, 
using the geneid program (http://genome.crg.es/geneid.html) (Figures 43 and 44).  
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Phylogenetic analysis of rhApobec3A 
The A3A amino acid sequences from various primate species were obtained 
from (Bulliard et al. 2011). Sequences were aligned using ClustalX using the Gonnet 
series, and neighbor-joining trees were constructed with 1000 subreplicates, correcting 
for multiple substitutions and excluding gaps. The C-terminal half of rhA3G was used as 
outgroup. A3 amino acid sequences from human, mouse, rat and rhesus macaque were 
likewise aligned using Clustal X, after splitting the sequences of rodent A3 and primate 
A3B, A3DE, A3F and A3G into N-terminal and C-terminal halves. Neighbor-joining trees 
were performed unrooted, with 1000 subreplicates and excluding gaps.  
 
Expression of rhA3A in rhesus macaque tissues 
A rhesus macaque that euthanized and perfused with 2 liters of Ringer’s saline to 
remove contaminating blood was used to examine the expression of rhA3A mRNA in 
different tissues (visceral organs and brain).  RhA3A was amplified from 30 µg of each 
visceral and CNS tissue using the RNAEasy kit (Qiagen; Valencia, CA). RNA was 
digested with 1 U/µl DNase-I (Fermentas) for 30 min. RT-PCR was performed using the 
Titan One RT-PCR kit (Roche). Each reaction used 100 ng of total RNA and was 
amplified using oligonucleotide primers specific for rhA3A. The oligonucleotides used for 
the reverse transcriptase reaction and first round PCR were 5’-
GGACGGCAGCCCAGCATCCAGGCCCAG-3’ (sense) and 5’-
CGTAGGTCATGATGGAGACTTGGGC -‘3 (antisense), which are complementary to 
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bases 3-29 and 451-475, respectively. The nested oligonucleotides used were 5’-
CCAGGCCCAGACACTTGATGGATCC-3’ (sense) and 5’-
CCGCAGCGTTCGCAGTGCCTCCTGATACAGG-3’ (antisense), which are 
complementary to bases 20-44 and 411-441, respectively. As a control, GAPDH was 
amplified to verify the integrity the RNA using oligonucleotides 5’-
GCCATCACTGCCACCCAG-3’ (sense) and 5’-GCCACATACCAGGAAATGAGC-3’ 
(antisense). The nested oligonucleotides used were 5’-CCTCCGGGAAACTGTGGC-3’ 
(sense) and 5’-CGTTGAGGGCAATGCCAG-3’ (antisense). The reactions were 
performed in an ABI 2720 Thermal Cycler using the following thermal profile: 42°C 30 
min for 1 cycle; 94°C 2 min for 1 cycle, 94°C 30 s, 55°C 30 s, and 68°C 45s for 10 
cycles; 94°C for 30 s, 55°C 30 s, and 68°C 2 min for 25 cycles. One µl of the initial 
reaction mixture used for nested PCR using rTaq (Takara) and performed with the 
following thermal cycle profile: 95°C for 1 min, 48°C 2 min, and 72°C 3 min for 35 
cycles. The 450 bp amplicon was visualized in a 1.5% agarose gel, excised and gel 
purified (Qiagen; Valencia, CA) and directly sequenced. 
 
Expression of rhA3 genes in activated CD4+ T cells 
Rhesus PBMCs were obtained from three donors by Ficoll separation.  5 ´ 106 
cells were seeded into each well of a 6-well plate containing 3 ml RPMI medium 
(Mediatech) with 10% Fetal Bovine Serum (Gemini Biosciences). Half of the cultured 
PBMCs were activated with 2.5 µg/ml Staphylococcal Enterotoxin B (SEB; Toxin 
Technology) overnight.  The following day, the PBMCs were stained with CD3-V450 
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(clone SP34-2), CD4-APC-H7 (L200) and CD25-PerCP-Cy5.5 (M-A251) (BD 
Biosciences) and analyzed in an LSR-II flow cytometer (BD Biosciences).  Histogram 
plots to highlight CD25 expression in CD4+ T cells were constructed using the FlowJo 
software (Treestar).  CD4+ T cells were purified from activated PBMCs by negative 
selection with magnetic beads (Miltenyi Biotec).  Total RNA was extracted from CD4+ T 
cells using the RNAEasy kit, and cDNA was synthesized by random hexamer priming 
using the RT2 EZ first strand kit (SA Biosciences). The cDNA was used for triplicate 
real-time PCR evaluations (25 µl) with optimized A3-specific primers and a 
housekeeping gene, GAPDH, in a BioRad real-time PCR machine. Briefly, 5 µl of cDNA 
was mixed with 12.5 µl of 1´ Universal Master Mix (Applied Biosystems), 10 pmol of 
primers and 5 pmol of probe and subjected to 40 cycles of denaturation and 
annealing/elongation.  The A3-specific primers, probes and cycling conditions are listed 
in Table VIII. Cloned cDNA sequences were used as standards and for evaluating 
cross-reactivity (Table VIIII). The A3-specific assays had a limit of detection of 5 copies 
per reaction, and standard curves had r2 values >98%.  
 
Subcellular localization of rhA3A 
For intracellular localization of rhA3A, 293 cells were plated onto 13 mm cover 
slips in a 6 well plate and transiently co-transfected with vectors expressing HA-tagged 
hA3A, rhA3G or rhA3A and one expressing a eGFP tagged nuclear marker using a 
polyethylenimine (PEI) transfection reagent (ExGenTM 500, MBI Fermentas) according 
to the manufacturer’s instructions. Cultures were maintained for 36-48 h before being 
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were fixed in 2% paraformaldehyde (4°C) for 10 min and washed twice for 5 min in 1x 
PBS (pH7.4). Cover slips were incubated with a rabbit polyclonal anti-HA antibody (HA-
probe, Santa Cruz) for 1 h at ambient temperature in 1x PBS plus 1% BSA. Cover slips 
were washed twice for 5 min in PBS and reacted with a Cy-5 conjugated secondary 
antibody (Abcam) 1x PBS plus 1% BSA for 30 min. The cover slips were washed twice 
for 5 min in 1x PBS and mounted in glycerol containing mounting media (Slowfade 
antifade solution A, Invitrogen). A Nikon A1 confocal microscope was used to collect 
100x images with a 2x digital zoom, using EZ-C1 software. The pinhole was set to large 
for all wavelengths used with Cy5 and eGFP excited using a 638 nm and 488 nm diode 
lasers, respectively.  Images were collected using a 670 nm filter for Cy5 and 525/25 
nm fiter for eGFP. 
 
Foreign DNA restriction by rhA3A 
293 cells were seeded into 6-well tissue culture plates 24 h prior to transfection. 
Cells were first transfected with 3 mg of either HA-rhA3A, HA-hA3A, HA-rhA3G HA-
rhA3ADSVR or pcDNA3.1(+) vector using a polyethylenimine transfection reagent 
(ExGenTM 500, MBI Fermentas) according to the manufacturer’s instructions. After 24 h, 
the cells were re-transfected with 3 mg of a vector expressing eGFP. Cells were 
incubated at 37oC in 5% CO2 atmosphere for either 2 or 5 days. The cells were 
removed from the plate using Ca2+/Mg2+-free PBS containing 10 mM EDTA. Cells were 
then fixed in 2% paraformaldehyde, for 5 min. The cells were washed twice in 1x PBS 
plus and analyzed using an LSRII flow cytometer. The mean fluorescence intensity 
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(MFI) for eGFP positive cells was calculated. The MFI ratio and percentage of eGFP 
positive cells was calculated for each sample. Normalized ratios from three separate 
experiments were averaged and the standard error calculated. All groups were 
compared to pcDNA3.1(+) plus eGFP control using a Student’s t-test with p<0.05 
considered significant.  
 
Production of HIV-1ΔVif and SHIVΔVif virions in the presence of A3A 
293 cells were seeded into a 12-well tissue culture plate 24 h prior to 
transfection. Cells were first transfected with 1 mg of HA-tagged rhA3A, hA3A, rhA3G or 
pcDNA3.1(+) vector using PEI (Fermentas). After 24 h, cells were transfected with 1 mg 
of SHIVΔvif or HIV-1Δvif plasmid.  Cells were incubated at 37°C in 5% CO2 atmosphere 
for 48 h. Supernatants were collected and cellular debris removed by low speed 
centrifugation. The cells were lysed in 500 ml of RIPA (50 mM Tris-HCl, pH 7.5, 50 mM 
NaCl, 0.5% deoxycholate, 0.2% SDS, 10 mM EDTA) and the nuclei were removed 
through high-speed centrifugation. The amount of Gag p27 or p24 present in the viral 
supernatants was measured using a commercially available p27 and p24 ELISA kits 
(Zeptometrix). The experiment was run at least three separate times, normalized to the 
empty vector control samples. Differences between mean percentages were calculated 
using a two-tailed Student’s t-test with p<0.05 considered significant.  
 
Inhibition of SHIV and HIV-1 virion infectivity by A3A 
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SHIV, SHIVΔVif, HIV-1 or HIVΔVif infectious molecular clones (3 µg) were co-
transfected (1.5 µg) with plasmids expressing rhA3A, rhA3AΔSVR, rhA3G, rhA3C, 
hA3A, hA3A+SVR, or hA3G using PEI (Fermentas) in a 6-well plate. At 48 h post-
transfection, the culture medium was harvested and clarified by low speed 
centrifugation. Equivalent amounts of p27 were serially diluted using 10-fold dilutions 
from 101 to 106 and used to inoculate TZM-bl cells.  At 48 h post-inoculation, the media 
was removed, cells washed with PBS and the monolayer fixed using 1% formaldehyde-
0.2% glutaraldehyde in PBS. The cells were washed and incubated in a solution for 2 h 
at 37°C containing 4 mM potassium ferrocyanide, 4 mM potassium ferricyanide, 4 mM 
magnesium chloride, and 0.4 mg X-gal per ml. The reaction was stopped and the 
infectious units (IU) per ml were calculated (Derdeyn et al., 2000; Wei et al., 2002).   
 
Site-directed mutagenesis 
Mutations introduced into all plasmids were accomplished using a QuikChange 
site-directed mutagenesis kit (Stratagene) according to the manufacturer’s protocol.  All 
plasmid inserts were sequenced to ensure the validity of the mutations and that no other 
mutations were introduced during the cloning process. 
 
Virion incorporation assays 
SHIV, SHIVΔVif, HIV-1 or HIVΔVif infectious molecular clones (3 µg) were co-
transfected with 1.5 µg of plasmids expressing either rhA3A, rhA3G, hA3G or hA3A 
proteins into 293 cells using PEI reagent (Ex-GenTM 500, Fermentas) in each well of a 
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6-well plate. At 48 h, virus supernatants were harvested and clarified by low speed 
centrifugation. The clarified supernatant was ultracentrifuged to pellet virions (SW41 
rotor, 247,000xg, 1 h, 4°C). The pellet was resuspended in PBS and layered on a 
20%/60% sucrose step gradient and again subjected to ultracentrifugation (SW55Ti, 
247,000´g, 1 h) at 4OC. The interface (containing virions) was harvested, pelleted again 
by ultracentrifugation as described above, and resuspended in 150 µl of PBS. An aliquot 
was saved to determine the p27 or p24 content by antigen capture assay (Zeptometrix). 
The remaining sample was boiled in 2´ sample reducing buffer. Equivalent amounts of 
p27 or p24 were loaded on a 12% SDS-PAGE gel. A3 proteins were detected by 
Western blotting using an anti-HA antibody (HA-probe; Santa Cruz). Blots were placed 
in stripping buffer (25 mM glycine, pH 2.0 and 1% SDS) and reprobed using either 
rabbit polyclonal antibody specific for p27 or a mouse monoclonal antibody to p24 (NIH 
AIDS Research and Reference Reagent Program).   
 
Stability of rhA3A in the presence of SHIV and HIV-1 genomes 
Infectious molecular clones of HIV-1, HIV-1Δvif or SHIV and SHIVΔvif were co-
transfected in a 2:1 ratio with rhA3A, rhA3AΔSVR, rhA3G, hA3G, or hA3A using PEI 
transfection reagent (Ex-Gen500; Fermentas) into a 12-well plate.  At 24 h post-
transfection, the supernatant was removed, the cells were harvested and lysed using 
RIPA buffer. Following lysis, the nuclei were removed by centrifugation at 14,000 rpm 
for 15 min in a microfuge at 4°C. The protein was precipitated using methanol, 
resuspended in 2x sample reducing buffer, and boiled for 5 min. Proteins were 
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separated on a 12% SDS-PAGE gel and probed using commercially available rabbit 
polyclonal HA antibody (HA-probe, Santa Cruz). All samples were normalized to the 
same amount of b-actin protein using a mouse monoclonal antibody specific for b-actin 
(AC15; Novous Biologicals).  
 
Hypermutation assays in the presence of rhA3A 
To determine whether virion-incorporated rhA3A can induce G-to-A mutations in 
nascent reverse transcripts, 293 cells were co-transfected with vectors containing the 
genomes SHIV or SHIVΔVif and vectors expressing rhA3G (positive control), rhA3C 
(negative control) or rhA3A using PEI (Fermentas). At 24 h post-transfection, cells were 
washed and fresh DMEM was added. At 48 h, the supernatant containing virus was 
subjected to ultracentrifugation through a 20% sucrose cushion. The resulting 
supernatant was DNase-I-treated (Fermentas) at 37°C for 30 min to minimize plasmid 
carry-over. Infectious titers in the supernatants were measured on TZM-bl cells. In 
addition, at 24 h post-infection of TZM-bl cells, total cellular DNA was harvested and 
extracted using the DNeasy kit (Qiagen). The DNA was used in a nested DNA PCR to 
amplify a 300 base pair fragment of nef. The PCR reaction was carried out using rTaq 
and the manufacturer’s instructions (Takara). The oligonucleotides employed during in 
the first round PCR to amplify SIV nef were 5’-GGTGGAGCTATTTCCATGAGG-3’ 
(sense) and 5’-GTCTTCTTGGACTGTAAT AAATCCC-3’ (anti-sense). One µl of the first 
PCR product was added to a nested reaction. The oligonucleotides used during the 
nested PCR reaction were 5’-CCATGAGGCGGTCCAGGCAGTCTAGAG-3’ (sense) 
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and 5’-CCTCCCAGTCCCCCCT TTTC-3’ (anti-sense). The PCR reactions were 
performed using an ABI 2720 Thermal Cycler with the following thermal profile: 95°C for 
2 min, 1 cycle; 95°C for 30 s, 55° for 30 s, 65°C for 2 min, for 35 cycles; 65°C for 7 min. 
The PCR products were separated by electrophoresis, isolated, purified, sequenced 
and sub-cloned into pGEM-TEasy (Promega). Fifteen independent clones were 
sequenced and assessed for each mutant SHIV as described above for each condition.    
 
Adeno-associated virus-2 (AAV-2) replication assay 
The ability of rhA3A to inhibit the replication of AAV2 was assessed. 293 cells 
were transfected using LipoD 293 transfection reagent (SignaGen Labs;, Rockville, MD) 
into 60 mm dishes in duplicate with 1 mg SSV9 (an AAV2 infectious clone, psub201) 
(Qiu et al., 2002), 2mg pHelper (Stratagene, La Jolla, CA) (Xiao et al., 1998), and 1 mg 
of an A3 expression vector, rhA3G, hA3A, rhA3A, or as a negative control pBluescript 
SK (+) (Stratagene, La Jolla, CA). Forty-eight h post-transfection, the cells were 
harvested and resuspended in PBS. The supernatant was discarded and Hirt DNA was 
extracted using Hirt solution (10 mM Tris, 10 mM EDTA, pH 7.5, 0.6% SDS) at room 
temperature for 10 min followed by 5 M NaCl at 4°C overnight. The mixture was 
centrifuged at 14,000 rpm at 4oC for 20 min. Following centrifugation, the pellet was 
discarded and the supernatant was treated with Proteinase K (50 mg/ml) at 37°C for 1 
h. The low molecular weight (LMW) DNA was extracted twice with saturated phenol and 
once with chloroform/isoamyl alcohol. The resulting DNA was ethanol precipitated and 
column purified using the Qiagen gel extraction kit (Qiagen). The LMW DNA was run on 
	  
	  
	  
	  
314	  
a 1% agarose gel, transferred to nitrocellulose and analyzed by Southern hybridization 
using a 32P-labeled probe consisting of a fragment representing nucleotides 184-4490 
(Xba I digestion) from SSV9 as previously described (Qiu et al., 2002). To ensure that 
all samples were expressing the desired A3 proteins, aliquots of harvested cells utilized 
in the Southern blot were lysed in RIPA buffer. The nuclei were removed and the protein 
was precipitated using methanol, resuspended in 2X sample reducing buffer, and boiled 
for 5 min. Proteins were separated on a 12% SDS-PAGE gel and probed using a rabbit 
polyclonal anti-HA antibody (HA-probe, Santa Cruz). 
 
L1 retrotransposition assay 
The engineered L1 enhanced green fluorescent protein (EGFP) reporter 
(Ostertag et al., 2000) was cloned into the pLRE3-EF1-mEGFPI, which contains a 
retrotransposition competent L1 element (LRE3) (Brouha et al., 2003) under the control 
of an EF-1α promoter in addition to the internal 5’ UTR promoter. The enhanced GFP 
(eGFP) retrotransposition indicator cassette is under the control of an ubiquitin promoter 
(UBC), and the SV40 late polyadenylation signal. The construct was cloned into 
pBSKS-II+ (Stratagene). The positive control pLRE3-EF1-mEGFP(Δintron) is similar to 
the pLRE3-EF1-mEGFPI but lacks the intron in the mEGFPI indicator cassette and 
therefore serves as a positive control for transfection efficiency. One µg of L1 construct 
and 200 ng of empty vector, hA3A, rhA3A or rhA3AΔSVR plasmid was co-transfected 
into 293T cells using Fugene 6 (Roche). All transfections were performed in triplicate. 
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Cells were harvested at 2 and 4 days and analyzed for eGFP expression using a 
FACSCalibur machine (BD Biosciences), collecting 150,000 events. 
Previous research has shown that human APOBEC3A (hA3A) lacks antiviral 
activity against HIV-1, but inhibits the replication of adeno-associated virus 2 (AAV-2), 
intracisternal A particles (IAP), and long interspersed nuclear element 1 (L1) (Bogerd et 
al., 2006a,b; Chen et al., 2006; Muckenfuss et al., 2006). Although hA3A contains one 
CDA, the deaminase activity of hA3A is not required for its inhibitory role against AAV or 
retrotransposons, suggesting that a deaminase-independent mechanism of inhibition is 
occurring (Narvaiza et al., 2009). Human A3A also contains significant homology to the 
N-terminal half of hA3G, does not associate with the viral nucleocapsid complex (NPC) 
of HIV-1 but is readily incorporated into virions (Goila-Gaur et al., 2007).  
SIV and SHIV have been invaluable models for studying various aspects of HIV-1 
pathogenesis. Sequencing of the rhesus macaque genome has led to the identification of 
rhesus homologues of A3B, A3C, A3D, A3F, A3G and A3H. Here we describe the 
identification of an A3A homologue in rhesus macaques (rhA3A) and present evidence 
that the human and macaque Apobec3 genes are orthologous. We show that the rhA3A 
protein is expressed well in activated macaque CD4+ T cells and other rhesus macaque 
tissues, is incorporated into virions, is degraded by both HIV-1 and SHIV in a Vif 
dependent manner, and restricts the replication of SHIV (expressing the SIVmac239 Vif) 
and HIV-1.       
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IX.  Conclusion  
 In the last thirty years, HIV-1 has become one of the most devastating infectious 
diseases in humans.  Developing countries display the greatest HIV-1-related morbidity 
and mortality, which is primarily due to the fact that only 10% of infected patients receive 
HAART therapy.  HAART therapy prolongs the lifespan of HIV-1 infected patients by 
decreasing CD4+ T cell loss and progression to AIDS.  Presently, HAART therapy does 
not cure the patient, and there is an increased frequency of multidrug resistant HIV-1 
strains.  Therefore, new small molecule inhibitors or a vaccine to prevent infection or 
reduce transmission of HIV-1 is necessary to minimize the expansion of this epidemic.  
 In addition to humans, HIV-1 only infects chimpanzees and a practical alternative 
to studying the role of HIV-1 accessory genes in viral pathogenesis is to use macaques 
infected with non-human primate lentiviruses (Heeney et al., 2006). Amino acid 
substitutions in these proteins can be studied using Asian (rhesus or pig-tailed) 
macaques infected with either SIV or SHIV to study disease progression, test anti-
retroviral therapy, and possible vaccine strategies (Ambrose et al., 2007).  While these 
models have provided us with insight into the role of these genes in pathogenesis, they 
also have short comings such as: 1) the diversity of viral protein sequences between 
different primate lentiviral lineages; 2) the evaluation of viral proteins in replication or as 
antiviral targets in vivo; 3) the testing of vaccine epitopes only identified in HIV-1; and 4) 
anti-retroviral drug efficacy and efficiency (Thippeshappa et al., 2011).  Our laboratory 
has studied the role of HIV-1 Vpu and its various domains in CD4+ T cell loss, virus 
release, and pathogenesis in macaques using the chimeric SHIVs: SHIVKU-1bMC33 and 
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SHIVKU-2MC4 (Stephens et al., 2002; Singh et al., 2003; Hout et al., 2005; 2006; Hill et al., 
2008).   
 
Highly Conserved Domains in the C-Terminus of Primate Lentivirus Vif Proteins 
 Cellular proteins termed restriction factors have been identified and found to 
function in preventing the spread of retroviruses and endogenous mobile genetic 
elements (Goff et al., 2004; Malim et al., 2008; Albin et al., 2010).  As a consequence, 
many retroviruses have evolved mechanisms to counter this restriction.    The HIV-1 
accessory protein Vif is required for lentivirus infectivity of specific cell types (except 
EIAV); therefore, HIV-1 virions deficient in the Vif protein cannot sustain a productive 
infection in either primary CD4+ T cells, macrophages, and many established CD4+ T cell 
lines (H9, C8166, CEMx174) (Gabuzda et al., 1992; Madani et al., 1998; Simon et al., 
1998; Sova et al., 1993).  These nonpermissive cells express an antiviral restriction 
factor known as APOBEC3G (A3G) (Sheehy et al., 2002).  Vif binds APOBEC3 through 
non-linear binding sites in the N-terminus.  Following the Vif-APOBEC3G interaction, Vif 
recruits the E3 ubiquitin ligase complex, which consists of elongin B (EloB), elongin C 
(EloC), Cullin-5 (Cul5), and Rbx-1 (Kao et al., 2003; Mehle et al., 2004a; 2006; Yu et al., 
2003).  This complex induces polyubiquitination of APOBEC3G and subsequent 
degradation by the 26S proteosome (Conticello et al., 2009; Marin et al., 2003; Mehle et 
al., 2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2004).  There are two highly 
conserved domains near the carboxy-terminus of Vif that have been implicated in the 
recruitment of the Cul5-E3 ubiquitin ligase machinery.  One of the domains identified is 
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the SLQ(Y/F)LA motif, which was shown to mediate the binding of Vif to EloC (Mehle et 
al., 2004b; Yu et al., 2003; Yu et al., 2004).   Therefore, one of the goals of this 
dissertation was to study highly conserved domains of primate lentivirus Vif in vivo, and 
determine their roles in pathogenicity.  
Previous in vitro research has shown that mutation of the serine, leucine, and 
glutamine prevent the association of Elongin BC complex subsequently disruption of the 
proteasomal targeting and degradation of the A3 proteins resulting in a non-productive 
infection (Fang et al., 2007; Mehle et al., 2004; Yu et al., 2003; Yu et al., 2004).  
Mutations in this motif have also been shown to increase A3 incorporation into virions 
resulting G-to-A hypermutation (Kobayashi et al., 2005).  The importance of the 
SLQ(Y/F)LA domain of Vif in its interaction with the Elongin BC complex in viral 
pathogenesis is essential to understanding the specific motifs required for the 
degradation of A3 proteins.  This data can potentially assist in the development of small 
molecule inhibitors or attenuated vif vaccines targeting both conserved and functional 
domains of Vif that limit viral replication and increase the host immune response.  
Therefore, the first study focused on determining if specific mutations in the SLQYLA 
motif of SIVmac239 Vif were critical for viral pathogenesis in rhesus macaques. 
    We mutated two residues of the highly conserved SLQYLA motif in SHIV, which 
expresses a SIVmac239 Vif.  The serine at amino acid position 147 and the leucine at 
amino acid position 148 were mutated to alanine residues resulting in a virus called 
SHIVVifAAQYLA, which was used to inoculate three rhesus macaques.  These macaques 
developed no significant loss in circulating CD4+ T cells, displayed 100-fold lower viral 
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loads, no histological lesions, and fewer visceral tissues positive for viral gag DNA or 
RNA in two of the three macaques, when compared to macaques inoculated with 
SHIVKU-1bMC33.    In two of the three macaques (RAK10 and RCS10), specific tissues 
such as the mesenteric, axillary, and inguinal lymph nodes, tonsil, and thymus, were 
positive for both viral RNA and DNA.  The presence of viral RNA suggests that these 
macaques have active viral replication in the primary and secondary lymphoid organs 
and that the virus may have persisted in these tissue populations.  Recently, Refsland 
and colleagues published studies regarding the profiling of the A3 mRNA repertoire in 
human lymphocytes and tissues using quantitative PCR methods (Refsland et al., 2010).  
From their studies they profiled the expression of A3 mRNA in twenty tissues such as 
adipose, bladder, brain, cervix, colon, esophagus, heart, kidney, liver, lung, ovary, 
placenta, prostate, skeletal muscle, small intestine, spleen, testes, thymus, thyroid, and 
the trachea.  Interestingly, the lung, adipose, spleen, bladder, thymus, heart, and cervix 
were among the tissues that showed a broad expression of A3 mRNA (Refsland et al., 
2010).  Previously, our laboratory used immunohistochemical analysis to determined 
whether A3G was expressed in the brain and kidney.  It was found that A3G expression 
in brain was limited to the pyramidal neurons in the gray matter of the cerebral and 
cerebellar cortices and restricted to the proximal convoluted tubules of kidney in the pig-
tailed macaque (Hill et al., 2006; 2007).  However, since we are using the rhesus 
macaque as a model of SHIV infection, both the visceral tissues and specific regions of 
the brain need to be identified for the expression of rhesus A3A/B/C/D/F/G/H mRNA.  No 
studies to date have examined this, and experimentally it would allow laboratories using 
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the rhesus macaque as a nonhuman primate to study the restricted replication patterns 
or identify reservoirs of vif attenuated SHIV replication.  The replication of virus in 
specific tissues may be explained by the expression patterns of A3 mRNA in those 
tissues. 
 In HIV-1 Vif deficient viruses, A3 proteins are incorporated into the virion, which 
are effectively introduced into the target cell upon the next round of infection (Soros et 
al., 2007).  The A3 proteins can then mediate extensive dC to dU mutations of the 
minus-strand of viral DNA during reverse transcription (Suspene et al., 2004; Yu et al., 
2004).  These mutated reverse transcripts can then be destroyed either by the DNA base 
repair enzymes such as uracil DNA glycosylase or apurinic-apyrimidinic endonuclease or 
survive to serve as a template for plus-strand synthesis resulting in the accumulation of 
G-to-A substitutions (Harris et al., 2003; Mangeat et al., 2003).  If these G-to-A 
substitutions (plus strand) exceed 10% of all of the viral dG residues, this is referred to a 
“hypermutation” of the viral genome (Harris et al., 2003; Lecossier et al., 2003; Mangeat 
et al., 2003; Zhang et al., 2003).  These mutations can result in alteration of viral open 
reading frames, decreased tRNALys3 primer annealing to the primer binding site on the 
genomic RNA, and mutation of essential viral genes required for a productive HIV-1 
infection (Harris et al., 2003; Lecossier et al., 2003; Mangeat et al., 2003; Suspene et al., 
2004; Yu et al., 2004; Zhang et al., 2003).  Often the G-to-A mutations (plus strand) 
occur within highly polarized mutational gradients in the viral genome from 5’ to 3’ due to 
the time that these regions of the minus-strand of DNA remain single-stranded (Suspene 
et al., 2006; Yu et al., 2004).  Our sequencing results of the thymus, mesenteric, axilary, 
	  
	  
	  
	  
321	  
and inguinal lymph nodes of macaques inoculated with SHIVVifAAQYLA indicated that a 
definite 5’ to 3’ (minus strand) gradient of G-to-A substitutions occurred in the viral 
genome.  The vif, vpu, nef, and env genes were sequenced and assessed in these 
tissues resulting in an overall gradient in two of the three macaques analyzed, 
nef>env>vpu>vif.  The exception to this gradient was macaque RPL10 who displayed an 
overall high number of G-to-A (plus strand) transitions in all four genes.  Over 85% of 
these mutations were in the dinucleotide sequence context of 5’-TC, we concluded that 
an A3 protein besides A3G was involved in the cytidine deamination mutational patterns 
observed.  It is important to note that not all lymphoid tissues showed G-to-A 
substitutions above background levels.  Since A3F, A3D, A3B, A3C, and A3H can 
display this mutational pattern, it is hard to decipher if one or many of these A3 proteins 
were involved in the cytidine deamination.  Therefore, tissue specific expression patterns 
of various A3 mRNA would help us further determine which of those four tissues we 
analyzed expressed higher levels of one A3 protein over another.  Recently, we 
discovered the A3A protein in the rhesus macaque and looked at an expression panel of 
rhA3 mRNA in Staphylococcal Enterotoxin B (SEB) activated CD4+ T cells.  Using 
quantitative real-time RT-PCR, the expression level of A3A, A3C, and A3H relative to 
A3G were 1.0-1.5-fold similar in magnitude, while A3F and A3D were expressed on 
average 2.4- and 13.6-fold lower in magnitude than A3G, respectively.  Therefore, one of 
these three A3 proteins (A3A, A3C, A3G, or A3H) is most likely causing cytidine 
deamination in the viral DNA with a dinucleotide context of 5’-TC (minus strand).  
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Interestingly, when assessing sequences from SHIVVifAAQYLA-inoculated macaque 
PBMC DNA at weeks 1, 3, 4, 8, 12, and 28 weeks post-inoculation, two of the three 
macaques (RPL10 and RAK10) displayed a G-to-A mutation at four weeks.  This 
mutation resulted in the mutation of the site-directed alanine at amino acid position 147 
to a threonine in the 147AAQYLA152 (to 147TAQYLA152) motif of Vif.  The mutation of amino 
acid residue 147 demonstrates that not all G-to-A substitutions are detrimental to the 
viral genome.  While we do not know why RAK10 and RPL10 selected for this mutation 
or how pathogenicity of the virus is affected, we do know that it did not alter viral burdens 
or levels of circulating CD4+ T cells in these macaques beyond four weeks post-
inoculation.  One possible theory could be that the A147T mutation could have permitted 
a more productive SHIV infection in these macaques resulting in a better antigenic 
stimulus.  Macaques RAK10 and RPL10 both had higher viral burders and developed 
immunoprecipitating antibodies similar to the positive control; whereas, macaque RCS10 
retained the A147A mutation, had lower viral burdens, and significantly less 
immunoprecipitating antibodies.  More research is needed to assess the replication 
fitness, pathogenicity, and structural/mechanistic implications of the A147T mutation 
selected from these rhesus macaques.     
 To extend our in vivo studies and further cripple the SHIVVifAAQYLA mutant, we 
constructed a SHIV mutant that expresses a Vif protein with the first five amino acids of 
the SLQYLA substituted for alanine residues (SHIVVif5A). In vitro SHIVVif5A in the 
presence of rhesus A3G was readily incorporated into virions, displayed a 1,000-fold 
decrease in viral infectivity, revealed a high frequency of G-to-A substitutions in the 
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dinucleotide context of 5’-TC (minus strand) in the nef gene. Macaque inoculated with 
SHIVVif5A displayed a further reduction in plasma viral loads compared to the 
SHIVVifAAQYLA inoculated macaques.  The initial burst of replication occurred at one-week 
post-inoculation and occasionally detected in the plasma thoughtout the duration of 
infection, but maintained levels of circulating CD4+ T cells at pre-inoculation levels.  
However, sequences were obtained from PBMC only during the first three weeks of 
infection.  At necropsy, the viral RNA copy number in the visceral and central nervous 
system tissues could not be quantified due to the limit of detection for this assay being 
~100 copies.  Since we were unable to sequence the nef gene in the PBMC through out 
the course of infection or at necropsy, we were unable to assess the number of G-to-A 
substitutions in the viral genome. Also, these macaques produced immunoprecipitating 
antibodies by 12 weeks post-inoculation that waned by necropsy.  Since viral RNA was 
not detected in the visceral tissues of macaques inoculated with SHIVVif5A at necropsy, 
the infectious virus could have been readily cleared by the macaque, and viral proteins 
may not have been produced to provide an antigenic stimulus for an increased immune 
response against the infection.  We were unable to detect any viral loads in the visceral 
organs or the CNS tissue in macaques inoculated with SHIVVif5A.  These results could be 
due to SHIVVif5A replicating initially in cell types that express a wide range of APOBEC3 
proteins that were incorporated into the virion and exerted an antiviral affect on the next 
target cell.  During the next round of replication, the viral genome could have been highly 
mutated with G-to-A substitutions, and the RNA polyermase II could not transcribe the 
viral RNA efficiently.  Also, there may have been tissue or cellular reservoirs where 
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APOBEC3 proteins are not expressed and there is no restriction on the replication of 
SHIVVif5A. As described above, further studies will be needed to determine if cell 
populations exist that do or do not express APOBEC3 proteins. These results show that 
primate lentiviruses expressing a Vif protein with targeted mutations in a highly 
conserved domain (SLQ(Y/F)LA) can be controlled by the host, are more detrimental to 
the virus in vivo, and that this domain is critical to Vif function in vivo.   
In addition, another highly conserved motif is the zinc-binding motif H-X5-C-X17-
18C-X3-5-H (HCCH) motif, which has been shown to interact with Cul5 (Luo et al., 2005; 
Mehle et al., 2004; Yu et al., 2004).  Previous tissue culture studies showed that 
mutation of the two cysteine residues or chelation of zinc inhibited proper folding of HIV-
1 Vif and prevented the recruitment of Cul5 resulting in the inability of Vif to recruit the E3 
ubiquitin ligase complex (Mehle et al., 2006; Paul et al., 2006; Xiao et al, 2006; 2007a; 
2007b).  For this study, we constructed a SHIV where four amino acids in the HCCH 
motif of the Vif protein were mutated to alanine residues, resulting in the virus 
SHIVVifHCCH(-).  In vitro SHIVVifHCCH(-) in the presence of rhesus A3G, readily incorporated 
rhA3G, showed a 100-fold decrease in viral titer, and displayed an increase in the 
number of G-to-A substitutions in the nef gene in the context of 5’-TC and not 5’-CC 
(minus strand).    Macaques inoculated with SHIVVifHCCH(-) showed slightly higher viral 
loads than SHIVVif5A at one week post-inoculation.   However, by three weeks post-
inoculation, the virus was effectively controlled by the macaque with bursts of replication 
at weeks 6, 20 and 24.  These bursts of replication correlated with G-to-A substitutions in 
the dinucleotide context of 5’TC (minus strand) that we observed in the vif gene amplified 
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from PBMC DNA.  Immunoprecipitating antibodies were detected at 12 weeks post-
inoculation, and were non-existent by necropsy.  We also assessed the distribution of 
viral loads in the visceral tissues of macaques inoculated with SHIVVifHCCH(-) relative to 
SHIVKU-2MC4.  We found that there was a significant decrease in viral loads of macaques 
infected with SHIVVifHCCH(-), when compared to macaques inoculated with SHIVKU-2MC4, 
suggesting that SHIVVifHCCH(-) infection is significantly less widespread.  As described 
above, these results suggest that SHIVVifHCCH(-) may replicate in the macaque in a cell 
type-specific manner depending on APOBEC3 expression.  Also, the viral RNA detected 
in visceral tissues of macaques inoculated with SHIVVifHCCH(-) at necropsy may not have 
been translated into viral proteins due to excessive G-to-A mutation; therefore, the 
infection may have been cleared by the macaque because no antigenic stimulation 
through viral proteins could occur.  Also, due to hypermutation viral quasipecies may 
exist allowing for the co-existence of functional, deleted, or truncated vif genes which can 
determine the degree of viral attenuation depending on the site and extension of the 
deletion (Rangel et al., 2009).  
Using lentiviruses as a live attenuated vaccine candidate has been involved in the 
removal of “non-essential” viral genes such as vpr, vpx, nef, or vpu, which results in low 
levels of viral replication, the accumulation of compensatory mutations in other genes, 
and/or recombination or reversion to a more pathogenic phenotype. These live 
attenuated virus vaccines are usually based on non-virulent cloned viral variants or 
clones engineered with deletions in accessory genes (Abel et al., 2003; Almond and 
Scott, 1999; Daniel et al., 1992; Lohman et al., 1994).  Following vaccination, challenge 
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with pathogenic SIV or SHIV should protect the host by suppressing the challenge viral 
loads, increasing the survival of the host, and preservation of the CD4+ T cell population.  
The live attenuated vaccine approach is not always successful in protecting against SIV 
and the length of time between vaccination and challenge seems to be a variable that 
influences efficacy; however, many of the factors required to determine the protective 
efficacy have not yet been identified (Clements et al., 1995; Marthas et al., 1990; Wyand 
et al., 1996).  While the immune correlates for HIV-1 infection are still unknown, a 
vaccine needs to ensure relative safety and induce a potent protective immune response 
in the host (Wyand et al., 1996). Vaccines consisting of the deletion or inactivation of one 
or more viral genes on HIV-1 or SIV seem to be the most effective (Koff et al., 2006).   
Macaque studies examining vif-deleted lentiviruses are limited, but all of the 
studies thus far have shown that Vif is required for viral replication in vivo (Desrosiers et 
al., 1998; Gabuzda et al., 1994; Harmache et al., 1996; Inoshima et al., 1996; 
Kristbjornsdottir et al., 2004; Lockridege et al., 1999; Sparger et al., 2008).  In a previous 
study the roles of various accessory proteins of SIVmac239, including the vif gene, were 
assessed.  Rhesus macaques inoculated with SIVmac239Δvif maintained low viral loads, 
did not show any viral DNA in PBMC at weeks 2 or 16, and did not produce antibodies to 
SIV viral proteins such as vpx or vpr (Desrosiers et al., 1998).  In a second study, 
investigators showed that a vif-deleted proviral DNA vaccine inoculated into rhesus 
macaques was immunogenic displaying a virus-specific T cell proliferative response 
even though the virus was severely attenuated.  Even though the virus was administered 
as a booster at 6 and 22 weeks post-inoculation, the vaccine was not protective against 
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challenge with SIVmac251 (Sparger et al., 2008).  Our studies showed that both 
SHIVVifHCCH(-) and SHIVVif5A were effectively controlled by rhesus macaques during the 
primary phase of infection. This suggests that viruses containing mutations in the 
conserved domains of vif may be useful to create a vaccine candidate for HIV-1.  Since 
these macaques were singly inoculated with each virus and developed an 
immunoprecipitating antibody response at 12 weeks post-inoculation, it would be of 
interest to determine if multiple inoculations would result in a stronger immune response 
that could protect against challenge with a pathogenic SHIV.  Since the Vif protein is 
required for replication of HIV-1 (SHIV/SIV) in CD4+ T cells and macrophages, mutations 
targeted in conserved motifs of Vif could permit limited replication and effective immune 
responses (both humoral and cell mediated) thus representing a novel means of 
producing a live attenuated lentivirus vaccine candidate.  Furthermore, more research is 
required to determine if mutations in other conserved motifs in Vif my permit more 
replication to improve immune responses prior to being controlled by the host, and 
whether they would protect against challenge with pathogenic virus.  For instance, while 
the C-terminal region of Vif has been studied in this dissertation, the N-terminal region of 
Vif has not been assessed in vivo (Figure 13).      The N-terminal region of HIV-1 
consists of various non-linear binding sites for A3 proteins.  Since there is only 50% 
amino acid homology between HIV-1 SIVmac239, it would be of interest to determine the 
amino acids in SIVmac239 that are responsible for binding A3 proteins.  It is important to 
functionally understand and identify these domains to determine if they are highly 
conserved, like “SLIK” or “YxxL.”  This would provide more conserved binding sites in Vif 
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that could be used as attenuated viruses to boost the host immune response and protect 
against challenge.   
 
Identification of Rhesus APOBEC3A 
Human APOBEC3 (hA3) genes are a large family of tissue specific cytidine 
deaminases that are tandemly arrayed on chromosome 22 (Jarmuz et al., 2002).  
Human A3B, A3C, A3D, A3G, and A3F have been shown to inhibit the replication of HIV-
1Δvif and SIVmac239Δvif to various extents (Dang et al., 2006; 2008; Doehle et al., 2005; 
Mariani et al., 2003; Wiegand et al., 2004; Yang et al., 2007; Yu et al., 2004b; Zennou 
and Bieniasz, 2006; Zheng et al., 2004).  While hA3A lacks antiviral activity against HIV-
1 and HIV-1Δvif, it inhibits the replication of adeno-associated virus 2 (AAV2), 
intracisternal A particles (IAP), long interspersed nuclear element 1 (LINE-1, L1), and 
Alu, through deaminase-independent mechanisms (Bogerd et al., 2006a; 2006b; Chen et 
al., 2006; Goila-Gaur et al., 2007; Muckenfuss et al., 2006). Even though hA3A lacks 
antiviral activity, it is still readily incorporated into the virions in the absence of the viral 
nucleoprotein complex (NPC) in the presence of a functional Vif.  Human A3A contains 
significant homology to the C-terminal region of hA3G.  Therefore, when the N-terminal 
half of hA3G was fused to hA3A, the A3G-A3A chimera was effectively packaged into 
only HIV-1Δvif virions by associating with the NPC, showed cytoplasmic localization 
similar to hA3G, and exhibited a strong antiviral activity against HIV-1Δvif (Goila-Gaur et 
al., 2007).  
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While hA3A has been extensively studied, no rhesus A3A (rhA3A) counterpart 
had been cloned from the rhesus macaque, suggesting that rhA3A may have been 
deleted in the rhesus macaque genome (OhAinle et al., 2008; Virgen and Hatziioannou, 
2007).  However, a recent publication showed that human A3A contains orthologs in 
eleven different non-human primate species such as owl and African green monkeys 
(Bulliard et al., 2011).  Therefore, we were interested in the isolating and characterizing 
the antiviral activities of rhesus A3A against HIV-1 and SIVmac239 Vif.  Based on the 
rhesus macaque genome sequence, we were able to clone rhesus A3A and determine 
that this gene is tandemly arrayed with the other six rhesus A3 genes on chromosome 
10 in the rhesus macaque.  We determined that the rhA3A cloned amplicon revealed 
82% nucleotide sequence identity with hA3A, and that the rhesus sequence together 
with Asian macaques (“Old World” monkeys) contained a primate lineage-specific 
insertion at amino acid positions 27 to 30 in A3A genes. We further classified the rhA3A 
gene in a phylogenetic analysis determining that the rhesus macaque and human A3A 
genes are orthologous.   
We found that rhesus A3A is widely expressed in both the visceral and central 
nervous system tissues of the rhesus macaque, is expressed at high levels in 
Staphylococcal Enterotoxin B (SEB) activated CD4+ T cells from three donor macaques, 
and degraded in the presence of both HIV-1 and SIVmac239 genomes. While it is thought 
that localization can partially explain the differences in antiviral activity against 
retroviruses and retrotransposons, this was not the case (Bogerd et al., 2006a; 2006b; 
Chen et al., 2006; Goila-Gaur et al., 2007; Muckenfuss et al., 2006). In our study, rhA3A 
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displayed nucleocytoplasmic localization similar to hA3A.  However, previous reports 
suggest that hA3A can inhibit AAV-2, IAP, L1, and Alu. In our studies rhA3A did not 
restrict the replication of AAV-2 or L1 retrotransposition (Bogerd et al., 2006a; 2006b; 
Chen et al., 2006; Goila-Gaur et al., 2007; Muckenfuss et al., 2006).   
 Recent research by Stenglein and colleagues suggests that hA3A in vitro can 
inhibit the expression of transfected plasmid DNA through deaminase-dependent 
mechanisms, while genomic DNA is not affected.  These authors suggest that foreign 
DNA restriction is a conserved innate immune defense mechanism predominantly in 
monocytes, macrophages, and neutrophils (Stenglein et al., 2010; 25, 29).  Therefore, 
genetic engineering, gene therapy, and DNA vaccines may be influenced by this foreign 
DNA defense mechanism effecting the efficiency and fidelity of these treatments 
(Stenglein et al., 2010).  However, our studies using an eGFP expression plasmid or full-
length viral molecular clones co-transfected with either hA3A or rhA3A did not show 
significant differences at 48 hours (the length of most of our tissue culture experiments).  
Human A3A had minimal impact  (<20%), while rhA3A did not have an impact on either 
reporter gene expression or full-length viral DNA molecular clone.  Also, when we 
examined the release of virus from these cells, rhA3A and hA3A had no post-entry 
restriction activity against SHIV or HIV-1.  Therefore, our studies should have minimal 
impact on plasmid DNA stability throughout the duration of our experiments.  Also, the 
DNA restriction properties of hA3A may be a recent evolutionary development in the 
hominid lineage.   
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Similar to rhA3G, rhA3A was a potent inhibitor of SHIVΔvif by reducing the levels 
of infectious virus by 20-fold.  Interestingly, we also found that hA3A effectively inhibited 
SHIVΔvif to a lesser extent by reducing the levels of infectious virus by 10-fold.  Unlike 
SHIVΔvif, rhA3A only reduced the infectivity of HIV-1Δvif by 3-fold.  Therefore, for the 
first time we were able to show an evolutionary switch in the antiviral activities of primate 
A3A by showing that rhA3A can inhibit lentiviral replication.   Previous research suggests 
that virion incorporation of A3 proteins is necessary for A3 to exhibit its antiviral 
deamination-dependent effects on HIV-1 in the next target cell (Gladdis et al., 2003; 
Sheehy et al., 2002; Suspene et al., 2004).  However, we were only able to detect small 
amounts of rhA3A incorporation into SHIV virions and unable to detect its incorporation 
into HIV-1 virions.  Also, even though hA3A inhibited SHIVΔvif, hA3A was not detected in 
SHIV virions.  This may be due to the sensitivity our virion incorporation technique 
suggesting that small amounts of rhA3A or hA3A are incorporated into SHIV virions.  
Using in vitro hypermutation assays, we were able to observe G-to-A (plus strand) 
substitutions in nef of SHIVΔvif in the presence of rhA3A.  However, the frequency of G-
to-A substitutions observed with rhA3A was significantly less (a 5-fold decrease) than the 
G-to-A substitutions observed with rhA3G.  Therefore, rhA3A may be potently restricting 
SHIVΔvif through both deaminase-dependent and deaminase-independent mechanisms.   
Since the hominid and monkey A3A’s are distinguished by a three amino acid 
indel (insertion and/or deletion) between residues 27 to 29 (SVR), we sought to 
determine if this region is necessary for the differential antiviral activity of hA3A and 
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rhA3A.  When the “SVR” amino acids were removed from rhA3A, SHIVΔvif and HIV-1Δvif 
were no longer restricted by rhA3AΔSVR but still remained sensitive to SHIV and HIV-1 
Vif-mediated degradation.  However, when the “SVR” amino acids were inserted into 
hA3A, hA3A+SVR gained partial activity against HIV-1Δvif.  This demonstrates that 
these amino acid residues are critical for rhA3A lentiviral inhibition, but they may have 
been functionally lost during the evolutionary split between humans and monkeys.  A 
recent publication by Bulliard and colleagues modeled the structure of hA3A based upon 
the known crystal structure of the hA3G C-terminus (Holden et al., 2008; Shandilya et al., 
2010).  This analysis found that the hA3A structure tightly correlates with loop 1 of the 
predicted DNA docking/editing groove (polynucleotide-accommodating groove) in the C-
terminus of hA3G.  Based upon their work, the “SVR” amino acids point towards the 
protein core providing stabilization to rhA3A and form a groove that accommodate a 
single-stranded DNA molecule for cytidine deamination (Bulliard et al., 2010).   
Previous research has determined that hA3A inhibits the replication of AAV-2, 
autonomously replicating parvoviruses, intracisternal A particles (IAP), long interspersed 
nuclear element 1 (LINE-1, L1), and Alu, through deaminase-independent mechanisms 
(Bogerd et al., 2006a; 2006b; Chen et al., 2006; Goila-Gaur et al., 2007; Muckenfuss et 
al., 2006).  As previously reported, we found that hA3A can inhibit AAV-2, while rhA3G 
cannot (Chen et al., 2006; Narvaiza et al., 2009).  However, we showed that rhA3A was 
unable to restrict the replication of AAV-2 and LINE-1 elements.  This necessity may not 
be required as no infectious AAVs have been isolated from rhesus macaques.   
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Based on of these results, further studies are needed to examine the restriction 
patterns of primate A3A genes from both a structural and evolutionary perspective.  
Therefore, experiments designed to determine why hA3A does not restrict HIV-1Δvif and 
why rhA3A potently restricts of SHIVΔvif and to a lesser extent HIV-1Δvif are necessary.  
Using the C-terminal crystal structure of hA3G and determining a molecular model 
obtained using the interactive SWISS-MODEL program of both hA3A and rhA3A, we will 
be able to identify residues near the polynucleotide binding groove or residues that are 
solvent exposed, suggesting that they may have the ability to interact with single-
stranded DNA (Figure 53) (Bulliard et al., 2010; Holden et al., 2008; Shandilya et al., 
2010).  In order to study this we would need to construct chimeric domain swapping 
protein mutants, this will allow us to examine which changes in molecular determinants 
of nucleic acid specificity of A3A proteins dictates the antiviral activity of A3A against 
lentiviruses or the restriction of AAV-2 replication and LINE-1 retrotransposition.  These 
domain-swapping proteins would be constructed as follows:  AC-Loop1 (accommodating 
loop 1; D35G, L26I, S27, V28, R29, Q33K), AC-Loop 2, AC-Loop 3 (C59H, K61Q, V64L, 
P66I, D69F, C72R, V74A), AC-Loop 5 (R106S, R107W), and α-helix 4 (Q140K, R144Q, 
T145M) (Bulliard et al., 2010; Holden et al., 2008; Shandilya et al., 2010).  The AC-Loop 
1 is thought to have proximity to the active center and bind the target DNA for 
deamination, while α-helix 4 may be important for A3A specificity and polynucleotide 
binding.  These studies will allow us to understand the structural basis involved in 
restriction of lentivirus and parvovirus replication as well as the inhibition of LINE-1 
retrotransposition.  Also, determining if the biological properties of the restriction by A3A 
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proteins from Old World and New World monkeys would be interesting.  This is because 
New World macaques have not been evolutionarily driven by SIV like Old World 
macaques.  Looking at these A3A proteins would help us deterimine the potential driving 
forces for A3A evolution.  For example, sequence analysis shows that A3A proteins from 
various Old World monkeys contain variable amino acids in the “SVR” motif.  Therefore, 
it would be interesting to see if other mutations from various Old World monkeys would 
still inhibit lentiviral replication.   
Viral protein X (Vpx) is uniquely encoded by HIV-2 and SIV (SIVmac/SIVsm) and 
has been found to bind hA3A to counteract its antiviral effects (Berger et al., 2010; 
Horton et al., 1994; Wolfrun et al., 2007).  Vpx is required for the infection of human 
monocytes and monocyte-derived cells such as macrophages and dendritic cells in vitro 
but dispensable for the infection of primary lymphocytes and cell lines (Berger et al., 
2010; Cheng et al., 2008; Fletcher et al., 1996; Sharova et al., 2008; Wolfrum et al., 
2007).   SIVmac Vpx partially binds hA3A and decreases its steady-state levels within the 
cell through degradation during the early phase of myeloid cell infection allowing for the 
replication of SIVmac.  A single-point mutation in SIVmac Vpx, H82A, prevents binding 
hA3A allowing hA3A to abrogate the infection of monocytes (Berger et al., 2010; Berger 
et al., 2011).  Therefore, it would be interesting to design experiments to determine if 
SIVmac Vpx binds rhesus A3A allowing rhA3A to abrogate the infection of monocytes.  
With the domain swap mutant proteins described above, we could determine which 
domains of human and rhesus A3A are required for this interaction.  This could reveal 
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another novel role for rhA3A by inhibiting lentiviral replication and shed light on the 
importance of myeloid cells during primate lentiviral pathogenesis.   
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Figure 53:  Structural differences between human and rhesus A3A.  Panel A.  The 
predicted human A3A structure based off of the x-ray crystal structure of the C-
terminal half of human A3G (Bulliard et al., 2010; Holden et al., 2008).  Panel B.  
The predicted structure of rhesus A3A based on the SWISS-MODEL program and 
the x-ray crystal structure of the C-terminal half of human A3G (Dr. Xiaojiang 
Chen, University of Southern California).   
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